
<html lang="en"     class="pb-page"  data-request-id="fac3339f-3bf3-4c7e-8568-538cf6d23d14"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.0c01550;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-22"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression" /></meta><meta name="dc.Creator" content="Jianyong  Chen" /></meta><meta name="dc.Creator" content="Yunlong  Zhou" /></meta><meta name="dc.Creator" content="Xuyuan  Dong" /></meta><meta name="dc.Creator" content="Liu  Liu" /></meta><meta name="dc.Creator" content="Longchuan  Bai" /></meta><meta name="dc.Creator" content="Donna  McEachern" /></meta><meta name="dc.Creator" content="Sally  Przybranowski" /></meta><meta name="dc.Creator" content="Chao-Yie  Yang" /></meta><meta name="dc.Creator" content="Jeanne  Stuckey" /></meta><meta name="dc.Creator" content="Xiaoqin  Li" /></meta><meta name="dc.Creator" content="Bo  Wen" /></meta><meta name="dc.Creator" content="Ting  Zhao" /></meta><meta name="dc.Creator" content="Siwei  Sun" /></meta><meta name="dc.Creator" content="Duxin  Sun" /></meta><meta name="dc.Creator" content="Lingling  Jiao" /></meta><meta name="dc.Creator" content="Yu  Jing" /></meta><meta name="dc.Creator" content="Ming  Guo" /></meta><meta name="dc.Creator" content="Dajun  Yang" /></meta><meta name="dc.Creator" content="Shaomeng  Wang" /></meta><meta name="dc.Description" content="We report herein the discovery of a class of potent small-molecule inhibitors of anaplastic lymphoma kinase (ALK) containing a fused indoloquinoline scaffold. The most promising compound CJ-2360 ha..." /></meta><meta name="Description" content="We report herein the discovery of a class of potent small-molecule inhibitors of anaplastic lymphoma kinase (ALK) containing a fused indoloquinoline scaffold. The most promising compound CJ-2360 ha..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 13, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01550" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01550" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01550" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01550" /></link>
        
    
    

<title>Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01550" /></meta><meta property="og:title" content="Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0020.jpeg" /></meta><meta property="og:description" content="We report herein the discovery of a class of potent small-molecule inhibitors of anaplastic lymphoma kinase (ALK) containing a fused indoloquinoline scaffold. The most promising compound CJ-2360 has an IC50 value of 2.2 nM against wild-type ALK and low-nanomolar potency against several clinically reported ALK mutants. This compound is capable of achieving complete tumor regression in the ALK-positive KARPAS-299 xenograft model with oral administration in mice. CJ-2360 represents a promising ALK inhibitor for advanced preclinical development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01550"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01550">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01550&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01550&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01550&amp;href=/doi/10.1021/acs.jmedchem.0c01550" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 13994-14016</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01544" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01479" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Jianyong Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianyong Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Rogel Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States</div><div class="loa-info-affiliations-info">Ascentage Pharma (Jiangsu), Medical City Avenue, QB3 Building First Floor, Taizhou, Jiangsu Province 225300, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianyong++Chen">Jianyong Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yunlong Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yunlong Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ascentage Pharma (Jiangsu), Medical City Avenue, QB3 Building First Floor, Taizhou, Jiangsu Province 225300, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yunlong++Zhou">Yunlong Zhou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xuyuan Dong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xuyuan Dong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Rogel Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xuyuan++Dong">Xuyuan Dong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Liu Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liu Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Rogel Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liu++Liu">Liu Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Longchuan Bai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Longchuan Bai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Rogel Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Longchuan++Bai">Longchuan Bai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Donna McEachern</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Donna McEachern</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Rogel Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Donna++McEachern">Donna McEachern</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sally Przybranowski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sally Przybranowski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Rogel Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sally++Przybranowski">Sally Przybranowski</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chao-Yie Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chao-Yie Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Rogel Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chao-Yie++Yang">Chao-Yie Yang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5445-0109" title="Orcid link">http://orcid.org/0000-0002-5445-0109</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeanne Stuckey</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeanne Stuckey</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Life Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeanne++Stuckey">Jeanne Stuckey</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaoqin Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoqin Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoqin++Li">Xiaoqin Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bo Wen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bo Wen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bo++Wen">Bo Wen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ting Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ting Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ting++Zhao">Ting Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Siwei Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Siwei Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Siwei++Sun">Siwei Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Duxin Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Duxin Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Duxin++Sun">Duxin Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lingling Jiao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lingling Jiao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ascentage Pharma (Jiangsu), Medical City Avenue, QB3 Building First Floor, Taizhou, Jiangsu Province 225300, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lingling++Jiao">Lingling Jiao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yu Jing</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yu Jing</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ascentage Pharma (Jiangsu), Medical City Avenue, QB3 Building First Floor, Taizhou, Jiangsu Province 225300, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yu++Jing">Yu Jing</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ming Guo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ming Guo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ascentage Pharma (Jiangsu), Medical City Avenue, QB3 Building First Floor, Taizhou, Jiangsu Province 225300, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ming++Guo">Ming Guo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dajun Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dajun Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Ascentage Pharma (Jiangsu), Medical City Avenue, QB3 Building First Floor, Taizhou, Jiangsu Province 225300, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dajun++Yang">Dajun Yang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Shaomeng Wang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shaomeng Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Rogel Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#74071c151b19111a133401191d171c5a111001"><span class="__cf_email__" data-cfemail="13607b727c7e767d7453667e7a707b3d767766">[email protected]</span></a>. Phone: 1-734-615-0362.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shaomeng++Wang">Shaomeng Wang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8782-6950" title="Orcid link">http://orcid.org/0000-0002-8782-6950</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01550&amp;href=/doi/10.1021%2Facs.jmedchem.0c01550" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 13994–14016</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 13, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 September 2020</li><li><span class="item_label"><b>Published</b> online</span>13 November 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01550" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01550</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D13994%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJianyong%2BChen%252C%2BYunlong%2BZhou%252C%2BXuyuan%2BDong%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D22%26contentID%3Dacs.jmedchem.0c01550%26title%3DDiscovery%2Bof%2BCJ-2360%2Bas%2Ba%2BPotent%2Band%2BOrally%2BActive%2BInhibitor%2Bof%2BAnaplastic%2BLymphoma%2BKinase%2BCapable%2Bof%2BAchieving%2BComplete%2BTumor%2BRegression%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D14016%26publicationDate%3DNovember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01550"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1110</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01550" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jianyong&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Yunlong&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Xuyuan&quot;,&quot;last_name&quot;:&quot;Dong&quot;},{&quot;first_name&quot;:&quot;Liu&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Longchuan&quot;,&quot;last_name&quot;:&quot;Bai&quot;},{&quot;first_name&quot;:&quot;Donna&quot;,&quot;last_name&quot;:&quot;McEachern&quot;},{&quot;first_name&quot;:&quot;Sally&quot;,&quot;last_name&quot;:&quot;Przybranowski&quot;},{&quot;first_name&quot;:&quot;Chao-Yie&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Jeanne&quot;,&quot;last_name&quot;:&quot;Stuckey&quot;},{&quot;first_name&quot;:&quot;Xiaoqin&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Bo&quot;,&quot;last_name&quot;:&quot;Wen&quot;},{&quot;first_name&quot;:&quot;Ting&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Siwei&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Duxin&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Lingling&quot;,&quot;last_name&quot;:&quot;Jiao&quot;},{&quot;first_name&quot;:&quot;Yu&quot;,&quot;last_name&quot;:&quot;Jing&quot;},{&quot;first_name&quot;:&quot;Ming&quot;,&quot;last_name&quot;:&quot;Guo&quot;},{&quot;first_name&quot;:&quot;Dajun&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Shaomeng&quot;,&quot;last_name&quot;:&quot;Wang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;13&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;13994-14016&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01550&quot;},&quot;abstract&quot;:&quot;We report herein the discovery of a class of potent small-molecule inhibitors of anaplastic lymphoma kinase (ALK) containing a fused indoloquinoline scaffold. The most promising compound CJ-2360 has an IC50 value of 2.2 nM against wild-type ALK and low-nanomolar potency against several clinically reported ALK mutants. This compound is capable of achieving complete tumor regression in the ALK-positive KARPAS-299 xenograft model with oral administration in mice. CJ-2360 represents a promising ALK inhibitor for advanced preclinical development.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01550&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01550" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01550&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01550" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01550&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01550" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01550&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01550&amp;href=/doi/10.1021/acs.jmedchem.0c01550" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01550" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01550" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01550%26sid%3Dliteratum%253Aachs%26pmid%3D33185101%26genre%3Darticle%26aulast%3DChen%26date%3D2020%26atitle%3DDiscovery%2Bof%2BCJ-2360%2Bas%2Ba%2BPotent%2Band%2BOrally%2BActive%2BInhibitor%2Bof%2BAnaplastic%2BLymphoma%2BKinase%2BCapable%2Bof%2BAchieving%2BComplete%2BTumor%2BRegression%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D22%26spage%3D13994%26epage%3D14016%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/jmcmar.2020.63.issue-22/20201125/jmcmar.2020.63.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We report herein the discovery of a class of potent small-molecule inhibitors of anaplastic lymphoma kinase (ALK) containing a fused indoloquinoline scaffold. The most promising compound CJ-2360 has an IC<sub>50</sub> value of 2.2 nM against wild-type ALK and low-nanomolar potency against several clinically reported ALK mutants. This compound is capable of achieving complete tumor regression in the ALK-positive KARPAS-299 xenograft model with oral administration in mice. CJ-2360 represents a promising ALK inhibitor for advanced preclinical development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48845" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48845" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase belonging to the insulin receptor (IR) kinase superfamily. ALK is expressed primarily in adult brain tissue and plays an important role in the development of the nervous system.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">Deregulation of ALK was originally discovered by the identification of a t(2;5) chromosomal translocation in anaplastic large cell non-Hodgkin’s lymphoma (ALCL).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The nucleophosmin (NPM)-ALK fusion protein produced by this translocation results in constitutive activation of the ALK kinase.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Subsequently, fusion of ALK with other genes has been identified in ALCL,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> inflammatory myofibroblastic tumor,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> diffuse large B-cell lymphoma,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> squamous cell carcinoma,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and non-small-cell lung cancer.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a> In addition to chromosomal translocations leading to fusion proteins, amplification of the ALK gene and activating point mutations of the wild-type ALK protein have been reported in neuroblastoma,<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11−13)</a> ovarian cancer,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and patients with inflammatory breast cancer.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Accordingly, ALK has been pursued as an attractive therapeutic target for treatment of various blood and solid tumors containing an ALK fusion (ALK-positive tumors).</div><div class="NLM_p">Extensive efforts have been devoted in the last decade to the discovery and development of ALK inhibitors.<a onclick="showRef(event, 'ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23">(16−23)</a> Crizotinib (<b>1</b>)<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> was the first ALK inhibitor approved by the U.S. FDA in 2011 as a first-line treatment for ALK-positive lung cancer patients. Subsequently, ceritinib (<b>2</b>, LDK378),<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> alectinib (<b>3</b>, CH5424802),<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> and brigatinib (<b>4</b>, AP26113)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> were approved by the U.S. FDA for treatment of patients with advanced (metastatic), ALK-positive non-small-cell lung cancer (NSCLC), whose disease has deteriorated after treatment, or who could not tolerate treatment with crizotinib (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Recently, lorlatinib<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> (<b>5</b>, PF-6463922) received accelerated approval by the U.S. FDA for patients with ALK-positive NSCLC, whose metastatic disease has progressed on crizotinib and at least one other ALK inhibitor or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease. Additional ALK inhibitors, including ASP3026 (<b>6</b>),<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> are currently in clinical development.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of ALK inhibitors approved or currently in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In the present study, we report the discovery of a new class of potent and selective ALK inhibitors, exemplified by CJ-2360 (<b>11n</b>). CJ-2360 (<b>11n</b>) potently inhibits wild-type ALK kinase and several clinically reported ALK mutants and is capable of achieving complete tumor regression in the ALK-positive KARPAS-299 xenograft model with oral administration.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83838" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83838" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Among all the ALK inhibitors that have been approved or are currently in clinical trials, alectinib (<b>3</b>) has a unique, fused tetracyclic system and has been shown to be highly selective against ALK over other kinases.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> We selected alectinib (<b>3</b>) as the template for the design of a new class of ALK inhibitors.</div><div class="NLM_p">We proposed that the indoloquinolone structure could mimic the tetracyclic core in alectinib and, to test this idea, we synthesized compounds <b>7a</b> and <b>7b</b> using the same soluble group as in alectinib (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). While <b>7a</b> shows no inhibitory activity in our <i>in vitro</i> ALK enzymatic assay at concentrations up to 50 μM, <b>7b</b> displays an IC<sub>50</sub> value of 2.5 μM (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Compound <b>7b</b> therefore represented a reasonable starting point for further optimization.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Design of Indoloquinolones as Potential ALK Inhibitors, Chemical Structures, and Their <i>In Vitro</i> ALK Inhibitory Activity</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0014.gif" alt="" id="gr13" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub>(nM) in inhibition of ALK enzymatic activity</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7a</b></td><td class="colsep0 rowsep0" align="left">>50,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7b</b></td><td class="colsep0 rowsep0" align="left">2503 ± 545</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7c</b></td><td class="colsep0 rowsep0" align="left">28.6 ± 12.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7d</b></td><td class="colsep0 rowsep0" align="left">21.3 ± 7.4</td></tr></tbody></table></div></div><div class="NLM_p">In our modeled structure of <b>7b</b> in complex with ALK, there is additional room available around the <i>N</i>-methyl group in <b>7b</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01550/suppl_file/jm0c01550_si_001.pdf" class="ext-link">Supporting Information</a>). We explored this site by changing the <i>N</i>-methyl group in <b>7b</b> to <i>N</i>-isopropyl, yielding <b>7c</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Compound <b>7c</b> exhibits an IC<sub>50</sub> value of 28.6 nM in ALK inhibition (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and is nearly 100 times more potent than <b>7b</b>.</div><div class="NLM_p">The 4-(piperidin-4-yl)morpholinyl soluble group in alectinib was shown to be the primary metabolic site.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Accordingly, we replaced the 4-(piperidin-4-yl)morpholinyl group in <b>7c</b> with 1-methyl-piperazinyl and obtained <b>7d</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Compound <b>7d</b> has an IC<sub>50</sub> value of 21.3 nM in ALK inhibition and is thus equipotent with <b>7c</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). We employed <b>7c</b> as our template compound for further modifications.</div><div class="NLM_p">We developed the binding model of <b>7d</b> in complex with ALK based on the cocrystal alectinib (CH5424802) complexed with ALK (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX">3AOX</a>,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A) to guide our further optimization efforts. The predicted binding model for <b>7d</b> shows that the tetracyclic core structure in <b>7d</b> mimics the tetracyclic core in alectinib, its cyano group interacts with a deep hydrophobic pocket formed by the L1196, L1171, and V1180 residues in ALK, and the carbonyl group of <b>7d</b> forms a hydrogen bond with the backbone amide group of L1198. Furthermore, the isopropyl group of <b>7d</b> occupies the same space as the dimethyl group in CH5424802.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Previously reported cocrystal structure of alectinib (CH5424802) in complex with ALK (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX">3AOX</a>). (B) Modeled structure of compound <b>7d</b> in complex with ALK. Four sites in <b>7d</b> identified for optimization are labeled with red arrows.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>7d</b> lacks the corresponding ethyl group in alectinib, which in the cocrystal structure (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A), has hydrophobic interactions with L1198, A1200, and L1122 residues in ALK. We thus performed modifications on the phenyl ring in <b>7d</b> to explore the interactions with L1198, A1200, and L1122 residues, obtaining the results summarized in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure–Activity Relationship Studies of Phenyl Substitutions on ALK Enzymatic Inhibition and Cell Growth Inhibitory Activity in the ALK-Positive KARPAS-299 Cell Line</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0015.gif" alt="" id="gr14" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0016.gif" alt="" id="gr15" /></img><div></div></div><div class="NLM_p">Installation of an ethyl group on the phenyl ring in <b>7d</b> yielded compound <b>8b</b>, which has an IC<sub>50</sub> value of 2.1 nM in inhibition of ALK and is therefore 10 times more potent than <b>7d</b>. Changing the ethyl group in <b>8b</b> to <i>n</i>-propyl resulted in <b>8c</b>, which has an IC<sub>50</sub> value of 1.0 nM in ALK inhibition and is thus 2 times more potent than <b>8b</b>. Replacing the ethyl group in <b>8b</b> with a bromine atom generated <b>8a</b>, which is slightly more potent than <b>8b</b>. Installation of an isobutyl group at the same site resulted in <b>8d</b>, which has an IC<sub>50</sub> value of 2.5 nM and is thus equipotent with <b>8b</b>. Interestingly, replacing the isobutyl group in <b>8d</b> with an isopropyl group, which led to <b>8e</b>, reduces the ALK inhibitory activity by a factor of 16.</div><div class="NLM_p">We next synthesized compounds <b>8f</b>–<b>8i</b> by introducing a series of alkoxy groups at this site. Compounds <b>8f</b> with a methoxyl group, <b>8g</b> with a propoxyl group, <b>8h</b> with a butoxyl group, and <b>8i</b> with an isopropoxyl group all have potent and similar ALK inhibitory activity with IC<sub>50</sub> values of 3.7–5.8 nM.</div><div class="NLM_p">We evaluated these potent ALK inhibitors in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> for their cell growth inhibitory activity in the KARPAS-299 cell line carrying an ALK fusion protein (ALK-positive), obtaining the results in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Compound <b>7d</b> has an IC<sub>50</sub> value of 514.6 nM. In comparison, compounds <b>8a</b>–<b>8d</b>, which have an improved ALK inhibitory activity over <b>7d</b>, have IC<sub>50</sub> values of 24.2–36.8 nM and are >10 times more potent than <b>7d</b>. Although <b>8e</b> is 2 times less potent than <b>7d</b> in ALK inhibition, <b>8e</b> is 4 times more potent than <b>7d</b> in inhibition of KARPAS-299 cell growth, suggesting enhanced cell permeability.</div><div class="NLM_p">Next, we installed one or two fluorine atoms onto the phenyl ring in <b>7d</b> to examine the effect on ALK inhibition and cell growth inhibition in the KARPAS-299 cell line and obtained the results summarized in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. Installation of a single fluorine atom onto the phenyl ring of <b>7d</b> gave <b>9a</b>, whose ALK inhibitory activity is similar to that of <b>7d</b>. However, the cellular activity of <b>9a</b> in KARPAS-299 is improved by 10 times over that of <b>7d</b>. Compound <b>9b</b> containing two fluorine substitutions in the phenyl ring of <b>7d</b> is 3 times more potent than <b>9a</b> in ALK inhibition but has a similar cell growth inhibitory activity in KARPAS-299 when compared to <b>9a</b>. Compound <b>9c</b>, which was obtained by introduction of a fluorine atom into <b>8f</b>, is 2 times less potent than <b>8f</b> in ALK inhibition but is 10 times more potent than <b>8f</b> in cell growth inhibition in the KARPAS-299 cell line. These data indicated that installation of one or two fluorine atoms on the phenyl ring significantly improves the cellular potency of the resulting compounds.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Effect of Fluorine Substitution on the Phenyl Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0017.gif" alt="" id="gr16" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (nM) (ALK inhibition)</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM) (cell growth inhibition in KARPAS-299)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7d</b></td><td class="colsep0 rowsep0" align="char" char="±">21.3 ± 7.4</td><td class="colsep0 rowsep0" align="char" char=".">514.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9a</b></td><td class="colsep0 rowsep0" align="char" char="±">19.8 ± 3.5</td><td class="colsep0 rowsep0" align="char" char=".">47.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9b</b></td><td class="colsep0 rowsep0" align="char" char="±">6.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char=".">66.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8f</b></td><td class="colsep0 rowsep0" align="char" char="±">4.8 ± 1.0</td><td class="colsep0 rowsep0" align="char" char=".">206.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9c</b></td><td class="colsep0 rowsep0" align="char" char="±">8.9 ± 1.5</td><td class="colsep0 rowsep0" align="char" char=".">19.7</td></tr></tbody></table></div></div><div class="NLM_p">Next, we explored the effect of different substitutions on the quinolone nitrogen in <b>8f</b> and obtained the results summarized in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Effect of Different Substitutions on the Quinolone Nitrogen Atom</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0018.gif" alt="" id="gr17" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM) (ALK Inhibition)</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM) (cell growth inhibition in KARPAS-299)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8f</b></td><td class="colsep0 rowsep0" align="char" char=".">4.8 ± 1.0</td><td class="colsep0 rowsep0" align="char" char=".">206.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10a</b></td><td class="colsep0 rowsep0" align="char" char=".">20.6 ± 4.1</td><td class="colsep0 rowsep0" align="char" char=".">>100,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10b</b></td><td class="colsep0 rowsep0" align="char" char=".">13.5 ± 3.7</td><td class="colsep0 rowsep0" align="char" char=".">4957</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10c</b></td><td class="colsep0 rowsep0" align="char" char=".">5.3 ± 2.1</td><td class="colsep0 rowsep0" align="char" char=".">271.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10d</b></td><td class="colsep0 rowsep0" align="char" char=".">8.2 ± 2.1</td><td class="colsep0 rowsep0" align="char" char=".">147.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10e</b></td><td class="colsep0 rowsep0" align="char" char=".">16.5</td><td class="colsep0 rowsep0" align="char" char=".">9884</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10f</b></td><td class="colsep0 rowsep0" align="char" char=".">12.7 ± 1.7</td><td class="colsep0 rowsep0" align="char" char=".">138</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10g</b></td><td class="colsep0 rowsep0" align="char" char=".">5.2 ± 0.7</td><td class="colsep0 rowsep0" align="char" char=".">129.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10h</b></td><td class="colsep0 rowsep0" align="char" char=".">1.6 ± 0.3</td><td class="colsep0 rowsep0" align="char" char=".">151.6</td></tr></tbody></table></div></div><div class="NLM_p">Replacement of the isopropyl group in <b>8f</b> by an ethyl or <i>n</i>-propyl group yielded <b>10a</b> and <b>10b</b>, respectively. While <b>10a</b> and <b>10b</b> are only 2–5 times less potent than <b>8f</b> in ALK inhibition, they are much less potent than <b>8f</b> in cell growth inhibition in the KARPAS-299 cell line. In fact, <b>10a</b> with an ethyl group has a minimal cell growth inhibitory activity at concentrations up to 100 μM. Replacement of the isopropyl group in <b>8f</b> with an isobutyl or isopentyl group yielded <b>10c</b> and <b>10d</b>, respectively. Compounds <b>10c</b> and <b>10d</b> display very similar ALK inhibition and cell growth inhibition activity compared to <b>8f</b>. Replacing the isopropyl group in <b>8f</b> with a cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl group resulted in <b>10e</b>, <b>10f</b>, <b>10g</b>, and <b>10h</b>, respectively. Compound <b>10e</b> is 3 times less potent in ALK inhibition than <b>8f</b> but is >30 times less potent than <b>8f</b> in inhibition of cell growth in the KARPAS-299 cell line. Compound <b>10g</b> has a similar ALK inhibitory activity as <b>8f</b>, whereas <b>10f</b> is 2 times less potent than <b>8f</b> in ALK inhibition, and <b>10h</b> is 3 times more potent than <b>8f</b>. However, these three compounds show very similar cell growth inhibition activity in the KARPAS-299 cell line when compared to <b>8f</b>.</div><div class="NLM_p">Among those ALK inhibitors shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, compound <b>9c</b> potently inhibits ALK enzymatic activity with an IC<sub>50</sub> value of 8.9 nM and is also the most potent compound in inhibition of cell growth in the KARPAS-299 cell line with an IC<sub>50</sub> value of 19.7 nM. We performed further optimization of <b>9c</b> by focusing on modifications of its solubilizing group (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Investigation of the Structure–Activity Relationships of the Solubilizing Group</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0019.gif" alt="" id="gr18" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM) (ALK inhibition)</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM) (cell growth inhibition in KARPAS-299)</th><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (nM) (ALK inhibition)</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM) (cell growth inhibition in KARPAS-299)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9c</b> (ALK-68)</td><td class="colsep0 rowsep0" align="char" char=".">8.9 ± 1.5</td><td class="colsep0 rowsep0" align="char" char=".">19.7</td><td class="colsep0 rowsep0" align="left">CJ-2349</td><td class="colsep0 rowsep0" align="char" char="±">4.9 ± 1.4</td><td class="colsep0 rowsep0" align="char" char=".">162</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK-73</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">40.5</td><td class="colsep0 rowsep0" align="left">CJ-2350</td><td class="colsep0 rowsep0" align="char" char="±">3.9 ± 1.6</td><td class="colsep0 rowsep0" align="char" char=".">116</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CJ-2355</td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="char" char=".">275</td><td class="colsep0 rowsep0" align="left">CJ-2351</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 1.6</td><td class="colsep0 rowsep0" align="char" char=".">117</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CJ-2212</td><td class="colsep0 rowsep0" align="char" char=".">0.49</td><td class="colsep0 rowsep0" align="char" char=".">9.7</td><td class="colsep0 rowsep0" align="left">CJ-2356</td><td class="colsep0 rowsep0" align="char" char="±">4.8 ± 0.8</td><td class="colsep0 rowsep0" align="char" char=".">29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CJ-2225</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="left">CJ-2357</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 0.9</td><td class="colsep0 rowsep0" align="char" char=".">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CJ-2226</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="left">CJ-2358</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.2</td><td class="colsep0 rowsep0" align="char" char=".">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CJ-2224</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="char" char=".">96</td><td class="colsep0 rowsep0" align="left">CJ-2359</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 0.9</td><td class="colsep0 rowsep0" align="char" char=".">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CJ-2227</td><td class="colsep0 rowsep0" align="char" char=".">0.62</td><td class="colsep0 rowsep0" align="char" char=".">36</td><td class="colsep0 rowsep0" align="left">CJ-2360</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 0.3</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td></tr></tbody></table></div></div><div class="NLM_p">We replaced the 1-methylpiperazine in <b>9c</b> (ALK-68) with 4-(piperidin-4-yl)morpholine, the same solubilizing group used in <b>3</b> (alectinib), yielding ALK-73. ALK-73 is similarly potent in inhibition of both ALK enzymatic activity and cell growth inhibition in the KARPAS-299 cell line, as compared to ALK-68.</div><div class="NLM_p">We replaced 1-methylpiperazine in ALK-68 with <i>N</i>,<i>N</i>-dimethylpiperidin-4-amine, which yielded CJ-2355. CJ-2355 is potent in inhibition of ALK (IC<sub>50</sub> = 5.8 nM) but has a much weaker activity in inhibition of KARPAS-299 cell growth (IC<sub>50</sub> = 275 nM) than ALK-68. Although the reason why CJ-2355 was much less potent than ALK-68 in inhibition of cell growth needed further investigation, the data nevertheless indicated the critical importance of the solubilizing group at this site for achieving potent cellular activity. Accordingly, we have synthesized a series of compounds with diverse solubilizing groups.</div><div class="NLM_p">Changing 1-methylpiperazine in ALK-68 with 1-methyl-piperidine resulted in CJ-2212, which is more potent than ALK-68 in inhibition of ALK activity (IC<sub>50</sub> = 0.49 nM) and cell growth in the KARPAS-299 cell line (IC<sub>50</sub> = 9.7 nM).</div><div class="NLM_p">Encouraged by the excellent potencies for CJ-2212, we replaced the 1-methyl group in CJ-2212 with oxetane, isopropyl, tetrahydro-2<i>H</i>-pyran, and ethan-1-ol, respectively, yielding CJ-CJ-2224, CJ-2225, CJ-2226, and CJ-2227, respectively. These four compounds all potently inhibit ALK activity with IC<sub>50</sub> values of 0.62–5.5 nM, with CJ-2224 being the least potent (IC<sub>50</sub> = 5.5 nM) among them. They also displayed potent cell growth inhibition in the KARPAS-299 cell line with IC<sub>50</sub> values of 17–96 nM, with CJ-2224 being the least potent (IC<sub>50</sub> = 96 nM).</div><div class="NLM_p">We next synthesized a total of eight compounds containing a piperazine group substituted with one or more methyl group (CJ-2349, CJ-2350, CJ-2351, CJ-2356, CJ-2357, CJ-2358, CJ-2359, and CJ-2360). These eight compounds display potent and similar inhibitory activities of ALK with IC<sub>50</sub> values of 1.5–4.9 nM. While CJ-2349, CJ-2350, and CJ-2351 only display moderate cell growth inhibition activity in the KARPAS-299 cell line with IC<sub>50</sub> values of 116–162 nM, CJ-2356, CJ-2357, CJ-2358, CJ-2359, and CJ-2360 achieve potent cell growth inhibition with IC<sub>50</sub> values of 1.8–29 nM. Among them, CJ-2360 achieves an IC<sub>50</sub> value of 1.8 nM in inhibition of cell growth in the KARPAS-299 cell line. We further tested CJ-2360 for its potency in cell growth inhibition in the H3122 non-small-cell lung cell line carrying EML4-ALK and obtained an IC<sub>50</sub> value of 3 nM. CJ-2360 is thus the most potent ALK inhibitor among all the ALK inhibitors we have synthesized and evaluated in this study.</div><div class="NLM_p">To understand the structural basis for its potent ALK inhibitory activity, we modeled the binding model for CJ-2360 in complex with ALK and compared the predicted binding model for CJ-2360 to the cocrystal structure of alectinib in complex with ALK (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Overall, CJ-2360 has a very similar binding mode as compared to alectinib. However, there are some subtle differences for alectinib and CJ-2360 on their interactions with CJ-2360. For example, the ethyl group in alectinib has hydrophobic interactions with the side chains of Ala1200 and Leu1122, the corresponding methoxyl group in CJ-2360 maintains those hydrophobic interactions with the side chains of Ala1200 and Leu1122, and the oxygen atom in the methoxyl group has close contacts with the guanidinium group of Arg1120.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Interaction residues in ALK with alectinib in previously reported cocrystal structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX">3AOX</a>). (B) Interaction residues in ALK in our modeled structure of CJ2360 in complex with ALK. (C) Detailed hydrophobic and hydrogen bonding interactions between alectinib and ALK and between CJ-2360 and ALK, as analyzed by LigPlot.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Evaluation of Pharmacokinetics of CJ-2360</h3><div class="NLM_p">Because CJ-2360 is the most potent ALK inhibitor we have identified based on its cell growth inhibitory activity in the KARPAS-299 cell line, we evaluated its pharmacokinetics of CJ-2360 in mice and rats, obtaining the results summarized in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetic Parameters of CJ-2360 in Mice and Rats with Intravenous and Oral Administration</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">dose (mg/kg)</th><th class="rowsep1 colsep0" colspan="2" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="rowsep1 colsep0" colspan="2" align="center">AUC<sub>0–<i>t</i></sub> (ng·h/mL)</th><th class="rowsep1 colsep0" colspan="2" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">CJ-2360</th><th class="colsep0 rowsep0" align="center">IV</th><th class="colsep0 rowsep0" align="center" char=".">PO</th><th class="colsep0 rowsep0" align="center">IV</th><th class="colsep0 rowsep0" align="center" char=".">PO</th><th class="colsep0 rowsep0" align="center">IV</th><th class="colsep0 rowsep0" align="center" char=".">PO</th><th class="colsep0 rowsep0" align="center">IV</th><th class="colsep0 rowsep0" align="center" char=".">PO</th><th class="colsep0 rowsep0" align="center">CL (IV) (L/h/kg)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub> (IV) (L/kg)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (PO)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">213</td><td class="colsep0 rowsep0" align="left">458</td><td class="colsep0 rowsep0" align="char" char=".">1783</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="char" char=".">7.5</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">7.5</td><td class="colsep0 rowsep0" align="left">38.2%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">202</td><td class="colsep0 rowsep0" align="left">639</td><td class="colsep0 rowsep0" align="char" char=".">2219</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="char" char=".">8.4</td><td class="colsep0 rowsep0" align="left">2.9</td><td class="colsep0 rowsep0" align="left">8.4</td><td class="colsep0 rowsep0" align="left">32.0%</td></tr></tbody></table></div></div><div class="NLM_p">The PK data for CJ-2360 in mice showed that it achieves a reasonable oral exposure and an overall oral bioavailability of 38.2%. It has a modest clearance rate of 1.2 L/h/kg and a large volume distribution of 7.5 L/kg, suggesting extensive tissue distribution in mice.</div><div class="NLM_p">CJ-2360 has a similar PK profile in rats as compared to that in mice. It achieves an overall oral bioavailability of 32.0%. It has a moderate clearance rate of 2.9 L/h/kg and a large volume distribution of 8.4 L/kg, suggesting extensive tissue distribution in rats.</div><div class="NLM_p">Seeking an understanding on the ability of CJ-2360 to penetrate into tumor tissues, we performed an analysis of the drug concentrations in plasma and tumor tissue in mice bearing KARPAS-299 xenograft tumors (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Our data showed that CJ-2360 achieves good plasma exposure in mice following a single dose of oral administration. Significantly, the drug concentrations in the tumor tissue are >5 times higher than those in the plasma at different time points, indicating drug accumulation in the tumor.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Analysis of CJ-2360 Concentrations in Mouse Plasma and Tumor Tissue<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" align="center" char=".">PO (100 mg/kg)</th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">concentration in plasma (ng/mL)</th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">concentration in tumor (ng/g)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">time point (h)</th><th class="colsep0 rowsep0" align="center" char=".">mouse 1</th><th class="colsep0 rowsep0" align="center" char=".">mouse 2</th><th class="colsep0 rowsep0" align="center" char=".">mean</th><th class="colsep0 rowsep0" align="center" char=".">right tumor</th><th class="colsep0 rowsep0" align="center" char=".">left tumor</th><th class="colsep0 rowsep0" align="center" char=".">right tumor</th><th class="colsep0 rowsep0" align="center" char=".">left tumor</th><th class="colsep0 rowsep0" align="center" char=".">mean</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">2780</td><td class="colsep0 rowsep0" align="char" char=".">3540</td><td class="colsep0 rowsep0" align="char" char=".">3160</td><td class="colsep0 rowsep0" align="char" char=".">10,000</td><td class="colsep0 rowsep0" align="char" char=".">14,050</td><td class="colsep0 rowsep0" align="char" char=".">12,100</td><td class="colsep0 rowsep0" align="char" char=".">12,850</td><td class="colsep0 rowsep0" align="char" char=".">12,250</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">2220</td><td class="colsep0 rowsep0" align="char" char=".">7000</td><td class="colsep0 rowsep0" align="char" char=".">4610</td><td class="colsep0 rowsep0" align="char" char=".">25,600</td><td class="colsep0 rowsep0" align="char" char=".">23,000</td><td class="colsep0 rowsep0" align="char" char=".">32,600</td><td class="colsep0 rowsep0" align="char" char=".">37,000</td><td class="colsep0 rowsep0" align="char" char=".">29,550</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">890</td><td class="colsep0 rowsep0" align="char" char=".">850</td><td class="colsep0 rowsep0" align="char" char=".">870</td><td class="colsep0 rowsep0" align="char" char=".">28,000</td><td class="colsep0 rowsep0" align="char" char=".">22,600</td><td class="colsep0 rowsep0" align="char" char=".">38,200</td><td class="colsep0 rowsep0" align="char" char=".">38,400</td><td class="colsep0 rowsep0" align="char" char=".">31,800</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="char" char=".">9.26</td><td class="colsep0 rowsep0" align="char" char=".">24.3</td><td class="colsep0 rowsep0" align="char" char=".">16.78</td><td class="colsep0 rowsep0" align="char" char=".">990</td><td class="colsep0 rowsep0" align="char" char=".">895</td><td class="colsep0 rowsep0" align="char" char=".">1335</td><td class="colsep0 rowsep0" align="char" char=".">790</td><td class="colsep0 rowsep0" align="char" char=".">1003</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Mice bearing KARPAS-299 tumors were dosed with a single dose of CJ-2360 at 100 mg/kg via oral gavage and mice were sacrificed at indicated time points, with two mice for each time point. Each mouse had two tumors.</p></div></div></div><div class="NLM_p">We next tested CJ-2360 in KARPAS-299 xenograft tumors for its ability to inhibit ALK activity with alectinib included as a positive control in a pharmacodynamic (PD) experiment (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pharmacodynamic study to evaluate CJ-2360 for its ability to inhibit ALK activity in KARPAS-299 tumors in mice. Mice were dosed with a single dose of CJ-2360 (2360) at 100 mg/kg or alectinib (Ale) at 20 mg/kg via oral gavage.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Our PD data showed that a single dose of CJ-2360 is very effective in inhibition of ALK phosphorylation, as well as ERK and STAT3 phosphorylation in KARPAS-299 tumor tissue, with the effect persisting for at least 24 h.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Evaluation of CJ-2360 for Its Antitumor Efficacy <i>In Vivo</i></h3><div class="NLM_p">Based on its promising <i>in vivo</i> PD data and excellent tumor tissue exposure, we evaluated CJ-2360 for its antitumor efficacy in the KARPAS-299 xenograft model in mice. Since CJ-2360 effectively inhibited the AKT activity at the 6 h time point but had a slightly reduced inhibition of the AKT activity at the 24 h time point in our PD experiment (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), we chose twice daily dosing for testing its antitumor activity. Ceritinib was included as a positive control in this efficacy experiment because of its demonstrated excellent efficacy in the KARPAS-299 xenograft model.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p">Our efficacy experiment showed that CJ-2360 is very efficacious in the KARPAS-299 xenograft model (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). It achieves complete tumor regression in 100% of tumors (7 out of 7) and all tumors did not return until day 53, 23 days after the last dose. Hence, CJ-2360 is capable of achieving complete and long-lasting tumor regression in the KARPAS-299 xenograft tumor model. CJ-2360 is well tolerated in mice and did not cause weight loss (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B) or other signs of toxicity during the entire experiment. In our experiment, ceritinib is also very efficacious, but it only achieved complete tumor regression in 4 out of 7 tumors with 50 mg/kg, daily administration, suggesting that higher doses or a more frequent dosing schedule is needed for ceritinib to achieve 100% tumor regression in mice.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Antitumor activity of CJ-2360 in the KARPAS-299 xenograft tumor model. CJ-2360 was orally administered twice daily at 100 mg/kg and ceritinib was orally administered daily at 50 mg/kg for 22 days (from days 9 to 30).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Inhibitory Activity of CJ-2360 against Clinically Relevant ALK Mutants</h3><div class="NLM_p">In clinic, patients with ALK-positive tumors treated with crizotinib (<b>1</b>) developed resistance to the drug due to generation of ALK mutations and a number of clinical ALK mutants have been identified.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> We evaluated CJ-2360, together with crizotinib (<b>1</b>), alectinib, and ceritinib, for its inhibitory activity against four clinically reported ALK mutants, namely, F1197M, G1269A, L1196M, and S1206Y, and obtained the results summarized in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Inhibitory Activity of Crizotinib, CJ-2360, Alectinib, and Ceritinib against Wild-Type ALK and Clinical ALK Mutants</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char="±">IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="±">ALK wild type</th><th class="colsep0 rowsep0" align="center">ALK F1197M</th><th class="colsep0 rowsep0" align="center">ALK G1269A</th><th class="colsep0 rowsep0" align="center" char="±">ALK L1196M</th><th class="colsep0 rowsep0" align="center" char="±">ALK S1206Y</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">crizotinib</td><td class="colsep0 rowsep0" align="char" char="±">34.5 ± 5.0</td><td class="colsep0 rowsep0" align="left">416 ± 43</td><td class="colsep0 rowsep0" align="left">1035 ± 194</td><td class="colsep0 rowsep0" align="char" char="±">1540 ± 270</td><td class="colsep0 rowsep0" align="char" char="±">1066 ± 232</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CJ-2360</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 0.3</td><td class="colsep0 rowsep0" align="left">4.0 ± 1.4</td><td class="colsep0 rowsep0" align="left">8.8 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±">6.3 ± 2.2</td><td class="colsep0 rowsep0" align="char" char="±">8.9 ± 2.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">alectinib</td><td class="colsep0 rowsep0" align="char" char="±">0.59 ± 0.09</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">3.9</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">0.96 ± 0.24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ceritinib</td><td class="colsep0 rowsep0" align="char" char="±">0.61 ± 0.02</td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">1.6 ± 0.3</td></tr></tbody></table></div></div><div class="NLM_p">Our data showed that CJ-2360 demonstrates potent inhibitory activity with IC<sub>50</sub> values of 2.2, 4.0, 8.8, 6.3, and 8.9 nM against wild-type ALK and F1197M, G1269A, L1196M, and S1206Y ALK mutants, respectively. Crizotinib has IC<sub>50</sub> values of 34.5, 416, 1035, 1540, and 1066 nM against wild-type ALK and F1197M, G1269A, L1196M, and S1206Y ALK mutants, respectively. Alectinib has IC<sub>50</sub> values of 0.59, 1.0, 3.9, 1.5, and 0.96 nM against wild-type ALK and F1197M, G1269A, L1196M, and S1206Y ALK mutants, respectively, whereas ceritinib achieves IC<sub>50</sub> values of 0.61, 3.5, 1.9, 1.1, and 1.6 nM against wild-type ALK and F1197M, G1269A, L1196M, and S1206Y ALK mutants, respectively.</div><div class="NLM_p last">Hence, the fold of resistance for crizotinib ranges from 12 to 44 for these clinically relevant ALK mutants over wild-type ALK, whereas the fold of resistance for CJ-2360 is 2–4 for these clinically relevant ALK mutants over wild-type ALK. Alectinib and ceritinib have 2–6-fold resistance for these clinically relevant ALK mutants over wild-type ALK. CJ-2360 is thus >100 times more effective than crizotinib against these four clinically relevant ALK mutants.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Selectivity of CJ-2360 against Other Human Kinases by KINOMEscan</h3><div class="NLM_p">CJ-2360 was evaluated by KINOMEscan in DiscoverX for its inhibitory activity in a panel of 468 kinases (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01550/suppl_file/jm0c01550_si_001.pdf" class="ext-link">Table S1</a>).</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Profiling the Selectivity of CJ-2360 against 468 Kinases by KINOMEscan</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char="."><i>K</i><sub>d</sub> (nM)</th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char="."><i>K</i><sub>d</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK</td><td class="colsep0 rowsep0" align="char" char=".">5.6</td><td class="colsep0 rowsep0" align="left">FAK</td><td class="colsep0 rowsep0" align="char" char=".">>3000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK (C1156Y)</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="left">IGF1R</td><td class="colsep0 rowsep0" align="char" char=".">>3000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK (L1196M)</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td><td class="colsep0 rowsep0" align="left">INSR</td><td class="colsep0 rowsep0" align="char" char=".">950</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLK1</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="left">INSRR</td><td class="colsep0 rowsep0" align="char" char=".">1600</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DAPK1</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="left">LTK</td><td class="colsep0 rowsep0" align="char" char=".">6.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DAPK2</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="left">MERTK</td><td class="colsep0 rowsep0" align="char" char=".">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DAPK3</td><td class="colsep0 rowsep0" align="char" char=".">260</td><td class="colsep0 rowsep0" align="left">ROS1</td><td class="colsep0 rowsep0" align="char" char=".">>3000</td></tr></tbody></table></div></div><div class="NLM_p">Consistent with the ALK inhibition data obtained in the ALK kinase assay developed in our laboratory, CJ-2360 achieves potent inhibitory activity against wild-type ALK with IC<sub>50</sub> = 5.6 nM. In addition, CJ-2360 is also potent against two clinically reported ALK mutants (C1156Y and L1196M) included in the 468 kinase panel.</div><div class="NLM_p">Outside of ALK, CJ-2360 only inhibited 11 other non-ALK kinases at 100 nM with >50% inhibition (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01550/suppl_file/jm0c01550_si_001.pdf" class="ext-link">Table S1</a>). CJ-2360 displays potent inhibitory activity against LTK (leukocyte receptor tyrosine kinase), which belongs to the same subfamily of the insulin receptor kinase superfamily (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). CJ-2360 inhibits Mer tyrosine-protein kinase (MERTK), CLK1, DAPK1, DAPK2, and DAPK3 with IC<sub>50</sub> values of 6.3, 11, 31, 23, 22, and 260 nM, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). CJ-2360 displays >100-fold selectivity for ALK over the insulin receptor kinase (INSR) and shows no significant activity against insulin-like growth factor 1 receptor (IGF1R), two kinases for which ALK belongs to the same subfamily of kinases. Hence, the KINOMEscan data showed that CJ-2360 is a potent inhibitor against wild-type ALK and clinically reported ALK mutants and displays potent inhibitory activity against only a few other kinases (LTK, MERTK, CLK1, DAPK1, and DAPK2) among the 468 kinases evaluated. Mer tyrosine kinase and DAPK kinases are considered as potential therapeutic targets for human cancer. Therefore, CJ-2360 may serve as a promising lead compound for these kinases.</div><div class="NLM_p last">Previously, alectinib was tested for its selectivity against 402 kinases at 10 and 1000 nM.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Alectinib inhibited 29 other non-ALK kinases with >95% inhibition at 1 μM among 402 kinases tested.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In our study, CJ-2360 only inhibited 11 other non-ALK kinases with >50% inhibition at 100 nM. Alectinib and CJ-2360 also inhibited the same kinases with different potencies. For example, alectinib inhibited GAK with 79% inhibition at 10 nM (IC<sub>50</sub> < 10 nM) and CJ-2360 inhibited GAK with 59% inhibition at 100 nM. Taken together, our data showed that CJ-2360 is a highly selective ALK inhibitor.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27351" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27351" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of compounds <b>7a</b>–<b>7d</b> is outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The intermediate methyl 2-(phenylamino)-1<i>H</i>-indole-3-carboxylates (<b>13a</b>–<b>13c</b>) were synthesized according to published methods<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> with minor modifications. Compounds <b>13a</b>–<b>13c</b> are obtained by chlorination of <b>12b</b> with NCS in the presence of DABCO, followed by addition of the aniline as its trichloroacetate.</div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>7a</b>–<b>7d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) NCS, DABCO, DCM, 0 °C, 2 h; (ii) trichloroacetic acid, DCM, RT, 2 h; (b) Ph<sub>2</sub>O, reflux, 1 h; (c) 4-morpholinopiperidine or 1-methylpiperazine, DIPEA, DMSO, 120–140 °C, 3 days.</p></p></figure><div class="NLM_p">Cyclization of <b>13a</b>–<b>13c</b> in boiling diphenyl ether affords the corresponding 5,6-dihydro-11<i>H</i>-indolo[2,3-<i>b</i>]quinolin-11-one (<b>14a</b>–<b>14c</b>).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Substitution with 4-morpholinopiperidine or 1-methylpiperazine in DMSO in the presence of DIPEA affords compounds <b>7a</b>–<b>7d</b>.</div><div class="NLM_p">The synthesis of compounds <b>8a</b>–<b>8e</b> is outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Methyl 2-((4-bromo-3-fluorophenyl)(isopropyl)amino)-6-cyano-1<i>H</i>-indole-3-carboxylate (<b>15</b>) is obtained by chlorination of <b>12b</b> with NCS in the presence of DABCO, followed by addition of the aniline as the trichloroacetate. Cyclization of <b>15</b> in boiling diphenyl ether affords 5,6-dihydro-11<i>H</i>-indolo[2,3-<i>b</i>]quinolin-11-one (<b>16</b>). Reaction with 1-methylpiperazine in DMSO in the presence of DIPEA afforded the designed compound (<b>8a</b>). Compounds <b>8b</b>–<b>8e</b> were obtained by Suzuki coupling of <b>8a</b> with appropriate 4,4,5,5-tetramethyl-1,3,2-dioxaborolanes, followed by hydrogenation in THF.</div><figure id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>8a</b>–<b>8e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) NCS, DABCO, DCM, 0 °C, 2 h; (ii) 4-bromo-3-fluoro-<i>N</i>-isopropylaniline, trichloroacetic acid, DCM, RT, 2 h; (b) Ph<sub>2</sub>O, reflux, 1 h; (c) 1-methylpiperazine, DIPEA, DMSO, 120–140 °C, 3 days; (d) (i) appropriate 4,4,5,5-tetramethyl-1,3,2-dioxaborolane, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>,CO<sub>3</sub>, DME/H<sub>2</sub>O, 80 °C; (ii) 10% Pd-C, H<sub>2</sub>, THF.</p></p></figure><div class="NLM_p">The synthesis of compounds <b>8f</b>–<b>8i</b> is outlined in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Alkoxyl-substituted methyl 2-((4-alkoxyl-3-fluorophenyl)(isopropyl)amino)-6-cyano-1<i>H</i>-indole-3-carboxylates (<b>17a</b>–<b>17d</b>) are obtained by chlorination of <b>12b</b> with NCS in the presence of DABCO, followed by addition of the aniline as its trichloroacetate. Cyclization of <b>17a</b>–<b>17d</b> in boiling diphenyl ether affords the alkoxyl-substituted 5,6-dihydro-11<i>H</i>-indolo[2,3-<i>b</i>]quinolin-11-ones (<b>18a</b>–<b>18d</b>). Substitution with 1-methylpiperazine in DMSO in the presence of DIPEA affords the designed compounds (<b>8f</b>–<b>8i</b>).</div><figure id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>8f</b>–<b>8i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) NCS, DABCO, SCM, 0 °C, 2 h; (ii) trichloroacetic acid; appropriate anilines, RT, 2 h; (b) Ph<sub>2</sub>O, reflux, 1 h; (c) 1-methylpiperazine, DIPEA, DMSO, 120–140 °C, 3 days.</p></p></figure><div class="NLM_p">The synthesis of compounds <b>9a</b>–<b>9c</b> is outlined in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Di- or trifluoro-substituted methyl 6-cyano-2-(isopropyl(phenyl)amino)-1<i>H</i>-indole-3-carboxylates (<b>19a</b>–<b>19c</b>) are obtained by chlorination of <b>12b</b> with NCS in the presence of DABCO, followed by addition of the appropriate aniline as its trichloroacetate. Cyclization of <b>19a</b>–<b>19c</b> in boiling diphenyl ether affords the di- or trifluoro-substituted 5,6-dihydro-11<i>H</i>-indolo[2,3-<i>b</i>]quinolin-11-ones (<b>20a</b>–<b>20c</b>), and substitution with 1-methylpiperazine in DMSO in the presence of DIPEA affords the designed compounds (<b>9a</b>–<b>9c</b>). The synthesis of compounds <b>10a</b>–<b>10h</b> is outlined in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. Methyl 6-cyano-2-(phenylamino)-1<i>H</i>-indole-3-carboxylates (<b>23a</b>–<b>23h</b>) are obtained by chlorination of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate with NCS in the presence of DABCO, followed by addition of the appropriate alkyl- or cycloalkyl-substituted aniline as the trichloroacetate. Cyclization of <b>23a</b>–<b>23h</b> in boiling diphenyl ether affords alkyl- or cycloalkyl-substituted 5,6-dihydro-11<i>H</i>-indolo[2,3-<i>b</i>]quinolin-11-ones (<b>24a</b>–<b>24h</b>). Substitution with 1-methylpiperazine in DMSO in the presence of DIPEA affords the designed compounds (<b>10a</b>–<b>10h</b>).</div><figure id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <b>9a</b>–<b>9c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) NCS, DABCO, DCM, 0 °C, 2 h; (ii) trichloroacetic acid, appropriate anilines, RT, 2 h; (b) Ph<sub>2</sub>O, reflux, 1 h; (c) 1-methylpiperazine, DIPEA, DMSO, 120–140 °C, 3 days.</p></p></figure><figure id="sch5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <b>10a</b>–<b>10h</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) methyl 6-cyano-1<i>H</i>-indole-3-carboxylate, NCS, DABCO, DCM, 0 °C, 2 h; (ii) trichloroacetic acid, appropriate anilines, RT, 2 h; (b) Ph<sub>2</sub>O, reflux, 1 h; (c) 1-methylpiperazine, DIPEA, DMSO, 120–140 °C, 3 days.</p></p></figure><div class="NLM_p">The synthesis of compounds ALK-73, CJ-2349-2351, and CJ-2356-2360 is outlined in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. Compound <b>20c</b> was substituted with 1-methylpiperazine in DMSO in the presence of DIPEA at 120–140 °C for 3 days to give the designed compounds.</div><figure id="sch6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of ALK-73, CJ-2349-2351, and CJ-2356-2360<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) appropriate amines, DIPEA, DMSO, 120–140 °C, 3 days.</p></p></figure><div class="NLM_p">The synthesis of compounds CJ-2212 and CJ-2224-2227 is outlined in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. Nucleophilic substitution of F in <b>25</b> by sodium methoxide gave anisole <b>26</b>. Aniline <b>28</b> was obtained by Suzuki coupling of <b>26</b> followed by hydrogenation. Reductive amination of <b>28</b> afforded isopropyl-substituted aniline <b>29</b>. Methyl 6-cyano-2-(phenylamino)-1<i>H</i>-indole-3-carboxylate <b>30</b> was obtained by chlorination of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate with NCS in the presence of DABCO, followed by addition of substituted aniline <b>29</b> and trichloroacetate. Deprotection of Boc in <b>30</b> followed by reductive amination gave piperidine <b>31b</b>–<b>31f</b>. Cyclization of <b>31b</b>–<b>31f</b> in boiling diphenyl ether affords target molecules.</div><figure id="sch7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of CJ-2212 and CJ-2224-2227<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) MeONa, MeOH, 0 °C to RT, 4 h, 55%; (b) <i>tert</i>-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridline-1(2<i>H</i>)-carboxylate, Pd(dppf)Cl<sub>2</sub>, and K<sub>2</sub>CO<sub>3</sub>, 92%; (c) 10% Pd-C, ethanol, RT, overnight, 92%; (d) acetone, acetic acid, NaBH(OAc)<sub>3</sub>, DCM, RT, 12 h, 94%; (e) (i) methyl 6-cyano-1<i>H</i>-indole-3-carboxylate, NCS, DABCO, DCM, 0 °C, 2 h; (ii) trichloroacetic acid, RT, 2 h, 69%; (f) (i) TFA; (ii) appropriate aldehyde or ketone, NaBH(OAc)<sub>3</sub>, acetic acid, DCM; (g) Ph<sub>2</sub>O, reflux, 1 h.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33120" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33120" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have designed, synthesized, and evaluated a new class of ALK inhibitors containing a fused indoloquinoline scaffold. Our efforts have resulted in the discovery of CJ-2360 as a potent, orally bioavailable, and highly efficacious ALK inhibitor. CJ-2360 effectively inhibits wild-type ALK activity with an IC<sub>50</sub> = 2.2 nM. Importantly, CJ-2360 displays potent inhibitory activity against four clinically reported ALK mutants with IC<sub>50</sub> values of 4.4–8.9 nM and is >100 times more potent than crizotinib against these clinical ALK mutants. CJ-2360 potently inhibits cell growth in the ALK-positive KARPAS-299 anaplastic large-cell lymphoma cell line carrying NPM-ALK fusion and the H3122 non-small-cell lung cell line carrying EML4-ALK with IC<sub>50</sub> values of 2 and 3 nM, respectively. CJ-2360 has good oral pharmacokinetics in mice and rats. CJ-2360 effectively inhibits ALK activity in the ALK-positive KARPAS-299 xenograft tumor with a single administration in mice. CJ-2360 is capable of achieving complete and long-lasting tumor regression in the KARPAS-299 xenograft model in mice at a well-tolerated dose schedule. Collectively, our data demonstrate that CJ-2360 is a promising ALK inhibitor for advanced preclinical development.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03166" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03166" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Methods</h3><div class="NLM_p last">Solvents and reagents were obtained commercially and used without further purification. Reactions were monitored by TLC on 250 μm E. Merck silica gel plates (60F-254) using UV light for visualization. E. Merck silica gel (60; particle size, 15–40 μm) was used for flash column chromatography. The NMR spectra were recorded on a Bruker Avance300 spectrometer (300 MHz) and Bruker Avance III spectrometer (400 MHz). Chemical shifts are reported as δ values (ppm) downfield relative to TMS as an internal standard, with multiplicities reported in the standard form. All final compounds have purities >95%, as determined by HPLC (UV detection at 254 nm).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Methyl 2-((3-Fluorophenyl)amino)-1<i>H</i>-indole-3-carboxylate (<b>13a</b>)</h3><div class="NLM_p last">DABCO (62 mg, 0.55 mmol) was added to a solution of methyl 1<i>H</i>-indole-3-carboxylate (175 mg, 1 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. NCS (147 mg, 1.1 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of 3-fluoroaniline (111 mg, 1 mmol) and trichloroacetic acid (41 mg, 0.25 mmol) in DCM (5 mL) was added dropwise and the reaction was stirred for 2 h at RT. The reaction was quenched by adding H<sub>2</sub>O and the mixture was extracted with DCM. Solvent was removed under vacuum and the residue was purified by silica gel chromatography with hexane/EtOAc (4/1, v/v) to afford the title compound as a colorless oil (200 mg, 70% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 9.14 (s, 1H), 8.30 (s, 1H), 7.88–7.81 (m, 1H), 7.43–7.37 (m, 1H), 7.30–7.16 (m, 2H), 7.16–6.95 (m, 3H), 6.94–6.87 (m, 1H), 3.98 (s, 3H).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Methyl 6-Cyano-2-((3-fluorophenyl)(methyl)amino)-1<i>H</i>-indole-3-carboxylate (<b>13b</b>)</h3><div class="NLM_p last">DABCO (62 mg, 0.55 mmol) was added to a solution of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate (200 mg, 1 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. NCS (147 mg, 1.1 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of 3-fluoro-<i>N</i>-methylaniline (125 mg, 1 mmol) and trichloroacetic acid (41 mg, 0.25 mmol) in DCM (5 mL) was added dropwise and the reaction was stirred for 2 h at RT. The reaction was quenched by adding H<sub>2</sub>O and the mixture was extracted with DCM. Solvent was removed under vacuum and the residue was purified by silica gel chromatography with hexane/EtOAc (4/1, v/v) to afford the title compound as a colorless oil (220 mg, 68% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.26 (s, 1H), 8.03 (d, <i>J</i> = 8.6 Hz, 1H), 7.46 (d, <i>J</i> = 1.8 Hz, 1H), 7.39 (dd, <i>J</i> = 8.6, 1.8 Hz, 1H), 7.21–7.18 (m, 1H), 6.66–6.49 (m, 3H), 3.85 (s, 3H), 3.43 (s, 3H).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Methyl 6-Cyano-2-((3-fluorophenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (<b>13c</b>)</h3><div class="NLM_p last">DABCO (62 mg, 0.55 mmol) was added to a solution of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate (200 mg, 1 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. NCS (147 mg, 1.1 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of 3-fluoro-<i>N</i>-isopropylaniline (153 mg, 1 mmol) and trichloroacetic acid (41 mg, 0.25 mmol) in DCM (5 mL) was added dropwise and the reaction was stirred for 2 h at RT. The reaction was quenched by adding H<sub>2</sub>O and the mixture was extracted with DCM. Solvent was removed under vacuum and the residue was purified by silica gel chromatography with hexane/EtOAc (4/1, v/v) to afford the title compound as a colorless oil (265 mg, 75% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.39 (s, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 1H), 7.64–7.59 (m, 1H), 7.50 (dd, <i>J</i> = 8.4, 1.5 Hz, 1H), 7.24–7.22 (m, 1H), 6.74–6.64 (m, 1H), 6.60–6.56 (m, 2H), 4.56–4.49 (m, 1H), 3.81 (s, 3H), 1.32 (d, <i>J</i> = 6.6 Hz, 6H).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 3-Fluoro-5,6-dihydro-11<i>H</i>-indolo[2,3-<i>b</i>]quinolin-11-one (<b>14a</b>)</h3><div class="NLM_p last">Methyl 2-((3-fluoro-phenyl)amino)-1<i>H</i>-indole-3-carboxylate (193 mg, 0.68 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was then cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration to afford the title compound as a pale yellow solid (82 mg, 48% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.41 (s, 1H), 11.80 (s, 1H), 8.32 (dd, <i>J</i> = 8.9, 6.6 Hz, 1H), 8.16 (d, <i>J</i> = 6.6 Hz, 1H), 7.48 (d, <i>J</i> = 7.7 Hz, 1H), 7.40 (dd, <i>J</i> = 10.5, 2.5 Hz, 1H), 7.30–7.10 (m, 3H).</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 3-Fluoro-5-methyl-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>14b</b>)</h3><div class="NLM_p last">Methyl 6-cyano-2-((3-fluorophenyl)(methyl)amino)-1<i>H</i>-indole-3-carboxylate (220 mg, 0.68 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration to afford the title compound as a pale yellow solid (178 mg, 90% yield). This product was used directly in the next step without further purification. MS: <i>m</i>/<i>z</i> = 292 [M + H].</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 3-Fluoro-5-isopropyl-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>14c</b>)</h3><div class="NLM_p last">Methyl 6-cyano-2-((3-fluorophenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (265 mg, 0.75 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration. The precipitate was purified by silica gel chromatography with hexane/EtOAc (2/1, v/v) to afford the title compound as a pale yellow solid (190 mg, 79% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 12.24 (s, 1H), 8.45 (dd, <i>J</i> = 8.8, 7.1 Hz, 1H), 8.32 (dd, <i>J</i> = 7.9, 2.7 Hz, 1H), 8.05–7.84 (m, 2H), 7.66–7.64 (m, 1H), 7.34–7.25 (m, 1H), 5.35–5.32 (m, 1H), 1.75 (d, <i>J</i> = 7.1 Hz, 6H).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 3-(4-Morpholinopiperidin-1-yl)-5,6-dihydro-11<i>H</i>-indolo[2,3-<i>b</i>]quinolin-11-one (<b>7a</b>)</h3><div class="NLM_p last">4-Morpholinopiperidine (262 mg, 1.56 mmol) and DIPEA (0.5 mL) were added to a solution of 3-fluoro-5<i>H</i>-indolo[2,3-<i>b</i>]quinolin-11(6<i>H</i>)-one (130 mg, 0.52 mmol) in DMSO (2 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound as a pale yellow solid (60 mg, 29% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.40 (s, 1H), 11.84 (s, 1H), 10.02 (s, 1H), 8.18–8.11 (m, 2H), 7.46 (d, <i>J</i> = 7.7 Hz, 1H), 7.28–7.14 (m, 2H), 7.09 (dd, <i>J</i> = 9.1, 2.3 Hz, 1H), 7.02 (d, <i>J</i> = 2.3 Hz, 1H), 4.00–3.85 (m, 8H), 3.75–3.68 (m, 2H), 3.55–3.40 (m, 3H), 3.18–3.08 (m, 2H), 2.91 (t, <i>J</i> = 12.5 Hz, 2H), 2.23–2.14 (m, 2H), 1.78–1.64 (m, 2H).</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 5-Methyl-3-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>7b</b>)</h3><div class="NLM_p last">4-Morpholinopiperidine (262 mg, 1.56 mmol) and DIPEA (0.5 mL) were added to a solution of 3-fluoro-5-methyl-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (150 mg, 0.52 mmol) in DMSO (2 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound as a pale yellow solid (70 mg, 31% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.30 (d, <i>J</i> = 7.0 Hz, 1H), 8.28 (d, <i>J</i> = 8.0 Hz, 1H), 7.58 (s, 1H), 7.52 (d, <i>J</i> = 8.0 Hz, 1H), 7.12 (d, <i>J</i> = 7.0 Hz,1H), 6.84 (s, 1H), 4.37–4.10 (m, 4H), 4.00–3.72 (m, 2H), 3.89 (s, 3H), 3.70–3.20 (m, 5H), 3.18–3.00 (m, 2H), 2.40–2.26 (m, 2H), 1.97–1.86 (m, 2H).</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 5-Isopropyl-3-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>7c</b>)</h3><div class="NLM_p last">4-Morpholinopiperidine (262 mg, 1.56 mmol) and DIPEA (0.5 mL) were added to a solution of 3-fluoro-5-isopropyl-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (190 mg, 0.59 mmol) in DMSO (2 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound as a pale yellow solid (75 mg, 27% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.39 (d, <i>J</i> = 8.0 Hz, 1H), 8.38 (d, <i>J</i> = 8.9 Hz, 1H), 7.82 (s, 1H), 7.56 (dd, <i>J</i> = 8.0, 1.3 Hz, 1H), 7.30–7.15 (m, 2H), 5.45–5.32 (m, 1H), 4.38–4.10 (m, 4H), 3.90–3.72 (m, 2H), 3.70–3.20 (m, 5H), 3.18–3.00 (m, 2H), 2.40–2.30 (m, 2H), 1.97–1.80 (m, 2H), 1.87 (d, <i>J</i> = 7.1 Hz, 6H).</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 5-Isopropyl-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]Quinoline-8-Carbonitrile (<b>7d</b>)</h3><div class="NLM_p last">1-Methylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 3-fluoro-5-isopropyl-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (190 mg, 0.59 mmol) in DMSO (2 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound as a pale yellow solid (48 mg, 20% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.42 (d, <i>J</i> = 8.1 Hz, 1H), 8.39 (d, <i>J</i> = 9.2 Hz, 1H), 7.81 (d, <i>J</i> = 1.3 Hz, 1H), 7.55 (dd, <i>J</i> = 8.1, 1.3 Hz, 1H), 7.28 (d, <i>J</i> = 1.8 Hz, 1H), 7.21 (dd, <i>J</i> = 9.2, 1.8 Hz, 1H), 5.50–5.30 (m, 1H), 4.36–4.10 (m, 2H), 3.80–3.60 (m, 2H), 3.55–3.20 (m, 4H), 3.04 (s, 3H), 1.87 (d, <i>J</i> = 7.1 Hz, 6H).</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Methyl 2-((4-Bromo-3-fluorophenyl)(isopropyl)amino)-6-cyano-1<i>H</i>-indole-3-carboxylate (<b>15</b>)</h3><div class="NLM_p last">DABCO (62 mg, 0.55 mmol) was added to a solution of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate (200 mg, 1 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. NCS (147 mg, 1.1 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of 4-bromo-3-fluoro-<i>N</i>-isopropylaniline (232 mg, 1 mmol) and trichloroacetic acid (41 mg, 0.25 mmol) in DCM (5 mL) was added dropwise and the reaction was stirred for 2 h at RT. The reaction was quenched by adding H<sub>2</sub>O and the mixture was extracted with DCM. Solvent was removed under vacuum and the residue was purified by silica gel chromatography with hexane/EtOAc (4/1, v/v) to afford the title compound as a colorless oil (245 mg, 57% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.44 (s, 1H), 8.27 (d, <i>J</i> = 8.3 Hz, 1H), 7.73–7.64 (m, 1H), 7.54 (dd, <i>J</i> = 8.3, 1.4 Hz, 1H), 7.34 (dd, <i>J</i> = 9.0, 7.9 Hz, 1H), 6.56 (dd, <i>J</i> = 11.3, 2.7 Hz, 1H), 6.41 (dd, <i>J</i> = 9.0, 2.7 Hz, 1H), 4.45–4.41 (m, 1H), 3.81 (s, 3H), 1.31 (d, <i>J</i> = 6.6 Hz, 6H).</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 2-Bromo-3-fluoro-5-isopropyl-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>16</b>)</h3><div class="NLM_p last">Methyl 2-((4-bromo-3-fluorophenyl)(isopropyl)amino)-6-cyano-1<i>H</i>-indole-3-carboxylate (245 mg, 0.57 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration. The precipitate was purified by silica gel chromatography with hexane/EtOAc (2/1, v/v) to afford the title compound as a pale yellow solid (110 mg, 49% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.30 (s, 1H), 8.54 (d, <i>J</i> = 8.3 Hz, 1H), 8.28 (d, <i>J</i> = 8.0 Hz, 1H), 8.08 (d, <i>J</i> = 11.9 Hz, 1H), 7.92 (d, <i>J</i> = 1.4 Hz, 1H), 7.63 (dd, <i>J</i> = 8.0, 1.4 Hz, 1H), 5.37–5.28 (m, 1H), 1.74 (d, <i>J</i> = 7.0 Hz, 6H).</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 2-Bromo-5-isopropyl-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>8a</b>)</h3><div class="NLM_p last">1-Methylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 2-bromo-3-fluoro-5-isopropyl-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (110 mg, 0.28 mmol) in DMSO (2 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound as a pale yellow solid (29 mg, 22% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.58 (s, 1H), 8.29 (d, <i>J</i> = 7.9 Hz, 1H), 7.77 (s, 1H), 7.52 (d, <i>J</i> = 7.9 Hz, 1H), 7.49 (s, 1H), 5.44–5.30 (m, 1H), 3.90–3.70 (m, 4H), 3.60–3.30 (m, 4H), 3.08 (s, 3H), 1.89 (d, <i>J</i> = 7.1 Hz, 6H).</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 2-Ethyl-5-isopropyl-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>8b</b>)</h3><div class="NLM_p last">A mixture of 2-bromo-5-isopropyl-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (30 mg, 0.063 mmol), Na<sub>2</sub>CO<sub>3</sub> (25 mg, 0.183 mmol), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (4.3 mg, 0.0061 mmol), and 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (14 mg, 0.091 mmol) in DME/H<sub>2</sub>O (4.8 mL, 5/1, v/v) was stirred under nitrogen at 80 °C overnight. After the reaction was complete as indicated by LC–MS, the mixture was purified by preparative HPLC to afford 5-isopropyl-3-(4-methylpiperazin-1-yl)-11-oxo-2-vinyl-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile, which was dissolved in THF (5 mL). Pd/C (10%, 20 mg) was added to the THF solution and the mixture underwent hydrogenation at RT overnight until LC–MS indicated that the reaction was complete. The filtrate after filtration was concentrated and the residue was purified by preparative HPLC to afford the title compound as a pale yellow solid (14 mg, 52% yield for two steps). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.38 (s, 1H), 8.29 (d, <i>J</i> = 8.0 Hz, 1H), 7.70 (s, 1H), 7.50 (s, 1H), 7.44 (d, <i>J</i> = 8.0 Hz, 1H), 5.40–5.30 (m, 1H), 3.75–3.65 (m, 2H), 3.63–3.25 (m, 6H), 3.06 (s, 3H), 2.90 (q, <i>J</i> = 7.4 Hz, 2H), 1.88 (d, <i>J</i> = 7.1 Hz, 6H), 1.40 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 5-Isopropyl-3-(4-methylpiperazin-1-yl)-11-oxo-2-propyl-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>8c</b>)</h3><div class="NLM_p last">A mixture of 2-bromo-5-isopropyl-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (30 mg, 0.061 mmol), Na<sub>2</sub>CO<sub>3</sub> (25 mg, 0.183 mmol), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (4.3 mg, 0.0061 mmol), and 4,4,5,5-tetramethyl-2-(prop-1-en-1-yl)-1,3,2-dioxaborolane (16 mg, 0.091 mmol) in DME/H<sub>2</sub>O (4.8 mL, 5/1, v/v) was stirred under N<sub>2</sub> at 80 °C overnight. After the reaction was complete as indicated by LC–MS, the mixture was purified by preparative HPLC to afford 5-isopropyl-3-(4-methylpiperazin-1-yl)-11-oxo-2-(prop-1-en-1-yl)-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile, which was dissolved in THF (5 mL). Pd/C (10%, 20 mg) was added to the THF solution. The mixture underwent hydrogenation at RT overnight until LC–MS indicated that the reaction was complete. The filtrate was concentrated and the residue was purified by preparative HPLC to afford the title compound as a pale yellow solid (8 mg, 29% yield for two steps). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.37 (s, 1H), 8.32 (d, <i>J</i> = 8.1 Hz, 1H), 7.74 (d, <i>J</i> = 1.3 Hz, 1H), 7.56–7.39(m, 2H), 5.39–5.32 (m, 1H), 3.71–3.68 (m, 2H), 3.55–3.37 (m, 4H), 3.29–3.22(m, 2H), 3.05 (s, 3H), 2.90–2.70 (m, 2H), 1.87 (d, <i>J</i> = 7.1 Hz, 6H), 1.85–1.73(m, 2H), 1.04 (t, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 2-Isobutyl-5-isopropyl-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>8d</b>)</h3><div class="NLM_p last">A mixture of 2-bromo-5-isopropyl-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (30 mg, 0.061 mmol), Na<sub>2</sub>CO<sub>3</sub> (25 mg, 0.183 mmol), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (4.3 mg, 0.0061 mmol), and 4,4,5,5-tetramethyl-2-(2-methylprop-1-en-1-yl)-1,3,2-dioxaborolane (16 mg, 0.091 mmol) in DME/H<sub>2</sub>O (4.8 mL, 5/1, v/v) was stirred under nitrogen at 80 °C overnight. After the reaction was complete as indicated by LC–MS, the mixture was purified by preparative HPLC to afford 5-isopropyl-3-(4-methylpiperazin-1-yl)-2-(2-methylprop-1-en-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile, which was dissolved in THF (5 mL). Pd/C (10%, 20 mg) was added to the THF solution. The mixture underwent hydrogenation at RT overnight until LC–MS indicated that the reaction was complete. The filtrate was concentrated and the residue was purified by preparative HPLC to afford the title compound as a pale yellow solid (10 mg, 35% yield for two steps). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.45 (s, 1H), 8.22 (d, <i>J</i> = 8.0 Hz, 1H), 7.62 (s, 1H), 7.39 (s, 1H), 7.18 (d, <i>J</i> = 8.0 Hz, 1H), 5.50–5.40 (m, 1H), 3.70–3.60 (m, 2H), 3.55–3.30 (m, 6H), 2.75 (d, <i>J</i> = 7.1 Hz, 2H), 2.53 (s, 3H), 2.25–2.15 (m, 1H), 1.90 (d, <i>J</i> = 7.1 Hz, 6H), 0.99 (d, <i>J</i> = 6.6 Hz, 6H).</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 2,5-Diisopropyl-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>8e</b>)</h3><div class="NLM_p last">A mixture of 2-bromo-5-isopropyl-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (30 mg, 0.061 mmol), Na<sub>2</sub>CO<sub>3</sub> (25 mg, 0.183 mmol), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (4.3 mg, 0.0061 mmol), and 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (16 mg, 0.091 mmol) in DME/H<sub>2</sub>O (4.8 mL, 5/1, v/v) was stirred under nitrogen at 80 °C overnight. After the reaction was complete as indicated by LC–MS, the mixture was purified by preparative HPLC to afford 5-isopropyl-3-(4-methylpiperazin-1-yl)-11-oxo-2-(prop-1-en-2-yl)-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile, which was dissolved in THF (5 mL). Pd/C (10%; 20 mg) was added to the THF solution. The resulting mixture underwent hydrogenation at RT overnight until LC–MS indicated that the reaction was complete. The filtrate after filtration was concentrated and the residue was purified by preparative HPLC to afford the title compound as a pale yellow solid (9 mg, 32% yield for two steps). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.53 (s, 1H), 8.42 (d, <i>J</i> = 8.0 Hz, 1H), 7.82 (m, 1H), 7.60–7.52 (m, 2H), 5.45–5.27 (m, 1H), 3.92–3.25 (m, 9H), 3.07 (s, 3H), 1.89 (d, <i>J</i> = 6.1 Hz, 6H), 1.38 (d, <i>J</i> = 6.8 Hz, 6H).</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Methyl 6-Cyano-2-((3-fluoro-4-methoxyphenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (<b>17a</b>)</h3><div class="NLM_p last">DABCO (62 mg, 0.55 mmol) was added to a solution of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate (200 mg, 1 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. NCS (147 mg, 1.1 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of 3-fluoro-<i>N</i>-isopropyl-4-methoxyaniline (183 mg, 1 mmol) and trichloroacetic acid (41 mg, 0.25 mmol) in DCM (5 mL) was added dropwise and the reaction was stirred for 2 h at RT. The reaction was quenched by adding H<sub>2</sub>O and the mixture was extracted with DCM. The solvent was removed under vacuum and the residue was purified by silica gel chromatography with hexane/EtOAc (4/1, v/v) to afford the title compound as a colorless oil (250 mg, 66% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.08–8.06 (m, 2H), 7.45–7.36 (m, 2H), 7.05–6.87 (m, 3H), 4.88–4.80 (m, 1H), 3.92 (s, 3H), 3.88 (s, 3H), 1.26 (d, <i>J</i> = 6.6 Hz, 6H).</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Methyl 6-Cyano-2-((3-fluoro-4-propoxyphenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (<b>17b</b>)</h3><div class="NLM_p last">DABCO (62 mg, 0.55 mmol) was added to a solution of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate (200 mg, 1 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. NCS (147 mg, 1.1 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of 3-fluoro-<i>N</i>-isopropyl-4-propoxyaniline (211 mg, 1 mmol) and trichloroacetic acid (41 mg, 0.25 mmol) in DCM (5 mL) was added dropwise and the reaction was stirred for 2 h at RT. The reaction was quenched by adding H<sub>2</sub>O and the mixture was extracted with DCM. Solvent was removed under vacuum and the residue was purified by silica gel chromatography with hexane/EtOAc (4/1, v/v) to afford the title compound as a colorless oil (235 mg, 57% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.05 (d, <i>J</i> = 8.3 Hz, 1H), 7.95 (s, 1H), 7.41 (dd, <i>J</i> = 8.3, 1.4 Hz, 1H), 7.37 (d, <i>J</i> = 1.4 Hz, 1H), 7.01 (t, <i>J</i> = 8.9 Hz, 1H), 6.97 (dd, <i>J</i> = 12.0, 2.6 Hz, 1H), 6.90–6.85 (m, 1H), 4.91–4.82 (m, 1H), 4.03 (t, <i>J</i> = 6.6 Hz, 2H), 3.89 (s, 3H), 1.90–1.88 (m, 2H), 1.26 (d, <i>J</i> = 6.6 Hz, 6H), 1.09 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Methyl 2-((4-Butoxy-3-fluorophenyl)(isopropyl)amino)-6-cyano-1<i>H</i>-indole-3-carboxylate (<b>17c</b>)</h3><div class="NLM_p last">DABCO (62 mg, 0.55 mmol) was added to a solution of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate (200 mg, 1 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. NCS (147 mg, 1.1 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of 4-butoxy-3-fluoro-<i>N</i>-isopropylaniline (225 mg, 1 mmol) and trichloroacetic acid (41 mg, 0.25 mmol) in DCM (5 mL) was added dropwise and the reaction was stirred for 2 h at RT. The reaction was quenched by adding H<sub>2</sub>O and the mixture was extracted with DCM. Solvent was removed under vacuum and the residue was purified by silica gel chromatography with hexane/EtOAc (4/1, v/v) to afford the title compound as a colorless oil (245 mg, 58% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.05 (d, <i>J</i> = 8.3 Hz, 1H), 7.86 (s, 1H), 7.41 (dd, <i>J</i> = 8.3, 1.4 Hz, 1H), 7.37 (d, <i>J</i> = 1.4 Hz, 1H), 7.01 (t, <i>J</i> = 8.9 Hz, 1H), 6.97 (dd, <i>J</i> = 12.1, 2.6 Hz, 1H), 6.91–6.88 (m, 1H), 4.91–4.83 (m, 1H), 4.08 (t, <i>J</i> = 6.5 Hz, 2H), 3.90 (s, 3H), 1.87–1.83 (m, 2H), 1.58–1.48 (m, 2H), 1.27 (d, <i>J</i> = 6.7 Hz, 6H), 1.02 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Methyl 6-Cyano-2-((3-fluoro-4-isopropoxyphenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (<b>17d</b>)</h3><div class="NLM_p last">DABCO (62 mg, 0.55 mmol) was added to a solution of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate (200 mg, 1 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. NCS (147 mg, 1.1 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of 3-fluoro-4-isopropoxy-<i>N</i>-isopropylaniline (211 mg, 1 mmol) and trichloroacetic acid (41 mg, 0.25 mmol) in DCM (5 mL) was added dropwise and the reaction was stirred for 2 h at RT. The reaction was quenched by adding H<sub>2</sub>O and the mixture was extracted with DCM. Solvent was removed under vacuum and the residue was purified by silica gel chromatography with hexane/EtOAc (4/1, v/v) to afford the title compound as a colorless oil (220 mg, 54% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 8.05 (d, <i>J</i> = 8.3 Hz, 1H), 7.85 (s, 1H), 7.45–7.33 (m, 2H), 6.99 (t, <i>J</i> = 8.9 Hz, 1H), 6.91 (dd, <i>J</i> = 12.1, 2.7 Hz, 1H), 6.82–6.80 (m, 1H), 4.81 (m, 1H), 4.54 (m, 1H), 3.86 (s, 3H), 1.39 (d, <i>J</i> = 6.1 Hz, 6H), 1.31–1.21 (m, 6H).</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 3-Fluoro-5-isopropyl-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>18a</b>)</h3><div class="NLM_p last">Methyl 6-cyano-2-((3-fluoro-4-methoxyphenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (250 mg, 0.66 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration. The precipitate was purified by silica gel chromatography with hexane/EtOAc (2/1, v/v) to afford the title compound as a pale yellow solid (175 mg, 76% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.15 (s, 1H), 8.32 (d, <i>J</i> = 8.0 Hz, 1H), 8.04–7.94 (m, 2H), 7.90 (d, <i>J</i> = 1.3 Hz, 1H), 7.63 (dd, <i>J</i> = 8.0, 1.3 Hz, 1H), 5.35–5.27 (m, 1H), 3.98 (s, 3H), 1.73 (d, <i>J</i> = 6.9 Hz, 6H).</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 3-Fluoro-5-isopropyl-11-oxo-2-propoxy-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>18b</b>)</h3><div class="NLM_p last">Methyl 6-cyano-2-((3-fluoro-4-propoxyphenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (235 mg, 0.57 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration to afford the title compound as a pale yellow solid (130 mg, 60% yield). This product was used directly in the next step without further purification. MS: <i>m</i>/<i>z</i> = 378 [M + H].</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 2-Butoxy-3-fluoro-5-isopropyl-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>18c</b>)</h3><div class="NLM_p last">Methyl 2-((4-butoxy-3-fluorophenyl)(isopropyl)amino)-6-cyano-1<i>H</i>-indole-3-carboxylate (245 mg, 0.58 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration to afford the title compound as a pale yellow solid (165 mg, 73% yield). This product was used directly in the next step without further purification. MS: <i>m</i>/<i>z</i> = 392 [M + H].</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 3-Fluoro-2-isopropoxy-5-isopropyl-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>18d</b>)</h3><div class="NLM_p last">Methyl 6-cyano-2-((3-fluoro-4-isopropoxyphenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (220 mg, 0.54 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration to afford the title compound as a pale yellow solid (130 mg, 70% yield). This product was used directly in the next step without further purification. MS: <i>m</i>/<i>z</i> = 378 [M + H].</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 5-Isopropyl-2-methoxy-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>8f</b>)</h3><div class="NLM_p last">1-Methylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 3-fluoro-5-isopropyl-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (175 mg, 0.50 mmol) in DMSO (2 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound as a pale yellow solid (56 mg, 26% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.42 (d, <i>J</i> = 8.1 Hz, 1H), 8.00 (s, 1H), 7.82 (s, 1H), 7.57 (d, <i>J</i> = 8.1 Hz, 1H), 7.36 (s, 1H), 5.44–5.35 (m, 1H), 4.05 (s, 3H), 4.02–3.92 (m, 2H), 3.70–3.63 (m, 2H), 3.50–3.18 (m, 4H), 3.05 (s, 3H), 1.88 (d, <i>J</i> = 7.1 Hz, 6H).</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 5-Isopropyl-3-(4-methylpiperazin-1-yl)-11-oxo-2-propoxy-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>8g</b>)</h3><div class="NLM_p last">1-Methylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 3-fluoro-5-isopropyl-11-oxo-2-propoxy-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (130 mg, 0.34 mmol) in DMSO (2 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound as a pale yellow solid (28 mg, 18% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.37 (d, <i>J</i> = 8.1 Hz, 1H), 7.93 (s, 1H), 7.78 (s, 1H), 7.54 (d, <i>J</i> = 8.1 Hz, 1H), 7.33 (s, 1H), 5.46–5.25 (m, 1H), 4.18 (t, <i>J</i> = 6.4 Hz, 2H), 4.10–3.97 (m, 2H), 3.75–3.65 (m, 2H), 3.50–3.20 (m, 4H), 3.06 (s, 3H), 2.03–1.94 (m, 2H), 1.88 (d, <i>J</i> = 7.1 Hz, 6H), 1.17 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 2-Butoxy-5-isopropyl-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>8h</b>)</h3><div class="NLM_p last">1-Methylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 2-butoxy-3-fluoro-5-isopropyl-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (165 mg, 0.42 mmol) in DMSO (2 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound as a pale yellow solid (36 mg, 18% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.39 (d, <i>J</i> = 8.1 Hz, 1H), 7.95 (s, 1H), 7.79 (d, <i>J</i> = 1.4 Hz, 1H), 7.55 (dd, <i>J</i> = 8.1, 1.4 Hz, 1H), 7.32 (s, 1H), 5.40–5.32 (m, 1H), 4.21 (t, <i>J</i> = 6.4 Hz, 2H), 3.99–3.95 (m, 2H), 3.71–3.69 (m, 2H), 3.43–3.40 (m, 2H), 3.28–3.12 (m, 2H), 3.04 (s, 3H), 1.96–1.89 (m, 2H), 1.87 (d, <i>J</i> = 7.1 Hz, 6H), 1.68–1.54 (m, 2H), 1.06 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 2-Isopropoxy-5-isopropyl-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>8i</b>)</h3><div class="NLM_p last">1-Methylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 3-fluoro-2-isopropoxy-5-isopropyl-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (130 mg, 0.34 mmol) in DMSO (2 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound as a pale yellow solid (35 mg, 22% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.43 (d, <i>J</i> = 8.6 Hz, 1H), 8.01 (s, 1H), 7.84 (s, 1H), 7.59 (d, <i>J</i> = 8.6 Hz, 1H), 7.36 (s, 1H), 5.42–5.35 (m, 1H), 4.90–4.80 (m, 1H), 4.02–3.95 (m, 2H), 3.70–3.63 (m, 2H), 3.50–3.10 (m, 4H), 3.05 (s, 3H), 1.88 (d, <i>J</i> = 7.1 Hz, 6H), 1.47 (d, <i>J</i> = 6.0 Hz, 6H).</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Methyl 6-Cyano-2-((2,3-difluorophenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (<b>19a</b>)</h3><div class="NLM_p last">DABCO (62 mg, 0.55 mmol) was added to a solution of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate (200 mg, 1 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. NCS (147 mg, 1.1 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of 2,3-difluoro-<i>N</i>-isopropylaniline (171 mg, 1 mmol) and trichloroacetic acid (41 mg, 0.25 mmol) in DCM (5 mL) was added dropwise and the reaction was stirred for 2 h at RT. The reaction was quenched by adding H<sub>2</sub>O and the mixture was extracted with DCM. Solvent was removed under vacuum and the residue was purified by silica gel chromatography with hexane/EtOAc (4/1, v/v) to afford the title compound as a colorless oil (200 mg, 54% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.18 (s, 1H), 8.09 (d, <i>J</i> = 8.4 Hz, 1H), 7.51 (d, <i>J</i> = 1.4 Hz, 1H), 7.45 (dd, <i>J</i> = 8.4, 1.4 Hz, 1H), 7.17–7.07 (m, 3H), 4.77–4.61 (m, 1H), 3.82 (s, 3H), 1.34 (d, <i>J</i> = 6.6 Hz, 6H).</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Methyl 6-Cyano-2-(isopropyl(2,3,4-trifluorophenyl)amino)-1<i>H</i>-indole-3-carboxylate (<b>19b</b>)</h3><div class="NLM_p last">DABCO (62 mg, 0.55 mmol) was added to a solution of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate (200 mg, 1 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. NCS (147 mg, 1.1 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of 2,3,4-trifluoro-<i>N</i>-isopropylaniline (189 mg, 1 mmol) and trichloroacetic acid (41 mg, 0.25 mmol) in DCM (5 mL) were added dropwise and the reaction was stirred for 2 h at RT. The reaction was quenched by adding H<sub>2</sub>O and the mixture was extracted with DCM. Solvent was removed under vacuum and the residue was purified by silica gel chromatography with hexane/EtOAc (4/1, v/v) to afford the title compound as a colorless oil (210 mg, 54% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.36 (s, 1H), 8.07 (d, <i>J</i> = 8.3 Hz, 1H), 7.53 (d, <i>J</i> = 1.4 Hz, 1H), 7.44 (dd, <i>J</i> = 8.3, 1.4 Hz, 1H), 7.15–7.10 (m, 1H), 7.05–7.00 (m, 1H), 4.65–4.60 (m, 1H), 3.82 (s, 3H), 1.33 (dd, <i>J</i> = 6.5, 0.9 Hz, 6H).</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Methyl 6-Cyano-2-((2,3-difluoro-4-methoxyphenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (<b>19c</b>)</h3><div class="NLM_p last">DABCO (62 mg, 0.55 mmol) was added to a solution of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate (200 mg, 1 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. NCS (147 mg, 1.1 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of 2,3-difluoro-<i>N</i>-isopropyl-4-methoxyaniline (201 mg, 1 mmol) and trichloroacetic acid (41 mg, 0.25 mmol) in DCM (5 mL) were added dropwise and the reaction was stirred for 2 h at RT. The reaction was quenched by adding H<sub>2</sub>O and the mixture was extracted with DCM. The solvent was removed under vacuum and the residue was purified by silica gel chromatography with hexane/EtOAc (4/1, v/v) to afford the title compound as a colorless oil (225 mg, 56% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.25 (s, 1H), 8.02 (d, <i>J</i> = 8.0 Hz, 1H), 7.45–7.36 (m, 2H), 7.13–7.06 (m, 1H), 6.846.80 (m, 1H), 4.85–4.79 (m, 1H), 3.95 (s, 3H), 3.85 (s, 3H), 1.27 (dd, <i>J</i> = 6.5, 1.1 Hz, 6H).</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 3,4-Difluoro-5-isopropyl-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>20a</b>)</h3><div class="NLM_p last">Methyl 6-cyano-2-((2,3-difluorophenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (200 mg, 0.54 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration to afford the title compound as a pale yellow solid (112 mg, 61% yield). This product was used directly in the next step without further purification. MS: <i>m</i>/<i>z</i> = 338 [M + H].</div></div><div id="sec5_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 2,3,4-Trifluoro-5-isopropyl-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>20b</b>)</h3><div class="NLM_p last">Methyl 6-cyano-2-(isopropyl(2,3,4-trifluorophenyl)amino)-1<i>H</i>-indole-3-carboxylate (210 mg, 0.54 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration to afford the title compound as a pale yellow solid (100 mg, 52% yield). This product was used directly in the next step without further purification. MS: <i>m</i>/<i>z</i> = 356 [M + H].</div></div><div id="sec5_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 3,4-Difluoro-5-isopropyl-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>20c</b>)</h3><div class="NLM_p last">Methyl 6-cyano-2-((2,3-difluoro-4-methoxyphenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (225 mg, 0.56 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration to afford the title compound as a pale yellow solid (135 mg, 65% yield). This product was used directly in the next step without further purification. MS: <i>m</i>/<i>z</i> = 368 [M + H].</div></div><div id="sec5_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 4-Fluoro-5-isopropyl-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>9a</b>)</h3><div class="NLM_p last">1-Methylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 3,4-difluoro-5-isopropyl-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (112 mg, 0.33 mmol) in DMSO (2 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound as a pale yellow solid (22 mg, 16% yield). MS: <i>m</i>/<i>z</i> = 418 [M + H].</div></div><div id="sec5_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 2,4-Difluoro-5-isopropyl-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>9b</b>)</h3><div class="NLM_p last">1-Methylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 2,3,4-trifluoro-5-isopropyl-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (100 mg, 0.28 mmol) in DMSO (2 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction was cooled down to RT and purified by preparative HPLC to afford the title compound as a pale yellow solid (25 mg, 20% yield). MS: <i>m</i>/<i>z</i> = 436 [M + H]. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.16 (s, 1H), 8.24 (d, <i>J</i> = 8.0 Hz, 1H), 7.90 (d, <i>J</i> = 1.3 Hz, 1H), 7.82 (dd, <i>J</i> = 11.8, 1.6 Hz, 1H), 7.61 (dd, <i>J</i> = 8.0, 1.3 Hz, 1H), 5.02 (hept, <i>J</i> = 7.0 Hz, 1H), 3.61–3.52 (m, 4H), 3.44–3.24 (m, 4H), 2.91 (s, 3H), 1.66 (dd, <i>J</i> = 7.0, 1.9 Hz, 6H).</div></div><div id="sec5_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 4-Fluoro-5-isopropyl-2-methoxy-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>9c</b>)</h3><div class="NLM_p last">1-Methylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 3,4-difluoro-5-isopropyl-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (135 mg, 0.37 mmol) in DMSO (2 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound as a pale yellow solid (24 mg, 15% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD + CDCl<sub>3</sub>) δ ppm 8.33 (d, <i>J</i> = 8.0 Hz, 1H), 7.77 (s, 1H), 7.72 (s, 1H), 7.48 (d, <i>J</i> = 8.0 Hz, 1H), 5.20–5.00 (m, 1H), 4.04 (s, 3H), 3.80–3.50 (m, 6H), 3.40–3.25 (m, 2H), 3.00 (s, 3H), 1.74 (dd, <i>J</i> = 5.6, 1.8 Hz, 6H).</div></div><div id="sec5_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Methyl 6-Cyano-2-(ethyl(3-fluoro-4-methoxyphenyl)amino)-1<i>H</i>-indole-3-carboxylate (<b>23a</b>)</h3><div class="NLM_p last">DABCO (62 mg, 0.55 mmol) was added to a solution of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate (200 mg, 1 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. NCS (147 mg, 1.1 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of <i>N</i>-ethyl-3-fluoro-4-methoxyaniline (169 mg, 1 mmol) and trichloroacetic acid (41 mg, 0.25 mmol) in DCM (5 mL) was added dropwise and the reaction was stirred for 2 h at RT. The reaction was quenched by adding H<sub>2</sub>O and the mixture was extracted with DCM. The solvent was removed under vacuum and the residue was purified by silica gel chromatography with hexane/EtOAc (4/1, v/v) to afford the title compound as a colorless oil (160 mg, 44% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.31 (s, 1H), 8.09 (d, <i>J</i> = 8.7 Hz, 1H), 7.47–7.39 (m, 2H), 7.02–6.84 (m, 3H), 4.01 (q, <i>J</i> = 7.1 Hz, 2H), 3.89 (s, 3H), 3.87 (s, 3H), 1.30 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec5_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Methyl 6-Cyano-2-((3-fluoro-4-methoxyphenyl)(propyl)amino)-1<i>H</i>-indole-3-carboxylate (<b>23b</b>)</h3><div class="NLM_p last">DABCO (62 mg, 0.55 mmol) was added to a solution of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate (200 mg, 1 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. NCS (147 mg, 1.1 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of <i>N</i>-propyl-3-fluoro-4-methoxyaniline (183 mg, 1 mmol) and trichloroacetic acid (41 mg, 0.25 mmol) in DCM (5 mL) was added dropwise and the reaction was stirred for 2 h at RT. The reaction was quenched by adding H<sub>2</sub>O and the mixture was extracted with DCM. The solvent was removed under vacuum and the residue was purified by silica gel chromatography with hexane/EtOAc (4/1, v/v) to afford the title compound as a colorless oil (170 mg, 45% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm δ 8.28 (s, 1H), 8.10 (d, <i>J</i> = 8.7 Hz, 1H), 7.47–7.41 (m, 2H), 7.02–6.79 (m, 3H), 4.00–3.79 (m, 8H), 1.80–1.65 (m, 2H), 0.96 (q, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec5_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Methyl 2-(<i>sec</i>-Butyl(3-fluoro-4-methoxyphenyl)amino)-6-cyano-1<i>H</i>-indole-3-carboxylate (<b>23c</b>)</h3><div class="NLM_p last">DABCO (62 mg, 0.55 mmol) was added to a solution of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate (200 mg, 1 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. NCS (147 mg, 1.1 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of <i>N</i>-(<i>sec</i>-butyl)-3-fluoro-4-methoxyaniline (197 mg, 1 mmol) and trichloroacetic acid (41 mg, 0.25 mmol) in DCM (5 mL) was added dropwise and the reaction was stirred for 2 h at RT. The reaction was quenched by adding H<sub>2</sub>O and the mixture was extracted with DCM. The solvent was removed under vacuum and the residue was purified by silica gel chromatography with hexane/EtOAc (4/1, v/v) to afford the title compound as a colorless oil (210 mg, 53% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.05 (d, <i>J</i> = 8.3 Hz, 1H), 7.93 (s, 1H), 7.41 (dd, <i>J</i> = 8.3, 1.4 Hz, 1H), 7.37 (d, <i>J</i> = 1.4 Hz, 1H), 7.07–6.85 (m, 3H), 4.60–4.54 (m, 1H), 3.93 (s, 3H), 3.88 (s, 3H), 1.79–1.75 (m, 1H), 1.54–1.51 (m, 1H), 1.26 (d, <i>J</i> = 6.7 Hz, 3H), 0.98 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec5_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Methyl 6-Cyano-2-((3-fluoro-4-methoxyphenyl)(pentan-2-yl)amino)-1<i>H</i>-indole-3-carboxylate (<b>23d</b>)</h3><div class="NLM_p last">DABCO (62 mg, 0.55 mmol) was added to a solution of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate (200 mg, 1 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. NCS (147 mg, 1.1 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of 3-fluoro-4-methoxy-<i>N</i>-(pentan-2-yl)aniline (211 mg, 1 mmol) and trichloroacetic acid (41 mg, 0.25 mmol) in DCM (5 mL) was added dropwise and the reaction was stirred for 2 h at RT. The reaction was quenched by adding H<sub>2</sub>O and the mixture was extracted with DCM. The solvent was removed under vacuum and the residue was purified by silica gel chromatography with hexane/EtOAc (4/1, v/v) to afford the title compound as a colorless oil (196 mg, 48% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.05 (d, <i>J</i> = 8.3 Hz, 1H), 7.77 (br s, 1H), 7.41 (dd, <i>J</i> = 8.3, 1.5 Hz, 1H), 7.36 (d, <i>J</i> = 1.5 Hz, 1H), 7.07–6.90 (m, 3H), 4.78–4.61 (m, 1H), 3.95 (s, 3H), 3.89 (s, 3H), 1.72–1.65 (m, 1H), 1.49–1.41 (m, 3H), 1.26 (d, <i>J</i> = 6.8 Hz, 3H), 0.92 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec5_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Methyl 6-Cyano-2-(cyclopropyl(3-fluoro-4-methoxyphenyl)amino)-1<i>H</i>-indole-3-carboxylate (<b>23e</b>)</h3><div class="NLM_p last">DABCO (62 mg, 0.55 mmol) was added to a solution of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate (200 mg, 1 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. <i>N</i>-Chlorosuccinimide (147 mg, 1.1 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of <i>N</i>-cyclopropyl-3-fluoro-4-methoxyaniline (181 mg, 1 mmol) and trichloroacetic acid (41 mg, 0.25 mmol) in DCM (5 mL) was added dropwise and the reaction was stirred for 2 h at room temperature. The reaction was quenched by adding water and the mixture was extracted with DCM. The solvent was removed under vacuum and the residue was purified by silica gel chromatography (Hex:EA = 4:1) to afford the title compound (180 mg, 47% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.94 (s, 1H), 8.17 (d, <i>J</i> = 8.4 Hz, 1H), 7.57 (d, <i>J</i> = 1.4 Hz, 1H), 7.48 (dd, <i>J</i> = 8.4, 1.4 Hz, 1H), 6.94–6.82 (m, 2H), 6.77–6.69 (m, 1H), 3.85 (s, 3H), 3.74 (s, 3H), 3.17–2.99 (m, 1H), 1.00–0.93 (m, 2H), 0.81–0.74 (m, 2H).</div></div><div id="sec5_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Methyl 6-Cyano-2-(cyclobutyl(3-fluoro-4-methoxyphenyl)amino)-1<i>H</i>-indole-3-carboxylate (<b>23f</b>)</h3><div class="NLM_p last">DABCO (62 mg, 0.55 mmol) was added to a solution of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate (200 mg, 1 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. NCS (147 mg, 1.1 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of <i>N</i>-cyclobutyl-3-fluoro-4-methoxyaniline (195 mg, 1 mmol) and trichloroacetic acid (41 mg, 0.25 mmol) in DCM (5 mL) was added dropwise and the reaction was stirred for 2 h at RT. The reaction was quenched by adding H<sub>2</sub>O and the mixture was extracted with DCM. The solvent was removed under vacuum and the residue was purified by silica gel chromatography with hexane/EtOAc (4/1, v/v) to afford the title compound as a colorless oil (245 mg, 62% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.62 (s, 1H), 8.17 (d, <i>J</i> = 8.4 Hz, 1H), 7.55 (d, <i>J</i> = 1.5 Hz, 1H), 7.47 (dd, <i>J</i> = 8.4, 1.5 Hz, 1H), 6.89 (t, <i>J</i> = 9.1 Hz, 1H), 6.64 (dd, <i>J</i> = 12.9, 2.8 Hz, 1H), 6.60–6.51 (m, 1H), 4.55–4.43 (m, 1H), 3.86 (s, 3H), 3.81 (s, 3H), 2.40–2.28 (m, 2H), 2.00–1.90 (m, 2H), 1.77–1.63 (m, 2H).</div></div><div id="sec5_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Methyl 6-Cyano-2-(cyclopentyl(3-fluoro-4-methoxyphenyl)amino)-1<i>H</i>-indole-3-carboxylate (<b>23g</b>)</h3><div class="NLM_p last">DABCO (62 mg, 0.55 mmol) was added to a solution of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate (200 mg, 1 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. NCS (147 mg, 1.1 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of <i>N</i>-cyclopentyl-3-fluoro-4-methoxyaniline (209 mg, 1 mmol) and trichloroacetic acid (41 mg, 0.25 mmol) in DCM (5 mL) was added dropwise and the reaction was stirred for 2 h at RT. The reaction was quenched by adding H<sub>2</sub>O and the mixture was extracted with DCM. Solvent was removed under vacuum and the residue was purified by silica gel chromatography with hexane/EtOAc (4/1, v/v) to afford the title compound as a colorless oil (280 mg, 69% yield).<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.55 (s, 1H), 8.13 (d, <i>J</i> = 8.3 Hz, 1H), 7.50 (d, <i>J</i> = 1.4 Hz, 1H), 7.44 (dd, <i>J</i> = 8.3, 1.4 Hz, 1H), 6.92 (t, <i>J</i> = 9.1 Hz, 1H), 6.79 (dd, <i>J</i> = 12.7, 2.7 Hz, 1H), 6.75–6.71 (m, 1H), 4.61–4.52 (m, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 2.09–1.98 (m, 2H), 1.66–1.62 (m, 4H), 1.59–1.47 (m, 2H).</div></div><div id="sec5_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Methyl 6-Cyano-2-(cyclohexyl(3-fluoro-4-methoxyphenyl)amino)-1<i>H</i>-indole-3-carboxylate (<b>23h</b>)</h3><div class="NLM_p last">DABCO (62 mg, 0.55 mmol) was added to a solution of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate (200 mg, 1 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. NCS (147 mg, 1.1 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of <i>N</i>-cyclohexyl-3-fluoro-4-methoxyaniline (223 mg, 1 mmol) and trichloroacetic acid (41 mg, 0.25 mmol) in DCM (5 mL) was added dropwise and the reaction was stirred for 2 h at RT. The reaction was quenched by adding H<sub>2</sub>O and the mixture was extracted with DCM. The solvent was removed under vacuum and the residue was purified by silica gel chromatography with hexane/EtOAc (4/1, v/v) to afford the title compound as a colorless oil (240 mg, 57% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.06 (d, <i>J</i> = 8.3 Hz, 1H), 8.02 (s, 1H), 7.45–7.37 (m, 2H), 7.04–6.82 (m, 3H), 4.37–4.26 (m, 1H), 3.92 (s, 3H), 3.88 (s, 3H), 2.10–2.06 (m, 2H), 1.85–1.62 (m, 2H), 1.67–1.63 (m, 2H), 1.47–1.35 (m, 2H), 1.30–1.27 (m, 2H).</div></div><div id="sec5_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 5-Ethyl-3-fluoro-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>24a</b>)</h3><div class="NLM_p last">Methyl 6-cyano-2-(ethyl(3-fluoro-4-methoxyphenyl)amino)-1<i>H</i>-indole-3-carboxylate (160 mg, 0.44 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h and then cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration. The precipitate was purified by silica gel chromatography with hexane/EtOAc (2/1, v/v) to afford the title compound as a colorless oil (98 mg, 67% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 12.58 (s, 1H), 8.29 (d, <i>J</i> = 8.1 Hz, 1H), 7.98 (d, <i>J</i> = 9.7 Hz, 1H), 7.94–7.84 (m, 2H), 7.62 (dd, <i>J</i> = 8.1, 1.5 Hz, 1H), 4.52 (d, <i>J</i> = 7.4 Hz, 2H), 3.97 (s, 3H), 1.38 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec5_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> 3-Fluoro-2-methoxy-11-oxo-5-propyl-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>24b</b>)</h3><div class="NLM_p last">Methyl 6-cyano-2-(propyl(3-fluoro-4-methoxyphenyl)amino)-1<i>H</i>-indole-3-carboxylate (150 mg, 0.39 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h and then cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration. The precipitate was purified by silica gel chromatography with hexane/EtOAc (2/1, v/v) to afford the title compound as a colorless oil (95 mg, 69% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 12.50 (s, 1H), 8.30 (d, <i>J</i> = 8.0 Hz, 1H), 7.98 (d, <i>J</i> = 9.7 Hz, 1H), 7.93–7.82 (m, 2H), 7.62 (dd, <i>J</i> = 8.0, 1.4 Hz, 1H), 4.41 (t, <i>J</i> = 7.8 Hz, 2H), 3.98 (s, 3H), 1.80 (q, <i>J</i> = 7.8 Hz, 2H), 1.02 (t, <i>J</i> = 7.8 Hz, 3H).</div></div><div id="sec5_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 5-(<i>sec</i>-Butyl)-3-fluoro-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>24c</b>)</h3><div class="NLM_p last">Methyl 2-(<i>sec</i>-butyl(3-fluoro-4-methoxyphenyl)amino)-6-cyano-1<i>H</i>-indole-3-carboxylate (210 mg, 0.53 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration. The precipitate (150 mg, 78% yield) was used directly in the next step without further purification.</div></div><div id="sec5_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> 3-Fluoro-2-methoxy-11-oxo-5-(pentan-2-yl)-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>24d</b>)</h3><div class="NLM_p last">Methyl 6-cyano-2-((3-fluoro-4-methoxyphenyl)(pentan-2-yl)amino)-1<i>H</i>-indole-3-carboxylate (196 mg, 0.48 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration. The precipitate was purified by silica gel chromatography with hexane/EtOAc (2/1, v/v) to afford the title compound as a pale yellow solid (148 mg, 82% yield). MS <i>m</i>/<i>z</i> = 378 [M + H]. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.43 (d, <i>J</i> = 8.0 Hz, 1H), 8.00 (s, 1H), 7.82 (s, 1H), 7.58 (d, <i>J</i> = 8.0 Hz, 1H), 7.36 (s, 1H), 5.05–4.85 (m, 1H), 4.05 (s, 3H), 4.00–3.82 (m, 2H), 3.75–3.60 (m, 2H), 3.50–3.10 (m, 4H), 3.05 (s, 3H), 2.50–2.10 (m, 2H), 1.95–1.75 (m, 3H), 1.50–1.15 (m, 2H), 0.91 (t, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec5_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> 5-Cyclopropyl-3-fluoro-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>24e</b>)</h3><div class="NLM_p last">Methyl 6-cyano-2-(cyclopropyl(3-fluoro-4-methoxyphenyl)amino)-1<i>H</i>-indole-3-carboxylate (180 mg, 0.47 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration. The precipitate was purified by silica gel chromatography (Hex:EA = 2:1) to afford the title compound (102 mg, 62% yield). MS <i>m</i>/<i>z</i> = 348 [M + H].</div></div><div id="sec5_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> 5-Cyclobutyl-3-fluoro-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>24f</b>)</h3><div class="NLM_p last">Methyl 6-cyano-2-(cyclobutyl(3-fluoro-4-methoxyphenyl)amino)-1<i>H</i>-indole-3-carboxylate (245 mg, 0.66 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration. The precipitate (155 mg, 65% yield) was used directly in the next step without further purification.</div></div><div id="sec5_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> 5-Cyclopentyl-3-fluoro-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>24g</b>)</h3><div class="NLM_p last">Methyl 6-cyano-2-(cyclopentyl(3-fluoro-4-methoxyphenyl)amino)-1<i>H</i>-indole-3-carboxylate (280 mg, 0.69 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration. The precipitate (130 mg, 50% yield) was used directly in the next step without further purification.</div></div><div id="sec5_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> 5-Cyclohexyl-3-fluoro-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>24h</b>)</h3><div class="NLM_p last">Methyl 6-cyano-2-(cyclohexyl(3-fluoro-4-methoxyphenyl)amino)-1<i>H</i>-indole-3-carboxylate (240 mg, 0.57 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration. The precipitate (160 mg, 72% yield) was used directly in the next step without further purification.</div></div><div id="sec5_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> 5-Ethyl-2-methoxy-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>10a</b>)</h3><div class="NLM_p last">1-Methylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 5-ethyl-3-fluoro-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (98 mg, 0.29 mmol) in DMSO (2 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound as a pale yellow solid (25 mg, 21% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.31 (d, <i>J</i> = 7.6 Hz, 1H), 7.91 (s, 1H), 7.59 (d, <i>J</i> = 0.7 Hz, 1H), 7.50 (dd, <i>J</i> = 7.6, 0.7 Hz, 1H), 7.06 (s, 1H), 4.50 (q, <i>J</i> = 7.3 Hz, 2H), 4.06 (s, 3H), 4.04–3.86 (m, 2H), 3.75–3.63 (m, 2H), 3.50–3.37 (m, 2H), 3.26–3.17 (m, 2H), 3.05 (s, 3H), 1.53 (t, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec5_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> 5-Propyl-2-methoxy-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>10b</b>)</h3><div class="NLM_p last">1-Methylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 5-propyl-3-fluoro-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (90 mg, 0.26 mmol) in DMSO (2 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound as a pale yellow solid (22 mg, 20% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.50 (s, 1H), 9.97 (s, 1H), 8.29 (d, <i>J</i> = 8.1 Hz, 1H), 7.92–7.74 (m, 2H), 7.60 (dd, <i>J</i> = 8.1, 1.5 Hz, 1H), 7.09 (s, 1H), 4.49 (t, <i>J</i> = 7.6 Hz, 2H), 3.94 (s, 3H), 3.84 (d, <i>J</i> = 11.8 Hz, 2H), 3.59 (d, <i>J</i> = 11.8 Hz, 2H), 3.33–3.25 (m, 2H), 3.10 (m, 2H), 2.92 (s, 3H), 1.86 (m, 2H), 1.01 (t, <i>J</i> = 7.5 Hz, 3H).</div></div><div id="sec5_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> 5-(<i>sec</i>-Butyl)-2-methoxy-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>10c</b>)</h3><div class="NLM_p last">1-Methylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 5-(<i>sec</i>-butyl)-3-fluoro-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (150 mg, 0.41 mmol) in DMSO (2 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound as a pale yellow solid (35 mg, 19% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.46 (d, <i>J</i> = 8.1 Hz, 1H), 8.02 (s, 1H), 7.84 (s, 1H), 7.59 (d, <i>J</i> = 8.1, Hz, 1H), 7.36 (s, 1H), 5.05–4.80 (m, 1H), 4.05 (s, 3H), 4.02–3.79 (m, 2H), 3.77–3.61 (m, 2H), 3.51–3.32 (m, 2H), 3.28–3.12 (m, 2H), 3.03 (s, 3H), 2.48–2.40 (m, 1H), 2.25–2.18 (m, 1H), 1.88 (d, <i>J</i> = 6.8 Hz, 3H), 0.90 (t, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec5_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> 2-Methoxy-3-(4-methylpiperazin-1-yl)-11-oxo-5-(pentan-2-yl)-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>10d</b>)</h3><div class="NLM_p last">1-Methylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 3-fluoro-2-methoxy-11-oxo-5-(pentan-2-yl)-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (148 mg, 0.39 mmol) in DMSO (2 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction was cooled down to RT and purified by preparative HPLC to afford the title compound as a pale yellow solid (45 mg, 23% yield). MS: <i>m</i>/<i>z</i> = 458 [M + H]. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.98 (s, 1H), 8.32 (d, <i>J</i> = 8.0 Hz, 1H), 7.91–7.87 (m, 2H), 7.61 (dd, <i>J</i> = 8.0, 1.4 Hz, 1H), 7.23 (s, 1H), 5.11–5.05 (m, 1H), 3.95 (s, 3H), 3.86–3.77 (m, 2H), 3.59 (d, <i>J</i> = 11.9 Hz, 2H), 3.35–3.23 (m, 2H), 3.12–3.02 (m, 2H), 2.92 (s, 3H), 2.35–2.20 (m, 1H), 2.05–2.01 (m, 1H), 1.76 (d, <i>J</i> = 6.9 Hz, 3H), 1.32–1.25 (m, 1H), 1.11–1.05 (m, 1H), 0.83 (t, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec5_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> 5-Cyclopropyl-2-methoxy-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>10e</b>)</h3><div class="NLM_p last">1-Methylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 5-cyclopropyl-3-fluoro-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (160 mg, 0.41 mmol) in DMSO (2 mL) and the mixture was heated to 120 to 140 °C for 3 days. The reaction was cooled down to RT and purified by preparative HPLC to afford the title compound (36 mg, 18% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.27 (d, <i>J</i> = 7.8 Hz, 1H), 7.84 (s, 1H), 7.70 (s, 1H), 7.54 (s, 1H), 7.47 (d, <i>J</i> = 7.8 Hz, 1H), 4.04 (s, 3H), 4.03–3.90 (m, 2H), 3.72–3.63 (m, 2H), 3.60–3.37 (m, 3H), 3.25–3.12 (m, 2H), 3.05 (s, 3H), 1.66–1.57 (m, 2H), 1.30–1.18 (m, 2H).</div></div><div id="sec5_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> 5-Cyclobutyl-2-methoxy-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>10f</b>)</h3><div class="NLM_p last">1-Methylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 5-cyclobutyl-3-fluoro-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (155 mg, 0.50 mmol) in DMSO (2 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound as a pale yellow solid (43 mg, 20% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.39 (d, <i>J</i> = 8.1 Hz, 1H), 7.94 (s, 1H), 7.79 (s, 1H), 7.55 (d, <i>J</i> = 8.1 Hz, 1H), 7.14 (s, 1H), 5.31–5.25 (m, 1H), 4.03 (s, 3H), 3.95–3.91 (m, 2H), 3.69–3.65 (m, 2H), 3.45–3.37 (m, 2H), 3.19–3.14 (m, 2H), 3.07–2.99 (m, 5H), 2.68–2.53 (m, 2H), 2.04–2.02 (m, 2H).</div></div><div id="sec5_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> 5-Cyclopentyl-2-methoxy-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>10g</b>)</h3><div class="NLM_p last">1-Methylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 5-cyclopentyl-3-fluoro-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (130 mg, 0.35 mmol) in DMSO (2 mL) and the mixture was heated to 120 to 140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound as a pale yellow solid (51 mg, 32% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.29 (d, <i>J</i> = 8.1 Hz, 1H), 7.94 (s, 1H), 7.65 (d, <i>J</i> = 1.3 Hz, 1H), 7.45 (dd, <i>J</i> = 8.1, 1.3 Hz, 1H), 7.08 (s, 1H), 5.40–5.28 (m, 1H), 4.03 (s, 3H), 3.96–3.94 (m, 2H), 3.71–3.67 (m, 2H), 3.51–3.18 (m, 4H), 3.03 (s, 3H), 2.54–2.47 (m, 2H), 2.41–2.13 (m, 4H), 2.10–1.89 (m, 2H).</div></div><div id="sec5_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> 5-Cyclohexyl-2-methoxy-3-(4-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (<b>10h</b>)</h3><div class="NLM_p last">1-Methylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 5-cyclohexyl-3-fluoro-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (160 mg, 0.41 mmol) in DMSO (2 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound as a pale yellow solid (53 mg, 27% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.42 (d, <i>J</i> = 8.1 Hz, 1H), 7.98 (s, 1H), 7.82 (d, <i>J</i> = 1.4 Hz, 1H), 7.57 (dd, <i>J</i> = 8.1, 1.4 Hz, 1H), 7.42 (s, 1H), 4.90–4.78 (m, 1H),4.03 (s, 3H), 4.00–3.82 (m, 2H), 3.69–3.63 (m, 2H), 3.50–3.37(m, 2H), 3.21–3.11(m, 2H), 3.04 (s, 3H), 2.70–2.49 (m, 2H), 2.11–1.40 (m, 8H).</div></div><div id="sec5_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> (<i>S</i>)-4-Fluoro-5-isopropyl-2-methoxy-3-(3-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (CJ-2349)</h3><div class="NLM_p last">(<i>S</i>)-2-Methylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 3,4-difluoro-5-isopropyl-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (367 mg, 1.0 mmol) in DMSO (3 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound (150 mg, 33% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.36 (d, <i>J</i> = 8.1 Hz, 1H), 7.82–7.76 (m, 2H), 7.55 (d, <i>J</i> = 8.1 Hz, 1H), 5.15–5.08 (m, 1H), 4.04 (s, 3H), 3.65–3.55 (m, 5H), 3.50–3.45 (m, 1H), 3.44–3.35 (m, 1H), 1.80–1.72 (m, 6H), 1.41 (d, <i>J</i> = 6.4 Hz, 3H).</div></div><div id="sec5_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> (<i>R</i>)-4-Fluoro-5-isopropyl-2-methoxy-3-(3-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (CJ-2350)</h3><div class="NLM_p last">(<i>R</i>)-2-Methylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 3,4-difluoro-5-isopropyl-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (367 mg, 1.0 mmol) in DMSO (3 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound (132 mg, 30% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.36 (d, <i>J</i> = 8.1 Hz, 1H), 7.82–7.76 (m, 2H), 7.55 (d, <i>J</i> = 8.1 Hz, 1H), 5.15–5.08 (m, 1H), 4.04 (s, 3H), 3.65–3.55 (m, 5H), 3.50–3.45 (m, 1H), 3.44–3.35 (m, 1H), 1.80–1.72 (m, 6H), 1.41 (d, <i>J</i> = 6.4 Hz, 3H).</div></div><div id="sec5_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> 3-(3,3-Dimethylpiperazin-1-yl)-4-fluoro-5-isopropyl-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (CJ-2351)</h3><div class="NLM_p last">2,2-Dimethylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 3,4-difluoro-5-isopropyl-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (367 mg, 1.0 mmol) in DMSO (3 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound (200 mg, 43% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 8.34 (d, <i>J</i> = 7.8 Hz, 1H), 7.80–7.76 (m, 2H), 7.53 (d, <i>J</i> = 7.8 Hz, 1H), 5.15–5.05 (m, 1H), 4.05 (s, 3H), 3.61–3.36 (m, 6H), 1.75 (d, <i>J</i> = 6.7 Hz, 6H), 1.56 (s, 6H).</div></div><div id="sec5_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> (<i>S</i>)-3-(3,4-Dimethylpiperazin-1-yl)-4-fluoro-5-isopropyl-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (CJ-2356)</h3><div class="NLM_p last">Formaldehyde solution (37%; 33 mg, 0.40 mmol), acetic acid (12 mg, 0.20 mmol), and sodium triacetoxyborohydride (43 mg, 0.20 mmol) were added to a solution of (<i>S</i>)-4-fluoro-5-isopropyl-2-methoxy-3-(3-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (60 mg, 0.134 mmol) in DCM (10 mL) and the mixture was stirred at RT for 12 h. Water was added to quench the reaction and the mixture was extracted with DCM. The solvent was removed under vacuum and the residue was purified by preparative HPLC to afford the title compound (40 mg, 65% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.32 (d, <i>J</i> = 8.0 Hz, 1H), 7.84–7.72 (m, 2H), 7.50 (d, <i>J</i> = 8.0 Hz, 1H), 5.20–5.01 (m, 1H), 4.04 (s, 3H), 3.71–3.59 (m, 5H), 3.50–3.44 (m, 1H), 3.40–3.34 (m, 1H), 3.05 (s, 3H), 1.75 (d, <i>J</i> = 6.8 Hz, 6H), 1.47 (d, <i>J</i> = 6.2 Hz, 3H).</div></div><div id="sec5_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> (<i>R</i>)-3-(3,4-Dimethylpiperazin-1-yl)-4-fluoro-5-isopropyl-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (CJ-2357)</h3><div class="NLM_p last">Formaldehyde solution (37%; 33 mg, 0.40 mmol), acetic acid (12 mg, 0.20 mmol), and sodium triacetoxyborohydride (43 mg, 0.20 mmol) were added to a solution of (<i>R</i>)-4-fluoro-5-isopropyl-2-methoxy-3-(3-methylpiperazin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (60 mg, 0.134 mmol) in DCM (10 mL) and the mixture was stirred at RT for 12 h. Water was added to quench the reaction and the mixture was extracted with DCM. The solvent was removed under vacuum and the residue was purified by preparative HPLC to afford the title compound (47 mg, 76% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.32 (d, <i>J</i> = 8.0 Hz, 1H), 7.84–7.72 (m, 2H), 7.50 (d, <i>J</i> = 8.0 Hz, 1H), 5.20–5.01 (m, 1H), 4.04 (s, 3H), 3.71–3.59 (m, 5H), 3.50–3.44 (m, 1H), 3.40–3.34 (m, 1H), 3.05 (s, 3H), 1.75 (d, <i>J</i> = 6.8 Hz, 6H), 1.47 (d, <i>J</i> = 6.2 Hz, 3H).</div></div><div id="sec5_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> 4-Fluoro-5-isopropyl-2-methoxy-11-oxo-3-(3,3,4-trimethylpiperazin-1-yl)-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (CJ-2358)</h3><div class="NLM_p last">Formaldehyde solution (37%; 175 mg, 2.17 mmol), acetic acid (39 mg, 0.65 mmol), and sodium triacetoxyborohydride (138 mg, 0.65 mmol) were added to a solution of 3-(3,3-dimethylpiperazin-1-yl)-4-fluoro-5-isopropyl-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (200 mg, 0.43 mmol) in DCM (10 mL) and the mixture was stirred at RT for 12 h. Water was added to quench the reaction and the mixture was extracted with DCM. The solvent was removed under vacuum and the residue was purified by preparative HPLC to afford the title compound (150 mg, 73% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD + CDCl<sub>3</sub>) δ 8.39 (d, <i>J</i> = 8.0 Hz, 1H), 7.81–7.75 (m, 2H), 7.53 (d, <i>J</i> = 8.0 Hz, 1H), 5.19–4.99 (m, 1H), 4.04 (s, 3H), 3.66–3.35 (m, 6H), 2.88 (s, 3H), 1.82–1.70 (m, 6H), 1.63 (s, 3H), 1.50 (s, 3H).</div></div><div id="sec5_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> 3-(<i>cis</i>-3,5-Dimethylpiperazin-1-yl)-4-fluoro-5-isopropyl-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (CJ-2359)</h3><div class="NLM_p last"><i>cis</i>-2,6-Dimethylpiperazine (0.5 mL) and DIPEA (0.5 mL) were added to a solution of 3,4-difluoro-5-isopropyl-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (300 mg, 0.817 mmol) in DMSO (3 mL) and the mixture was heated to 120–140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound (162 mg, 43% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 8.39 (d, <i>J</i> = 8.1 Hz, 1H), 7.88–7.82 (m, 2H), 7.59 (d, <i>J</i> = 8.1 Hz, 1H), 5.15–5.01 (m, 1H), 4.04 (s, 3H), 3.70–3.50 (m, 4H), 3.40–3.32 (m, 2H), 1.76 (d, <i>J</i> = 6.5 Hz, 6H), 1.39 (d, <i>J</i> = 6.3 Hz, 6H).</div></div><div id="sec5_71" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> 4-Fluoro-5-isopropyl-2-methoxy-11-oxo-3-(<i>cis</i>-3,4,5-trimethylpiperazin-1-yl)-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (CJ-2360)</h3><div class="NLM_p last">Formaldehyde solution (37%; 175 mg, 2.17 mmol), acetic acid (39 mg, 0.65 mmol), and sodium triacetoxyborohydride (138 mg, 0.65 mmol) were added to a solution of 3-(<i>cis</i>-3,5-dimethylpiperazin-1-yl)-4-fluoro-5-isopropyl-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (200 mg, 0.43 mmol) in DCM (10 mL) and methanol (2 mL) and the mixture was stirred at RT for 12 h. Water was added to quench the reaction and the mixture was extracted with DCM. The solvent was removed under vacuum and the residue was purified by preparative HPLC to afford the title compound (135 mg, 66% yield). Purity by HPLC >99%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.33 (d, <i>J</i> = 8.1 Hz, 1H), 7.87–7.70 (m, 2H), 7.52 (d, <i>J</i> = 8.1 Hz, 1H), 5.25–5.10 (m, 1H), 4.05 (s, 3H), 3.66–3.40 (m, 6H), 3.06 (s, 3H), 1.72 (d, <i>J</i> = 7.1 Hz, 6H), 1.49 (d, <i>J</i> = 6.0 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 172.14, 151.29 (d, <i>J</i><sub>C–F</sub> = 5 Hz), 148.37, 148.16 (d, <i>J</i><sub>C–F</sub> = 245 Hz), 134.22, 130.56 (d, <i>J</i><sub>C–F</sub> = 13 Hz), 126.29, 125.68 (d, <i>J</i><sub>C–F</sub> = 8 Hz), 124.56, 122.86, 120.47, 119.58, 114.18, 104.95, 103.67, 101.40, 61.81, 56.42, 56.31, 55.26, 54.89, 36.01, 19.43, 19.39, 13.59. MS <i>m/z</i> = 476 [M + H].</div></div><div id="sec5_72" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> 2-Bromo-3-fluoro-1-methoxy-4-nitrobenzene (<b>26</b>)</h3><div class="NLM_p last">Sodium methoxide (25%; 0.9 g, 4.2 mmol) was added dropwise to a solution of 2-bromo-1,3-difluoro-4-nitrobenzene (1 g, 4.2 mmol) in MeOH (5 mL) and the mixture was stirred at 0 °C for 1 h and RT for 4 h. The reaction was quenched by addition of water and the product was extracted with EtOAc. Solvent was removed under reduced pressure and the residue was purified by silica gel chromatography (Hex:EA = 10:1) to afford the title compound (0.58 g, 55% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 8.14 (dd, <i>J</i> = 9.3, 8.3 Hz, 1H), 6.80 (dd, <i>J</i> = 9.3, 1.7 Hz, 1H), 4.03 (s, 3H).</div></div><div id="sec5_73" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> <i>tert</i>-Butyl 4-(2-Fluoro-6-methoxy-3-nitrophenyl)-5,6-dihydropyridine-1(2<i>H</i>)-carboxylate (<b>27</b>)</h3><div class="NLM_p last"><i>tert</i>-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2<i>H</i>)-carboxylate (1.854 g, 6 mmol), Pd(dppf)Cl<sub>2</sub> (117 mg, 0.16 mmol), and K<sub>2</sub>CO<sub>3</sub> (1.656 g, 12 mmol) were added to a solution of 1-bromo-2-iodo-4-nitrobenzene (1 g, 4 mmol) in DME-H<sub>2</sub>O (22 mL, 10:1 mixture). The mixture was stirred at 80 °C for 12 h under nitrogen. The reaction was cooled down to RT and the product was extracted with EtOAc. The solvent was removed under reduced pressure and the residue was purified by silica gel chromatography (Hex:EA = 3:1) to afford the title compound (1.3 g, 92% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 8.06 (m, 1H), 6.74 (d, <i>J</i> = 9.3 Hz, 1H), 5.72 (s, 1H), 4.15–4.03 (m, 2H), 3.82 (s, 3H), 3.70–3.60 (m, 2H), 2.40–2.30 (m, 2H), 1.50 (s, 9H).</div></div><div id="sec5_74" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> <i>tert</i>-Butyl 4-(3-Amino-2-fluoro-6-methoxyphenyl)piperidine-1-carboxylate (<b>28</b>)</h3><div class="NLM_p last">Pd-C (10%; 140 mg) was added to a solution of <i>tert</i>-butyl 4-(2-fluoro-6-methoxy-3-nitrophenyl)-5,6-dihydropyridine-1(2<i>H</i>)-carboxylate (1.3 g, 3.69 mmol) in ethanol (20 mL) and the mixture underwent hydrogenation at RT overnight. The Pd-C was filtered off. Evaporation of ethanol under reduced pressure afforded the title compound (1.1 g, 92% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 6.65–6.45 (m, 2H), 4.30–4.10 (m, 2H), 3.74 (s, 3H), 3.43 (s, 2H), 3.30–3.20 (m, 1H), 2.80–2.70 (m, 2H), 2.20–2.00 (m, 2H), 1.70–1.55 (m, 2H), 1.49 (s, 9H).</div></div><div id="sec5_75" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> <i>tert</i>-Butyl 4-(2-Fluoro-3-(isopropylamino)-6-methoxyphenyl)piperidine-1-carboxylate (<b>29</b>)</h3><div class="NLM_p last">Acetone (1.74 g, 30 mmol), acetic acid (0.27 g, 4.5 mmol), and sodium triacetoxyborohydride (0.98 g, 4.5 mmol) were added to a solution of <i>tert</i>-butyl 4-(3-amino-2-fluoro-6-methoxyphenyl)piperidine-1-carboxylate (1.0 g, 3 mmol) in DCM (20 mL) and the mixture was stirred at RT for 12 h. Water was added to quench the reaction and the mixture was extracted with DCM. The solvent was removed under and the residue was purified by silica gel chromatography to afford the title compound (1.06 g, 94% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 6.58–6.44 (m, 2H), 4.30–4.10 (m, 2H), 3.74 (s, 3H), 3.60–3.50 (m, 1H), 3.74 (s, 1H), 3.30–3.17 (m, 1H), 2.83–2.70 (m, 2H), 2.40–2.00 (m, 2H), 1.63–1.55 (m, 2H), 1.49 (s, 9H), 1.21 (d, <i>J</i> = 6.2 Hz, 6H).</div></div><div id="sec5_76" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> Methyl 2-((3-(1-(<i>tert</i>-Butoxycarbonyl)piperidin-4-yl)-2-fluoro-4-methoxyphenyl)(isopropyl)amino)-6-cyano-1<i>H</i>-indole-3-carboxylate (<b>30</b>)</h3><div class="NLM_p last">DABCO (84 mg, 0.75 mmol) was added to a solution of methyl 6-cyano-1<i>H</i>-indole-3-carboxylate (273 mg, 1.366 mmol) in DCM (20 mL) and the mixture was cooled down to 0 °C. <i>N</i>-Chlorosuccinimide (200 mg, 1.5 mmol) was then added and the reaction was stirred at 0 °C for 2 h. A solution of <i>tert</i>-butyl 4-(2-fluoro-3-(isopropylamino)-6-methoxyphenyl)piperidine-1-carboxylate (500 mg, 1.366 mmol) and trichloroacetic acid (56 mg, 0.342 mmol) in DCM (10 mL) was added dropwise and the reaction was stirred for 2 h at room temperature. The reaction was quenched by adding water and the mixture was extracted with DCM. The solvent was removed under vacuum and the residue was purified by silica gel chromatography (Hex:EA = 4:1) to afford the title compound (530 mg, 69% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 8.34 (s, 1H), 7.96 (d, <i>J</i> = 8.2 Hz, 1H), 7.40–7.30 (m, 2H), 7.18 (t, <i>J</i> = 8.7 Hz, 1H), 6.72 (dd, <i>J</i> = 8.9, 1.1 Hz, 1H), 4.90–4.75 (m, 1H), 4.25–4.10 (m, 2H), 3.86 (s, 3H), 3.84 (s, 3H), 3.30–3.20 (m, 1H), 2.80–2.65 (m, 2H), 2.20–2.00 (m, 2H), 1.65–1.50 (m, 2H), 1.46 (s, 9H), 1.20 (d, <i>J</i> = 6.5 Hz, 6H).</div></div><div id="sec5_77" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> Methyl 6-Cyano-2-((2-fluoro-4-methoxy-3-(1-methylpiperidin-4-yl)phenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (<b>31b</b>)</h3><div class="NLM_p last">TFA (1 mL) was added to a solution of methyl 2-((3-(1-(<i>tert</i>-butoxycarbonyl)piperidin-4-yl)-2-fluoro-4-methoxyphenyl)(isopropyl)amino)-6-cyano-1<i>H</i>-indole-3-carboxylate (240 mg, 0.425 mmol) in DCM (5 mL) and the mixture was stirred at RT for 12 h. The solvent was removed under reduced pressure and the residue was neutralized with NaHCO<sub>3</sub> and extracted with EtOAc. EtOAc was removed under reduced pressure and the residue was dissolved in DCM (5 mL). HCHO (37%; 100 mg, 1.28 mmol), acetic acid (38 mg, 0.64 mmol), and NaBH(OAc)<sub>3</sub> (135 mg, 0.64 mmol) were then added and the reaction mixture was stirred at RT for 6 h. The solvent was removed under reduced pressure and the product was extracted with EtOAc. EtOAc was evaporated under reduced pressure and the residue was purified by silica gel chromatography (EA:MeOH = 80:20) to afford the title compound (180 mg, 89% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 8.85 (s, 1H), 7.94 (d, <i>J</i> = 8.3 Hz, 1H), 7.38 (s, 1H), 7.32 (d, <i>J</i> = 8.3 Hz, 1H), 7.15 (t, <i>J</i> = 8.7 Hz, 1H), 6.69 (d, <i>J</i> = 8.7 Hz, 1H), 4.95–4.80 (m, 1H), 3.83 (s, 3H), 3.81 (s, 3H), 3.20–3.00 (m, 3H), 2.45–2.25 (m, 2H), 2.35 (s, 3H), 2.20–2.02 (m, 2H), 1.73–1.60 (m, 2H), 1.19 (d, <i>J</i> = 6.6 Hz, 6H).</div></div><div id="sec5_78" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> Methyl 6-Cyano-2-((2-fluoro-3-(1-isopropylpiperidin-4-yl)-4-methoxyphenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (<b>31c</b>)</h3><div class="NLM_p last">TFA (1 mL) was added to a solution of methyl 2-((3-(1-(<i>tert</i>-butoxycarbonyl)piperidin-4-yl)-2-fluoro-4-methoxyphenyl)(isopropyl)amino)-6-cyano-1<i>H</i>-indole-3-carboxylate (365 mg, 0.647 mmol) in DCM (5 mL) and the mixture was stirred at RT for 12 h. The solvent was removed under reduced pressure and the residue was neutralized with NaHCO<sub>3</sub> and extracted with EtOAc. EtOAc was removed under reduced pressure and the residue was dissolved in DCM (5 mL). Acetone (113 mg, 1.94 mmol), acetic acid (58 mg, 0.97 mmol), and NaBH(OAc)<sub>3</sub> (206 mg, 0.97 mmol) were then added and the reaction mixture was stirred at RT for 12 h. The solvent was removed under reduced pressure and the product was extracted with EtOAc. EtOAc was evaporated under reduced pressure and the residue was purified by silica gel chromatography (EA:MeOH = 80:20) to afford the title compound (150 mg, 46% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 7.98–7.90 (m, 2H), 7.35 (dd, <i>J</i> = 8.3, 1.4 Hz, 1H), 7.31 (d, <i>J</i> = 1.4 Hz, 1H), 7.16 (t, <i>J</i> = 8.8 Hz, 1H), 6.72 (d, <i>J</i> = 8.8 Hz, 1H), 4.95–4.80 (m, 1H), 3.87 (s, 6H), 3.20–2.75 (m, 4H), 2.40–2.20 (m, 4H), 1.75–1.55 (m, 2H), 1.19 (d, <i>J</i> = 6.4 Hz, 6H), 1.08 (d, <i>J</i> = 6.5 Hz, 6H).</div></div><div id="sec5_79" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> Methyl 6-Cyano-2-((2-fluoro-4-methoxy-3-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)piperidin-4-yl)phenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (<b>31d</b>)</h3><div class="NLM_p last">TFA (1 mL) was added to a solution of methyl 2-((3-(1-(<i>tert</i>-butoxycarbonyl)piperidin-4-yl)-2-fluoro-4-methoxyphenyl)(isopropyl)amino)-6-cyano-1<i>H</i>-indole-3-carboxylate (365 mg, 0.647 mmol) in DCM (5 mL) and the mixture was stirred at RT for 12 h. The solvent was removed under reduced pressure and the residue was neutralized with NaHCO<sub>3</sub> and extracted with EtOAc. EtOAc was removed under reduced pressure and the residue was dissolved in DCM (5 mL). Dihydro-2<i>H</i>-pyran-4(3<i>H</i>)-one (194 mg, 1.94 mmol), acetic acid (58 mg, 0.97 mmol), and NaBH(OAc)<sub>3</sub> (206 mg, 0.97 mmol) were then added and the reaction mixture was stirred at RT for 12 h. The solvent was removed under reduced pressure and the product was extracted with EtOAc. EtOAc was evaporated under reduced pressure and the residue was purified by silica gel chromatography (EA:MeOH = 80:20) to afford the title compound (140 mg, 39% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 8.55 (s, 1H), 7.95 (d, <i>J</i> = 8.3 Hz, 1H), 7.40–7.27 (m, 2H), 7.16 (t, <i>J</i> = 8.7 Hz, 1H), 6.70 (d, <i>J</i> = 8.3 Hz, 1H), 4.95–4.75 (m, 1H), 4.12–4.00 (m, 2H), 3.84 (s, 3H), 3.82 (s, 3H), 3.45–3.25 (m, 2H), 3.15–3.02 (m, 3H), 2.75–2.27 (m, 5H), 1.80–1.60 (m, 6H), 1.20 (d, <i>J</i> = 6.5 Hz, 6H).</div></div><div id="sec5_80" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> Methyl 6-Cyano-2-((2-fluoro-4-methoxy-3-(1-(oxetan-3-yl)piperidin-4-yl)phenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (<b>31e</b>)</h3><div class="NLM_p last">TFA (1 mL) was added to a solution of methyl 2-((3-(1-(<i>tert</i>-butoxycarbonyl)piperidin-4-yl)-2-fluoro-4-methoxyphenyl)(isopropyl)amino)-6-cyano-1<i>H</i>-indole-3-carboxylate (365 mg, 0.647 mmol) in DCM (5 mL) and the mixture was stirred at RT for 12 h. The solvent was removed under reduced pressure and the residue was neutralized with NaHCO<sub>3</sub> and extracted with EtOAc. EtOAc was removed under reduced pressure and the residue was dissolved in DCM (5 mL). Cyclobutanone (140 mg, 1.94 mmol), acetic acid (58 mg, 0.97 mmol), and NaBH(OAc)<sub>3</sub> (206 mg, 0.97 mmol) were then added and the reaction mixture was stirred at RT for 6 h. The solvent was removed under reduced pressure and the product was extracted with EtOAc. EtOAc was evaporated under reduced pressure and the residue was purified by silica gel chromatography (EA:MeOH = 80:20) to afford the title compound (190 mg, 58% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 8.20 (s, 1H), 7.96 (d, <i>J</i> = 8.2 Hz, 1H), 7.48–7.30 (m, 2H), 7.17 (t, <i>J</i> = 8.7 Hz, 1H), 6.73 (d, <i>J</i> = 8.9 Hz, 1H), 4.95–4.80 (m, 1H), 4.64 (d, <i>J</i> = 6.7 Hz, 4H), 3.88 (s, 3H), 3.85 (s, 3H), 3.51–3.49 (m, 1H), 3.25–3.05 (m, 1H), 2.95–2.75 (m, 2H), 2.45–2.25 (m, 2H), 2.00–1.80 (m, 2H), 1.73–1.60 (m, 2H), 1.20 (d, <i>J</i> = 6.5 Hz, 6H).</div></div><div id="sec5_81" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> Methyl 2-((3-(1-(2-((<i>tert</i>-Butyldimethylsilyl)oxy)ethyl)piperidin-4-yl)-2-fluoro-4-methoxyphenyl)(isopropyl)amino)-6-cyano-1<i>H</i>-indole-3-carboxylate (<b>31f</b>)</h3><div class="NLM_p last">TFA (1 mL) was added to a solution of methyl 2-((3-(1-(<i>tert</i>-butoxycarbonyl)piperidin-4-yl)-2-fluoro-4-methoxyphenyl)(isopropyl)amino)-6-cyano-1<i>H</i>-indole-3-carboxylate (365 mg, 0.647 mmol) in DCM (5 mL) and the mixture was stirred at RT for 12 h. The solvent was removed under reduced pressure and the residue was neutralized with NaHCO<sub>3</sub> and extracted with EtOAc. EtOAc was removed under reduced pressure and the residue was dissolved in DCM (5 mL). 2-((<i>tert</i>-Butyldimethylsilyl)oxy)acetaldehyde (164 mg, 0.97 mmol), acetic acid (58 mg, 0.97 mmol), and NaBH(OAc)<sub>3</sub> (206 mg, 0.97 mmol) were then added and the reaction mixture was stirred at RT for 6 h. The solvent was removed under reduced pressure and the product was extracted with EtOAc. EtOAc was evaporated under reduced pressure and the residue was purified by silica gel chromatography (EtOAc) to afford the title compound (180 mg, 45% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ ppm 8.61 (s, 1H), 7.95 (d, <i>J</i> = 8.3 Hz, 1H), 7.40–7.30 (m, 2H), 7.15 (t, <i>J</i> = 8.7 Hz, 1H), 6.69 (d, <i>J</i> = 8.7 Hz, 1H), 4.95–4.78 (m, 1H), 3.90–3.75 (m, 8H), 3.20–3.05 (m, 3H), 2.62 (t, <i>J</i> = 6.3 Hz, 2H), 2.45–2.20 (m, 4H), 1.70–1.55 (m, 2H), 1.20 (d, <i>J</i> = 6.5 Hz, 6H), 0.89 (s, 9H), 0.06 (s, 6H).</div></div><div id="sec5_82" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> 4-Fluoro-5-isopropyl-2-methoxy-3-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (ALK-73)</h3><div class="NLM_p last">4-Morpholinopiperidine (0.5 g) and DIPEA (0.5 mL) were added to a solution of 3,4-difluoro-5-isopropyl-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (135 mg, 0.37 mmol) in DMSO (2 mL) and the mixture was heated to 120 to 140 °C for 3 days. The reaction mixture was cooled down to RT and purified by preparative HPLC to afford the title compound (24 mg, 15% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.21 (d, <i>J</i> = 8.0 Hz, 1H), 7.64 (s, 1H), 7.60 (s, 1H), 7.39 (d, <i>J</i> = 8.0 Hz, 1H), 5.10–4.90 (m, 1H), 4.20–4.10 (m, 2H), 4.00 (s, 3H), 3.90–3.70 (m, 2H), 3.65–3.50 (m, 4H), 3.45–3.20 (m, 5H), 2.33–2.20 (m, 2H), 2.10–1.85 (m, 2H), 1.70 (dd, <i>J</i> = 6.9, 1.9 Hz, 6H).</div></div><div id="sec5_83" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> 4-Fluoro-5-isopropyl-2-methoxy-3-(1-methylpiperidin-4-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (CJ-2212)</h3><div class="NLM_p last">Methyl 6-cyano-2-((2-fluoro-4-methoxy-3-(1-methylpiperidin-4-yl)phenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (180 mg, 0.38 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration. The precipitate was purified by preparative HPLC to afford the title compound (100 mg, 59% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.25 (d, <i>J</i> = 8.0 Hz, 1H), 7.76 (s, 1H), 7.67 (s, 1H), 7.44 (d, <i>J</i> = 8.0 Hz, 1H), 5.10–5.00 (m, 1H), 4.03 (s, 3H), 3.80–3.62 (m, 3H), 3.30–3.12 (m, 2H), 2.96 (s, 3H), 2.80–2.60 (m, 2H), 2.18–2.00 (m, 2H), 1.73 (dd, <i>J</i> = 7.0, 2.0 Hz, 6H).</div></div><div id="sec5_84" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> 4-Fluoro-5-isopropyl-3-(1-isopropylpiperidin-4-yl)-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (CJ-2225)</h3><div class="NLM_p last">Methyl 6-cyano-2-((2-fluoro-3-(1-isopropylpiperidin-4-yl)-4-methoxyphenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (150 mg, 0.296 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration. The precipitate was purified by preparative HPLC to afford the title compound (35 mg, 25% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.26 (d, <i>J</i> = 8.0 Hz, 1H), 7.76 (s, 1H), 7.68 (s, 1H), 7.44 (d, <i>J</i> = 8.0 Hz, 1H), 5.10–5.00 (m, 1H), 4.03 (s, 3H), 3.80–3.50 (m, 4H), 3.30–3.20 (m, 2H), 2.80–2.60 (m, 2H), 2.15–2.03 (m, 2H), 1.73 (dd, <i>J</i> = 7.0, 2.0 Hz, 6H), 1.45 (d, <i>J</i> = 6.7 Hz, 6H).</div></div><div id="sec5_85" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> 4-Fluoro-5-isopropyl-2-methoxy-11-oxo-3-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)piperidin-4-yl)-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (CJ-2226)</h3><div class="NLM_p last">Methyl 6-cyano-2-((2-fluoro-4-methoxy-3-(1-(tetrahydro-2<i>H</i>-pyran-4-yl)piperidin-4-yl)phenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (140 mg, 0.255 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration. The precipitate was purified by preparative HPLC to afford the title compound (70 mg, 53% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.25 (d, <i>J</i> = 8.0 Hz, 1H), 7.75 (s, 1H), 7.66 (s, 1H), 7.43 (d, <i>J</i> = 8.0 Hz, 1H), 5.15–4.95 (m, 1H), 4.20–4.07 (m, 2H), 4.03 (s, 3H), 3.82–3.70 (m, 3H), 3.60–3.40 (m, 3H), 3.30–3.20 (m, 2H), 2.80–2.60 (m, 2H), 2.20–1.80 (m, 6H), 1.73 (dd, J = 6.9, 1.8 Hz, 6H).</div></div><div id="sec5_86" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> 4-Fluoro-5-isopropyl-2-methoxy-3-(1-(oxetan-3-yl)piperidin-4-yl)-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (CJ-2224)</h3><div class="NLM_p last">Methyl 6-cyano-2-((2-fluoro-4-methoxy-3-(1-(oxetan-3-yl)piperidin-4-yl)phenyl)(isopropyl)amino)-1<i>H</i>-indole-3-carboxylate (190 mg, 0.37 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration. The precipitate was purified by preparative HPLC to afford the title compound (90 mg, 51% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.28 (d, <i>J</i> = 8.0 Hz, 1H), 7.78 (d, <i>J</i> = 1.1 Hz, 1H), 7.69 (d, <i>J</i> = 0.7 Hz, 1H), 7.46 (dd, <i>J</i> = 8.0, 1.1 Hz, 1H), 5.18–5.02 (m, 1H), 4.95–4.80 (m, 4H), 4.55–4.40 (m, 1H), 4.04 (s, 3H), 3.80–3.60 (m, 3H), 3.20–3.10 (m, 2H), 2.80–2.60 (m, 2H), 2.18–2.02 (m, 2H), 1.74 (dd, <i>J</i> = 7.0, 2.1 Hz, 6H).</div></div><div id="sec5_87" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> 4-Fluoro-3-(1-(2-hydroxyethyl)piperidin-4-yl)-5-isopropyl-2-methoxy-11-oxo-6,11-dihydro-5<i>H</i>-indolo[2,3-<i>b</i>]quinoline-8-carbonitrile (CJ-2227)</h3><div class="NLM_p last">Methyl 2-((3-(1-(2-((<i>tert</i>-butyldimethylsilyl)oxy)ethyl)piperidin-4-yl)-2-fluoro-4-methoxyphenyl)(isopropyl)amino)-6-cyano-1<i>H</i>-indole-3-carboxylate (180 mg, 0.29 mmol) was dissolved in diphenyl ether (10 mL) and the solution was refluxed for 1 h. The mixture was cooled down to RT. Hexane (20 mL) was added and the precipitate was collected by filtration. The precipitate was dissolved in MeOH (10 mL) and the solution was treated with KHSO<sub>4</sub> (197 mg, 1.45 mmol). The mixture was stirred at RT for 12 h. The solvent was removed under reduced pressure and the residue was purified by preparative HPLC to afford the title compound (80 mg, 58% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ ppm 8.26 (d, <i>J</i> = 8.0 Hz, 1H), 7.75 (s, 1H), 7.68 (s, 1H), 7.44 (d, <i>J</i> = 8.0 Hz, 1H), 5.20–5.02 (m, 1H), 4.03 (s, 3H), 4.00–3.84 (m, 2H), 3.80–3.60 (m, 3H), 3.35–3.20 (m, 4H), 2.80–2.60 (m, 2H), 2.15–2.00 (m, 2H), 1.73 (dd, <i>J</i> = 6.9, 1.6 Hz, 6H).</div></div><div id="sec5_88" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> Enzymatic Inhibition Assay</h3><div class="NLM_p last">The cytoplasmic domain (amino acid 1058–1620) of wild-type human ALK protein expressed as N-terminal GST-fusion protein was purchased from Carna Biosciences, Inc. (Japan). Mutated ALK proteins were expressed in SF9 insect cells with N-terminal tags cleaved after purification. Kinase activities of all enzymes were assessed using a Lance TR-FRET assay kit from PerkinElmer Life Sciences (Waltham, MA). Compound solution (2.5 μL) and 5 μL of protein solution were added into a black low volume 384-well microtiter plate, which was incubated for 30 min with gentle shaking at RT, followed by addition of 2.5 μL of fluorescently labeled peptide substrate (Ulight-CKKSRGDYMTMQIG) and ATP mixture solution. The kinase reaction was performed in 50 mM HEPES (pH 7.5) with 1 mM EGTA, 1 mM MgCl<sub>2</sub>, and 2 mM DTT, and 0.01% Tween 20 was added immediately prior to the assay. Final concentrations of ATP, substrates, and DMSO were 100 μM, 20 nM, and 0.5%, respectively. Concentrations of different ALK proteins were adjusted accordingly to achieve comparable enzymatic activities for both wild-type and all mutated ALK proteins. The final ALK concentrations were 1, 1, 1, 128, 2, and 4 nM for wild type, F1174L, L1196M, S1206Y, G1269A, and G1202R, respectively. The reaction was allowed to proceed for 90 min in the dark with gentle shaking at RT after which 10 μL of 20 mM EDTA and 2 nM Eu-W1024 anti-phosphotyrosine antibody (PT66) mixture solution in the detection buffer from the manufacturer was added to terminate the reaction and detect the phosphorylation of the peptide substrate. The final mixture was incubated in the dark for 1 h before the plate was read on a Tecan Infinite M<sup>–1000</sup> multimode plate reader (Tecan, Durham, NC) with an excitation wavelength of 320 nm. Emission intensities were measured at both 620 and 665 nm with the intensity ratio between 665 and 620 nm corresponding to the peptide substrate phosphorylation. IC<sub>50</sub> values of inhibitors were obtained by fitting the ratio of 665/620 nm <i>vs</i> inhibitor concentrations in a sigmoidal dose–response curve (variable slope) with a nonlinear regression.</div></div><div id="sec5_89" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> Kinase Selectivity Enzymatic Assays</h3><div class="NLM_p last">The experiments were conducted at DiscoveRx Corporation. For most assays, kinase-tagged T7 phage strains were prepared in an <i>Escherichia coli</i> host derived from the BL21 strain. <i>E. coli</i> were grown to log phase, infected with T7 phage, and incubated with shaking at 32 °C until lysis. The lysates were centrifuged and filtered to remove cell debris. The remaining kinases were produced in HEK-293 cells and subsequently tagged with DNA for qPCR detection. Streptavidin-coated magnetic beads were treated with biotinylated small-molecule ligands for 30 min at RT to generate affinity resins for kinase assays. The liganded beads were blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, and 1 mM DTT) to remove unbound ligand and to reduce nonspecific binding. Binding reactions were assembled by combining kinases, liganded affinity beads, and test compounds in 1× binding buffer (20% SeaBlock, 0.17× PBS, 0.05% Tween 20, and 6 mM DTT). All reactions were performed in polystyrene 96-well plates in a final volume of 0.135 mL. The assay plates were incubated at RT with shaking for 1 h and the affinity beads were washed with wash buffer (1× PBS and 0.05% Tween 20). The beads were then resuspended in elution buffer (1× PBS, 0.05% Tween 20, and 0.5 μM nonbiotinylated affinity ligand) and incubated at RT with shaking for 30 min. The kinase concentration in the eluates was measured by qPCR.</div></div><div id="sec5_90" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> Cell Viability Assay</h3><div class="NLM_p">The effect of compounds on cell viability was determined in a 4 day proliferation assay. Cells were maintained in RPMI1640 culture medium with 10% FBS at 37 °C and an atmosphere of 5% CO<sub>2</sub>. All the cell lines were used within 3 months of thawing fresh vials. Cells were seeded in 96-well plates at a density of 3000–10,000 cells/well in 75 μL of culture medium. Compounds were serially diluted in the appropriate medium, and 75 μL of the diluted compounds was added to the appropriate wells of the cell plate. After the addition of compounds, the cells were incubated at 37 °C in an atmosphere of 5% CO<sub>2</sub> for 4 days. Cell viability was determined using the CellTiter-Glo Luminescent Cell Viability Assay Kit (Promega, Madison, WI) (for KARPAS-299 cells) or WST (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfo-phenyl)-2<i>H</i>-tetrazolium, monosodium salt) Cell Counting-8 Kit (Dojindo Molecular Technologies, Inc., Rockville, MD) (for H3122 cells) according to the manufacturer’s instructions.</div><div class="NLM_p">For WST assays, the WST-8 reagent was added to each well at a final concentration of 10% (v/v), and then the plates were incubated at 37 °C for 1–2 h for color development. The absorbance was measured at 450 nm using a SPECTRAmax PLUS plate reader (Molecular Devices, Sunnyvale, CA). The readings were normalized to the DMSO-treated cells and the half-maximal inhibitory concentration (IC<sub>50</sub>) was calculated by nonlinear regression analysis using GraphPad Prism 5 software (GraphPad Software, La Jolla, CA).</div><div class="NLM_p last">For CellTiter-Glo assay, 100 μL of CellTiter-Glo Reagent was added to each well, and then the plates were incubated at RT for 10–20 min. The luminescent signal was measured using a Tecan Infinite M1000 multimode microplate reader (Tecan, Morrisville, NC). The readings were normalized to the DMSO-treated cells and the IC<sub>50</sub> values were calculated by nonlinear regression analysis using GraphPad Prism 5 software.</div></div><div id="sec5_91" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117"> Computational Docking Simulations</h3><div class="NLM_p last">All the docking simulations were performed using GOLD (version 4.0.11).<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34,35)</a> The ALK structural coordinates were extracted from the cocrystal structure of ALK in complex with CH5424802 (PDBID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX3">3AOX3</a>)<a onclick="showRef(event, 'ref27 ref35'); return false;" href="javascript:void(0);" class="ref ref27 ref35">(27,35)</a> and used for the docking calculations. ALK protein and the designed compounds were prepared using the MOE program.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The N- and C-termini of ALK were capped with a methyl group and acetyl group, respectively, and the missing hydrogen atoms were added by setting the pH at 7.0. The binding site of ALK was centered at Glu1132 with a radius of 20 Å. In each genetic algorithm (GA) run, a maximum number of 200,000 operations were set on a population of 5 islands of 100 individuals. Operator weights for crossover, mutation, and migration were set to 95, 95, and 10, respectively. Twenty docking runs were used for each compound. The PLP scoring function in the GOLD program<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> was used as the fitness function to assess the docked conformations. The highest ranked docked conformation of compounds <b>7d</b> and CJ-2360 were selected as their predicted binding poses, as shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>, respectively.</div></div><div id="sec5_92" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> <i>In Vivo</i> Pharmacodynamic and Efficacy Studies</h3><div class="NLM_p">Human anaplastic large cell lymphoma (ALCL) KARPAS-299 cells were purchased from Sigma and maintained at 37 °C, 95% air, and 5% carbon dioxide in RPMI-1640 medium (with 2.05 mM <span class="smallcaps smallerCapital">l</span>-glutamine; 0.1 μM, sterile filtered) supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 units/mL streptomycin (GIBCO, Invitrogen Corp.) and passaged twice weekly.</div><div class="NLM_p">Tumor cells for xenografts were passaged into fresh medium the day before injection. For injection, a cell sample was mixed 1:1 with Trypan Blue (GIBCO, Invitrogen Corp.) and counted on a hemocytometer to determine the number of live/dead cells. Cells were washed twice with 1× PBS (GIBCO, Invitrogen Corp.) and resuspended in an ice-cold mixture of 1:1 PBS and Matrigel (BD Biosciences, Invitrogen Corp.) for a final Matrigel protein concentration of 5 mg/mL. All tumors were inoculated subcutaneously (s.c.) into female SCID mice (strain: 236 C.B-17 SCID, Charles River) with 5 × 10<sup>6</sup> KARPAS-299 cells in 0.1 mL with Matrigel in each mouse. The size of tumors growing in the mice was measured in two dimensions using calipers. Tumor volume (mm<sup>3</sup>) = (<i>A</i> × <i>B</i><sup>2</sup>)/2, where <i>A</i> and <i>B</i> are the tumor length and width (in mm), respectively.</div><div class="NLM_p">For pharmacodynamic (PD) experiments, tumors were grown to 200–600 mm<sup>3</sup> and mice were randomly assigned for a single oral dose of CJ-2360 or alectinib. The control group mice were treated with vehicle alone. Tumor samples were collected at indicated time points post dose. Control mice were given vehicle only and collected at the 6 h time point. The mice were euthanized with CO<sub>2</sub> and 0.3–0.5 mL of blood was drawn from a cardiac puncture using a 25g needle and 1 mL syringe, which was pretreated with heparin. Tumors were removed and samples were placed in cassettes in 10% neutral-buffered formalin for 24 h and then transferred to 70% ethanol. Tumor sample was immediately frozen in liquid nitrogen, ground into fine powder, and stored at −80 °C.</div><div class="NLM_p">For western blot analysis, tumor tissues were lysed with radioimmunoprecipitation assay buffer (RIPA buffer). The protein concentration of tissue lysate was determined with Bio-Rad Protein Assay Dye Reagent Concentrate (#5000006). The levels of phosphorylated STAT3 protein (pTyr705 rabbit, Cell Signaling Technology, Beverly, MA), phosphorylated AKT protein (pSer473, rabbit, Cell Signaling Technology, Beverly, MA), and phosphorylated ERK protein (pThr202/Tyr204, rabbit, Cell Signaling Technology, Beverly, MA) in tissue lysate were examined by western blotting analysis. GAPDH (sc-25,778, Santa Cruz Biotechnology) was used as a loading control.</div><div class="NLM_p">For the efficacy study, the size of tumors growing in the mice was measured in two dimensions using calipers. Tumor volume (mm<sup>3</sup>) = (<i>A</i> × <i>B</i><sup>2</sup>)/2, where <i>A</i> and <i>B</i> are the tumor length and width (in mm), respectively. During treatment, tumor volume and body weight were measured three times a week. After the treatment was stopped, tumor volume and body weight were measured at least once a week. Before treatment began, tumors were allowed to grow to an average of 150 mm<sup>3</sup> (70–270 mm<sup>3</sup>) in volume. Mice with tumors within the acceptable size range were randomized into treatment groups of seven to eight mice for each group. CJ-2360 or alectinib was administered <i>via</i> oral gavage, twice or once daily for 3 weeks. Mice in the control group received vehicle alone once daily for 3 weeks.</div><div class="NLM_p last">All animal experiments were performed under the guidelines of the University of Michigan Committee for Use and Care of Animals and using an approved animal protocol (PI, Shaomeng Wang).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i119"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01550" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68035" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68035" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01550?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01550</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Summary of KINOMEscan screening data for CJ-2360 against 468 kinases; HPLC trace of CJ-2360 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01550/suppl_file/jm0c01550_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Modeled structure for compound <b>7d</b> in complex with ALK (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01550/suppl_file/jm0c01550_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Modeled structure for CJ-2369 in complex with ALK (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01550/suppl_file/jm0c01550_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular string file for all the final target compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01550/suppl_file/jm0c01550_si_004.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01550/suppl_file/jm0c01550_si_001.pdf">jm0c01550_si_001.pdf (934.56 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01550/suppl_file/jm0c01550_si_002.pdb">jm0c01550_si_002.pdb (452.18 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01550/suppl_file/jm0c01550_si_003.pdb">jm0c01550_si_003.pdb (452.96 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01550/suppl_file/jm0c01550_si_004.csv">jm0c01550_si_004.csv (3.4 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01550" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45037" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45037" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shaomeng Wang</span> - <span class="hlFld-Affiliation affiliation">Rogel Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8782-6950" title="Orcid link">http://orcid.org/0000-0002-8782-6950</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#24574c454b49414a436451494d474c0a414051"><span class="__cf_email__" data-cfemail="e4978c858b89818a83a491898d878cca818091">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianyong Chen</span> - <span class="hlFld-Affiliation affiliation">Rogel Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Ascentage Pharma (Jiangsu), Medical City Avenue, QB3 Building First Floor, Taizhou, Jiangsu Province 225300, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yunlong Zhou</span> - <span class="hlFld-Affiliation affiliation">Ascentage Pharma (Jiangsu), Medical City Avenue, QB3 Building First Floor, Taizhou, Jiangsu Province 225300, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xuyuan Dong</span> - <span class="hlFld-Affiliation affiliation">Rogel Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liu Liu</span> - <span class="hlFld-Affiliation affiliation">Rogel Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Longchuan Bai</span> - <span class="hlFld-Affiliation affiliation">Rogel Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donna McEachern</span> - <span class="hlFld-Affiliation affiliation">Rogel Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sally Przybranowski</span> - <span class="hlFld-Affiliation affiliation">Rogel Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chao-Yie Yang</span> - <span class="hlFld-Affiliation affiliation">Rogel Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5445-0109" title="Orcid link">http://orcid.org/0000-0002-5445-0109</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeanne Stuckey</span> - <span class="hlFld-Affiliation affiliation">Life Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoqin Li</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bo Wen</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ting Zhao</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Siwei Sun</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Duxin Sun</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lingling Jiao</span> - <span class="hlFld-Affiliation affiliation">Ascentage Pharma (Jiangsu), Medical City Avenue, QB3 Building First Floor, Taizhou, Jiangsu Province 225300, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu Jing</span> - <span class="hlFld-Affiliation affiliation">Ascentage Pharma (Jiangsu), Medical City Avenue, QB3 Building First Floor, Taizhou, Jiangsu Province 225300, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ming Guo</span> - <span class="hlFld-Affiliation affiliation">Ascentage Pharma (Jiangsu), Medical City Avenue, QB3 Building First Floor, Taizhou, Jiangsu Province 225300, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dajun Yang</span> - <span class="hlFld-Affiliation affiliation">Ascentage Pharma (Jiangsu), Medical City Avenue, QB3 Building First Floor, Taizhou, Jiangsu Province 225300, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>J.C., Y.Z., and X.D. contributed equally to this work.</p></li><li><span class="author-information-subsection-header">Funding</span><p>This work is supported by Ascentage Pharma Group (to S.W.).</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Ascentage has filed a patent application on this class of ALK inhibitors, in which S. Wang, J. Chen, Y. Zhou L. Jiao, Y. Jing, X. Qian, L. Liu, L. Bai, C-Y. Yang, and D. McEachern are co-inventors. S. Wang is a paid consultant of Ascentage and owns stock in Ascentage. J. Chen, Y. Zhou L. Jiao, Y. Jing, X. Qian, L. are employees of Ascentage and owns stock in Ascentage. The University of Michigan also owns stock in Ascentage.<br /></br></div></li></ul></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i121">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80642" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80642" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 36 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naeve, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirstein, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, D. P.</span></span> <span> </span><span class="NLM_article-title">ALK, the Chromosome 2 Gene Locus Altered by the t(2;5) in Non-Hodgkin’s Lymphoma, Encodes a Novel Neural Receptor Tyrosine Kinase that is Highly Related to Leukocyte Tyrosine Kinase (LTK)</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2175</span>– <span class="NLM_lpage">2188</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1201062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1038%2Fsj.onc.1201062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=9174053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=2175-2188&author=S.+W.+Morrisauthor=C.+Naeveauthor=P.+Mathewauthor=P.+L.+Jamesauthor=M.+N.+Kirsteinauthor=X.+Cuiauthor=D.+P.+Witte&title=ALK%2C+the+Chromosome+2+Gene+Locus+Altered+by+the+t%282%3B5%29+in+Non-Hodgkin%E2%80%99s+Lymphoma%2C+Encodes+a+Novel+Neural+Receptor+Tyrosine+Kinase+that+is+Highly+Related+to+Leukocyte+Tyrosine+Kinase+%28LTK%29&doi=10.1038%2Fsj.onc.1201062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)</span></div><div class="casAuthors">Morris, Stephan W.; Naeve, Clayton; Mathew, Prasad; James, Payton L.; Kirstein, Mark N.; Cui, Xiaoli; Witte, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2175-2188</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">Anaplastic Lymphoma Kinase (ALK) was originally identified as a member of the insulin receptor subfamily of receptor tyrosine kinases that acquires transforming capability when truncated and fused to nucleophosmin (NPM) in the t(2;5) chromosomal rearrangement assocd. with non-Hodgkin's lymphoma, but further insights into its normal structure and function are lacking.  Here, we characterize a full-length normal human ALK cDNA and its product, and det. the pattern of expression of its murine homolog in embryonic and adult tissues as a first step toward the functional assessment of the receptor.  Anal. of the 6226 bp ALK cDNA identified an open reading frame encoding a 1620-amino acid (aa) protein of predicted mass ∼177 kDa that is most closely related to leukocyte tyrosine kinase (LTK), the two exhibiting 57% aa identity and 71% similarity over their region of overlap.  Biochem. anal. demonstrated that the ∼177 kDa ALK polypeptide core undergoes co-translational N-linked glycosylation, emerging in its mature form as a 200 kDa single chain receptor.  Surface labeling studies indicated that the 200 kDa glycoprotein is exposed at the cell membrane, consistent with the prediction that ALK serves as the receptor for an unidentified ligand(s).  In situ hybridization studies revealed Alk expression beginning on embryonic day 11 and persisting into the neonatal and adult periods of development.  Alk transcripts were confined to the nervous system and included several thalamic and hypothalamic nuclei; the trigeminal, facial, and acoustic cranial ganglia; the anterior horns of the spinal cord in the region of the developing motor neurons; the sympathetic chain; and the ganglion cells of the gut.  Thus, ALK is a novel orphan receptor tyrosine kinase that appears to play an important role in the normal development and function of the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4F75l637BuLVg90H21EOLACvtfcHk0ljvtq2MFiHqRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnt7k%253D&md5=fdf7a14e88be831b2577891145cb6082</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1201062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1201062%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DNaeve%26aufirst%3DC.%26aulast%3DMathew%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DP.%2BL.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DWitte%26aufirst%3DD.%2BP.%26atitle%3DALK%252C%2520the%2520Chromosome%25202%2520Gene%2520Locus%2520Altered%2520by%2520the%2520t%25282%253B5%2529%2520in%2520Non-Hodgkin%25E2%2580%2599s%2520Lymphoma%252C%2520Encodes%2520a%2520Novel%2520Neural%2520Receptor%2520Tyrosine%2520Kinase%2520that%2520is%2520Highly%2520Related%2520to%2520Leukocyte%2520Tyrosine%2520Kinase%2520%2528LTK%2529%26jtitle%3DOncogene%26date%3D1997%26volume%3D14%26spage%3D2175%26epage%3D2188%26doi%3D10.1038%2Fsj.onc.1201062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Beau, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitter, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doane, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadin, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vardiman, J. W.</span></span> <span> </span><span class="NLM_article-title">The T(2;5)(P23;Q35): a Recurring Chromosomal Abnormality in Ki-1-Positive Anaplastic Large Cell Lymphoma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">866</span>– <span class="NLM_lpage">870</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=2555633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A280%3ADyaK3c%252FmsFOhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1989&pages=866-870&author=M.+M.+Le+Beauauthor=M.+A.+Bitterauthor=R.+A.+Larsonauthor=L.+A.+Doaneauthor=E.+D.+Ellisauthor=W.+A.+Franklinauthor=C.+M.+Rubinauthor=M.+E.+Kadinauthor=J.+W.+Vardiman&title=The+T%282%3B5%29%28P23%3BQ35%29%3A+a+Recurring+Chromosomal+Abnormality+in+Ki-1-Positive+Anaplastic+Large+Cell+Lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma</span></div><div class="casAuthors">Le Beau M M; Bitter M A; Larson R A; Doane L A; Ellis E D; Franklin W A; Rubin C M; Kadin M E; Vardiman J W</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">866-70</span>
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    </div><div class="casAbstract">In lymphoid neoplasms, nonrandom cytogenetic abnormalities correlate with clinical, morphologic and immunophenotypic features.  A subtype of non-Hodgkin's lymphoma, which expresses the Ki-1 antigen (CD30) and has distinct morphologic and clinical features, has recently been described.  We now report the association of a reciprocal translocation involving the short arm of chromosome 2 (band p23) and the long arm of chromosome 5 (band q35), t(2;5)(p23;q35), with Ki-1 positive anaplastic large cell lymphoma.  Rearrangement of the genes that are located at the breakpoints on chromosomes 2 and 5 may be a critical step in the pathogenesis of this lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfhXSXFhBAtZZoeNcnHOQ9fW6udTcc2eYI3t9z8QJ1R7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3c%252FmsFOhug%253D%253D&md5=83cdde3ddd6263fe6037d18f0eca846d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BBeau%26aufirst%3DM.%2BM.%26aulast%3DBitter%26aufirst%3DM.%2BA.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DDoane%26aufirst%3DL.%2BA.%26aulast%3DEllis%26aufirst%3DE.%2BD.%26aulast%3DFranklin%26aufirst%3DW.%2BA.%26aulast%3DRubin%26aufirst%3DC.%2BM.%26aulast%3DKadin%26aufirst%3DM.%2BE.%26aulast%3DVardiman%26aufirst%3DJ.%2BW.%26atitle%3DThe%2520T%25282%253B5%2529%2528P23%253BQ35%2529%253A%2520a%2520Recurring%2520Chromosomal%2520Abnormality%2520in%2520Ki-1-Positive%2520Anaplastic%2520Large%2520Cell%2520Lymphoma%26jtitle%3DLeukemia%26date%3D1989%26volume%3D3%26spage%3D866%26epage%3D870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirstein, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittmer, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, A. T.</span></span> <span> </span><span class="NLM_article-title">Fusion of a Kinase Gene, Alk, to a Nucleolar Protein Gene, Npm, in Non-Hodgkins-Lymphoma</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>263</i></span>,  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1284</span>, <span class="refDoi"> DOI: 10.1126/science.8122112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1126%2Fscience.8122112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=8122112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+G.+Dittmerauthor=D.+N.+Shapiroauthor=D.+L.+Saltmanauthor=A.+T.+Look&title=Fusion+of+a+Kinase+Gene%2C+Alk%2C+to+a+Nucleolar+Protein+Gene%2C+Npm%2C+in+Non-Hodgkins-Lymphoma&doi=10.1126%2Fscience.8122112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma</span></div><div class="casAuthors">Morris, Stephan, W.; Kirstein, Mark, N.; Valentine, Marcus B.; Dittmer, Kristopher G.; Shapiro, David N.; Saltman, David L.; Look, A. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5151</span>),
    <span class="NLM_cas:pages">1281-4</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The 2;5 chromosomal translocation occurs in most anaplastic large-cell non-Hodgkin's lymphomas arising from activated T lymphocytes.  This rearrangement was shown to fuse the NPM nucleolar phosphoprotein gene on chromosome 5q35 to a previously unidentified protein tyrosine kinase gene, ALK, on chromosome 2p23.  In the predicted hybrid protein, the amino terminus of nucleophosmin (NPM) is linked to the catalytic domain of anaplastic lymphoma kinase (ALK).  Expressed in the small intestine, testis, and brain but not in normal lymphoid cells, ALK shows greatest sequence similarity to the insulin receptor subfamily of kinases.  Unscheduled expression of the truncated ALK may contribute to malignant transformation in these lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3KZnxLYaerVg90H21EOLACvtfcHk0ljvtq2MFiHqRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D&md5=219ee9615e613be456a05f8f1ded6066</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.8122112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8122112%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%2BG.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DFusion%2520of%2520a%2520Kinase%2520Gene%252C%2520Alk%252C%2520to%2520a%2520Nucleolar%2520Protein%2520Gene%252C%2520Npm%252C%2520in%2520Non-Hodgkins-Lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284%26doi%3D10.1126%2Fscience.8122112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Webb, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slavish, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rentrop, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span> <span> </span><span class="NLM_article-title">Anaplastic Lymphoma Kinase: Role in Cancer Pathogenesis and Small-Molecule Inhibitor Development for Therapy</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1586/14737140.9.3.331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1586%2F14737140.9.3.331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=19275511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFaltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=331-356&author=T.+R.+Webbauthor=J.+Slavishauthor=R.+E.+Georgeauthor=A.+T.+Lookauthor=L.+Xueauthor=Q.+Jiangauthor=X.+Cuiauthor=W.+B.+Rentropauthor=S.+W.+Morris&title=Anaplastic+Lymphoma+Kinase%3A+Role+in+Cancer+Pathogenesis+and+Small-Molecule+Inhibitor+Development+for+Therapy&doi=10.1586%2F14737140.9.3.331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy</span></div><div class="casAuthors">Webb, Thomas R.; Slavish, Jake; George, Rani E.; Look, A. Thomas; Xue, Liquan; Jiang, Qin; Cui, Xiaoli; Rentrop, Walter B.; Morris, Stephan W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">331-356</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, was initially identified in constitutively activated oncogenic fusion forms - the most common being nucleophosmin-ALK - in anaplastic large-cell lymphomas, and subsequent studies have identified ALK fusions in diffuse large B-cell lymphomas, systemic histiocytosis, inflammatory myofibroblastic tumors, esophageal squamous cell carcinomas and non-small-cell lung carcinomas.  More recently, genomic DNA amplification and protein overexpression, as well as activating point mutations, of ALK have been described in neuroblastomas.  In addn. to those cancers for which a causative role for aberrant ALK activity is well validated, more circumstantial links implicate the full-length, normal ALK receptor in the genesis of other malignancies - including glioblastoma and breast cancer - via a mechanism of receptor activation involving autocrine and/or paracrine growth loops with the reported ALK ligands, pleiotrophin and midkine.  This review summarizes normal ALK biol., the confirmed and putative roles of ALK in the development of human cancers and efforts to target ALK using small-mol. kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoERzbvlik_c7Vg90H21EOLACvtfcHk0lhLkRcHps-AwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFaltrc%253D&md5=a980ef18ac316bd3894b72ddd2748c17</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1586%2F14737140.9.3.331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.9.3.331%26sid%3Dliteratum%253Aachs%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DSlavish%26aufirst%3DJ.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DRentrop%26aufirst%3DW.%2BB.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26atitle%3DAnaplastic%2520Lymphoma%2520Kinase%253A%2520Role%2520in%2520Cancer%2520Pathogenesis%2520and%2520Small-Molecule%2520Inhibitor%2520Development%2520for%2520Therapy%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2009%26volume%3D9%26spage%3D331%26epage%3D356%26doi%3D10.1586%2F14737140.9.3.331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellingham, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlman, E. J.</span></span> <span> </span><span class="NLM_article-title">Recurrent Involvement of 2p23 in Inflammatory Myofibroblastic Tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2776</span>– <span class="NLM_lpage">2780</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10383129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=2776-2780&author=C.+A.+Griffinauthor=A.+L.+Hawkinsauthor=C.+Dvorakauthor=C.+Henkleauthor=T.+Ellinghamauthor=E.+J.+Perlman&title=Recurrent+Involvement+of+2p23+in+Inflammatory+Myofibroblastic+Tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors</span></div><div class="casAuthors">Griffin, Constance A.; Hawkins, Anita L.; Dvorak, Cecily; Henkle, Carol; Ellingham, Tara; Perlman, Elizabeth J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2776-2780</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Inflammatory myofibroblastic tumor (IMT) is a relatively rare soft tissue tumor.  The reactive vs. neoplastic pathogenesis of this tumor is unresolved.  We found clonal chromosome aberrations involving 2p23 upon metaphase anal. of two IMTs.  Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 demonstrated rearrangement of the probe in both of these cases and in a third case, and immunohistochem. revealed ALK expression in all three cases.  A 2p22-24 involvement has been reported previously in four addnl. cases of IMT.  We suggest that chromosomal rearrangements involving 2p23 near or within ALK are recurrent alterations in IMT and that ALK may have a novel role outside its previously recognized realm of lymphoid neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocvXV2ukz3crVg90H21EOLACvtfcHk0lhLkRcHps-AwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D&md5=8054eeaaf0cb85ee85afff461797c84c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DC.%2BA.%26aulast%3DHawkins%26aufirst%3DA.%2BL.%26aulast%3DDvorak%26aufirst%3DC.%26aulast%3DHenkle%26aufirst%3DC.%26aulast%3DEllingham%26aufirst%3DT.%26aulast%3DPerlman%26aufirst%3DE.%2BJ.%26atitle%3DRecurrent%2520Involvement%2520of%25202p23%2520in%2520Inflammatory%2520Myofibroblastic%2520Tumors%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D2776%26epage%3D2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gascoyne, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamant, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Subero, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lestou, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Hermelink, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsman, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auvigne, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delsol, G.</span></span> <span> </span><span class="NLM_article-title">ALK-positive Diffuse Large B-cell Lymphoma is Associated with Clathrin-ALK Rearrangements: Report of 6 Cases</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">2568</span>– <span class="NLM_lpage">2573</span>, <span class="refDoi"> DOI: 10.1182/blood-2003-03-0786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1182%2Fblood-2003-03-0786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=12763927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnslykurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=2568-2573&author=R.+D.+Gascoyneauthor=L.+Lamantauthor=J.+I.+Martin-Suberoauthor=V.+S.+Lestouauthor=N.+L.+Harrisauthor=H.+K.+M%C3%BCller-Hermelinkauthor=J.+F.+Seymourauthor=L.+J.+Campbellauthor=D.+E.+Horsmanauthor=I.+Auvigneauthor=E.+Espinosauthor=R.+Siebertauthor=G.+Delsol&title=ALK-positive+Diffuse+Large+B-cell+Lymphoma+is+Associated+with+Clathrin-ALK+Rearrangements%3A+Report+of+6+Cases&doi=10.1182%2Fblood-2003-03-0786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">ALK-positive diffuse large B-cell lymphoma is associated with clathrin-ALK rearrangements: Report of 6 cases</span></div><div class="casAuthors">Gascoyne, Randy D.; Lamant, Laurence; Martin-Subero, Jose I.; Lestou, Valia S.; Harris, Nancy Lee; Mueller-Hermelink, Hans-Konrad; Seymour, John F.; Campbell, Lynda J.; Horsman, Douglas E.; Auvigne, Isabelle; Espinos, Estelle; Siebert, Reiner; Delsol, Georges</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2568-2573</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Expression of ALK protein by lymphoid cells and the description of variant anaplastic lymphoma kinase (ALK) translocations have typically been restricted to cases of T-cell and null anaplastic large-cell lymphoma (ALCL).  All such cases result from a novel fusion created by the ALK gene on chromosome 2p23 and NPM on 5q35 or other variant translocation partners.  A rare variant of diffuse large B-cell lymphoma (DLBCL), originally described in 1997, was thought to overexpress full-length ALK in contrast to a chimeric protein characteristic of ALCL.  However, full-length ALK protein lacks tyrosine kinase activity and thus the mechanism of oncogenesis has remained elusive.  We describe 6 cases of ALK+ DLBCL characterized by a simple or complex t(2;17)(p23;q23) involving the clathrin gene (CLTC) at chromosome band 17q23 and the ALK gene at chromosome band 2p23.  All cases were studied using fluorescence in situ hybridization (FISH), complemented in one case with std. cytogenetic anal., multicolor karyotyping (M-FISH), and reverse transcriptase-polymerase chain reaction.  These results clearly demonstrate that most cases of ALK+ DLBCL share the same mechanism of deregulated ALK expression.  Moreover, these results demonstrate the presence of CLTC-ALK fusions in these tumors and extend the list of diseases assocd. with this genetic abnormality to include classical T-cell or null ALCL, ALK+ DLBCL, and inflammatory myofibroblastic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3UcmsuahiXLVg90H21EOLACvtfcHk0lhLkRcHps-AwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnslykurw%253D&md5=9eedc8c22c580dbadee982b4d3da35a8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-03-0786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-03-0786%26sid%3Dliteratum%253Aachs%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DLamant%26aufirst%3DL.%26aulast%3DMartin-Subero%26aufirst%3DJ.%2BI.%26aulast%3DLestou%26aufirst%3DV.%2BS.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DM%25C3%25BCller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26aulast%3DCampbell%26aufirst%3DL.%2BJ.%26aulast%3DHorsman%26aufirst%3DD.%2BE.%26aulast%3DAuvigne%26aufirst%3DI.%26aulast%3DEspinos%26aufirst%3DE.%26aulast%3DSiebert%26aufirst%3DR.%26aulast%3DDelsol%26aufirst%3DG.%26atitle%3DALK-positive%2520Diffuse%2520Large%2520B-cell%2520Lymphoma%2520is%2520Associated%2520with%2520Clathrin-ALK%2520Rearrangements%253A%2520Report%2520of%25206%2520Cases%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D2568%26epage%3D2573%26doi%3D10.1182%2Fblood-2003-03-0786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jazii, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najafi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malekzadeh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrads, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziaee, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abnet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yazdznbod, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkhane, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salekdeh, G. H.</span></span> <span> </span><span class="NLM_article-title">Identification of Squamous Cell Carcinoma Associated Proteins by Proteomics and Loss of Beta Tropomyosin Expression in Esophageal Cancer</span>. <i>World J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">7104</span>– <span class="NLM_lpage">7112</span>, <span class="refDoi"> DOI: 10.3748/wjg.v12.i44.7104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.3748%2Fwjg.v12.i44.7104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=17131471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD2sXls1GksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=7104-7112&author=F.+R.+Jaziiauthor=Z.+Najafiauthor=R.+Malekzadehauthor=T.+P.+Conradsauthor=A.+A.+Ziaeeauthor=C.+Abnetauthor=M.+Yazdznbodauthor=A.+A.+Karkhaneauthor=G.+H.+Salekdeh&title=Identification+of+Squamous+Cell+Carcinoma+Associated+Proteins+by+Proteomics+and+Loss+of+Beta+Tropomyosin+Expression+in+Esophageal+Cancer&doi=10.3748%2Fwjg.v12.i44.7104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer</span></div><div class="casAuthors">Jazii, Ferdous Rastgar; Najafi, Zahra; Malekzadeh, Reza; Conrads, Thomas P.; Ziaee, Abed Ali; Abnet, Christian; Yazdznbod, Mansour; Karkhane, Ali Asghar; Salekdeh, Ghasem H.</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">7104-7112</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">World Journal of Gastroenterology</span>)
        </div><div class="casAbstract">To assess the proteome of normal vs. tumor tissue in squamous cell carcinoma of the esophagus (SCCE) in Iranian patients and compare our results with former reports by using proteomics.  Protein was extd. from normal and tumor tissues.  Two dimensional electrophoresis was carried out and spots with differential expression were identified with mass spectrometry.  RNA extn. and RT-PCR along with immunodetection were performed.  Fourteen proteins were found whose expression levels differed in tumor compared to normal tissues.  Mass spectrometric anal. resulted in the identification of β-tropomyosin (TMβ), myosin light chain 2 (and its isoform), myosin regulatory light chain 2, peroxyredoxin 2, annexin I and an unknown polypeptide as the down regulated polypeptides in tumor tissue.  Heat shock protein 70 (HSP70), TPM4-ALK fusion oncoprotein 2, myosin light polypeptide 6, keratin I, GH16431p and calreticulin were the up-regulated polypeptides found in tumor tissue.  Several of these proteins, such as TMβ, HSP70, annexin I, calreticulin, TPM4-ALK and isoforms of myosins, have been well recognized in tumorigenesis of esophageal or other types of cancers.  The study not only supports the involvement of some of the formerly reported proteins in SCCE but also introduces addnl. proteins found to be lost in SCCE, including TMβ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqQBiL27ZRH7Vg90H21EOLACvtfcHk0lgbtgmGcMQGnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1GksA%253D%253D&md5=2de4e4dc1639b4414afa8ea6e072c22c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v12.i44.7104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v12.i44.7104%26sid%3Dliteratum%253Aachs%26aulast%3DJazii%26aufirst%3DF.%2BR.%26aulast%3DNajafi%26aufirst%3DZ.%26aulast%3DMalekzadeh%26aufirst%3DR.%26aulast%3DConrads%26aufirst%3DT.%2BP.%26aulast%3DZiaee%26aufirst%3DA.%2BA.%26aulast%3DAbnet%26aufirst%3DC.%26aulast%3DYazdznbod%26aufirst%3DM.%26aulast%3DKarkhane%26aufirst%3DA.%2BA.%26aulast%3DSalekdeh%26aufirst%3DG.%2BH.%26atitle%3DIdentification%2520of%2520Squamous%2520Cell%2520Carcinoma%2520Associated%2520Proteins%2520by%2520Proteomics%2520and%2520Loss%2520of%2520Beta%2520Tropomyosin%2520Expression%2520in%2520Esophageal%2520Cancer%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2006%26volume%3D12%26spage%3D7104%26epage%3D7112%26doi%3D10.3748%2Fwjg.v12.i44.7104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enomoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurashina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bando, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">Identification of the Transforming EML4-ALK Fusion Gene in Non-small-cell Lung Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nature05945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.-i.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+Transforming+EML4-ALK+Fusion+Gene+in+Non-small-cell+Lung+Cancer&doi=10.1038%2Fnature05945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0lgbtgmGcMQGnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.-i.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520Transforming%2520EML4-ALK%2520Fusion%2520Gene%2520in%2520Non-small-cell%2520Lung%2520Cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnature05945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">Non-solid Oncogenes in Solid Tumors: EML4-ALK Fusion Genes in Lung Cancer</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">2349</span>– <span class="NLM_lpage">2355</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2008.00972.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1111%2Fj.1349-7006.2008.00972.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=19032370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisF2gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2008&pages=2349-2355&author=H.+Mano&title=Non-solid+Oncogenes+in+Solid+Tumors%3A+EML4-ALK+Fusion+Genes+in+Lung+Cancer&doi=10.1111%2Fj.1349-7006.2008.00972.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer</span></div><div class="casAuthors">Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2349-2355</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  It is generally accepted that recurrent chromosome translocations play a major role in the mol. pathogenesis of hematol. malignancies but not of solid tumors.  However, chromosome translocations involving the e26 transformation-specific sequence transcription factor loci have been demonstrated recently in many prostate cancer cases.  Furthermore, through a functional screening with retroviral cDNA expression libraries, we have discovered the fusion-type protein tyrosine kinase echinoderm microtubule-assocd. protein like-4 (EML4)-anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) specimens.  A recurrent chromosome translocation, inv(2)(p21p23), in NSCLC generates fused mRNA encoding the amino-terminal half of EML4 ligated to the intracellular region of the receptor-type protein tyrosine kinase ALK.  EML4-ALK oligomerizes constitutively in cells through the coiled coil domain within the EML4 region, and becomes activated to exert a marked oncogenicity both in vitro and in vivo.  Break and fusion points within the EML4 locus may diverge in NSCLC cells to generate various isoforms of EML4-ALK, which may constitute -5% of NSCLC cases, at least in the Asian ethnic group.  In the present review I summarize how detection of EML4-ALK cDNA may become a sensitive diagnostic means for NSCLC cases that are pos. for the fusion gene, and discuss whether suppression of ALK enzymic activity could be an effective treatment strategy against this intractable disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbxSS7U51wKbVg90H21EOLACvtfcHk0ljEDUdf_Wtgxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisF2gsw%253D%253D&md5=84386550daedbd29b3a34b11a4774684</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2008.00972.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2008.00972.x%26sid%3Dliteratum%253Aachs%26aulast%3DMano%26aufirst%3DH.%26atitle%3DNon-solid%2520Oncogenes%2520in%2520Solid%2520Tumors%253A%2520EML4-ALK%2520Fusion%2520Genes%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Sci.%26date%3D2008%26volume%3D99%26spage%3D2349%26epage%3D2355%26doi%3D10.1111%2Fj.1349-7006.2008.00972.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B.</span></span> <span> </span><span class="NLM_article-title">Targeting Anaplastic Lymphoma Kinase in Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2081</span>– <span class="NLM_lpage">2086</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-1591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1158%2F1078-0432.CCR-10-1591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=21288922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslCgs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2081-2086&author=A.+T.+Shawauthor=B.+Solomon&title=Targeting+Anaplastic+Lymphoma+Kinase+in+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-10-1591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Anaplastic Lymphoma Kinase in Lung Cancer</span></div><div class="casAuthors">Shaw, Alice T.; Solomon, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2081-2086</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Several decades of cancer research have revealed a pivotal role for tyrosine kinases as key regulators of signaling pathways, controlling cell growth and differentiation.  Deregulation of tyrosine kinase-mediated signaling occurs frequently in cancer and is believed to drive the initiation and progression of disease.  Chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (ALK) occur in a variety of human malignancies including non-small cell lung cancer (NSCLC), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.  The aberrant activation of ALK signaling leads to "oncogene addiction" and marked sensitivity to ALK inhibitors such as crizotinib (PF-02341066).  This review focuses on ALK rearrangements in NSCLC, starting with the discovery of the EML4-ALK fusion oncogene, and culminating in the recent validation of ALK as a therapeutic target in patients with ALK-rearranged NSCLC.  Current efforts seek to expand the role of ALK kinase inhibition in lung and other cancers and to address the mol. basis for the development of resistance.  Clin Cancer Res; 17(8); 2081-6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCqEzvXv0qJrVg90H21EOLACvtfcHk0ljEDUdf_Wtgxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslCgs7k%253D&md5=6d0f5e1174ba934f00c10a877a3b17e1</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-1591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-1591%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB.%26atitle%3DTargeting%2520Anaplastic%2520Lymphoma%2520Kinase%2520in%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D2081%26epage%3D2086%26doi%3D10.1158%2F1078-0432.CCR-10-1591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osajima-Hakomori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, R.</span></span> <span> </span><span class="NLM_article-title">Biological Role of Anaplastic Lymphoma Kinase in Neuroblastoma</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1016/S0002-9440(10)62966-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1016%2FS0002-9440%2810%2962966-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=15972965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD2MXms1eitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2005&pages=213-222&author=Y.+Osajima-Hakomoriauthor=I.+Miyakeauthor=M.+Ohiraauthor=A.+Nakagawaraauthor=A.+Nakagawaauthor=R.+Sakai&title=Biological+Role+of+Anaplastic+Lymphoma+Kinase+in+Neuroblastoma&doi=10.1016%2FS0002-9440%2810%2962966-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Biological role of anaplastic lymphoma kinase in neuroblastoma</span></div><div class="casAuthors">Osajima-Hakomori, Yuko; Miyake, Izumi; Ohira, Miki; Nakagawara, Akira; Nakagawa, Atsuko; Sakai, Ryuichi</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">213-222</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor originally identified as part of the chimeric nucleophosmin-ALK protein in the t(2;5) chromosomal rearrangement assocd. with anaplastic large cell lymphoma.  We recently demonstrated that the ALK kinase is constitutively activated by gene amplification at the ALK locus in several neuroblastoma cell lines.  Forming a stable complex with hyperphosphorylated ShcC, activated ALK modifies the responsiveness of the mitogen-activated protein kinase pathway to growth factors.  In the present study, the biol. role of activated ALK was examd. by suppressing the expression of ALK kinase in neuroblastoma cell lines using an RNA interference technique.  The suppression of activated ALK in neuroblastoma cells by RNA interference significantly reduced the phosphorylation of ShcC, mitogen-activated protein kinases, and Akt, inducing rapid apoptosis in the cells.  By immunohistochem. anal., the cytoplasmic expression of ALK was detected in most of the samples of neuroblastoma tissues regardless of the stage of the tumor, whereas significant amplification of ALK was obsd. in only 1 of 85 cases of human neuroblastoma samples.  These data demonstrate the limited frequency of ALK activation in the real progression of neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3yzyhgfKX4rVg90H21EOLACvtfcHk0ljEDUdf_Wtgxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXms1eitrc%253D&md5=591aceb254b3e707d315b6309ec5fba0</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2962966-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252962966-5%26sid%3Dliteratum%253Aachs%26aulast%3DOsajima-Hakomori%26aufirst%3DY.%26aulast%3DMiyake%26aufirst%3DI.%26aulast%3DOhira%26aufirst%3DM.%26aulast%3DNakagawara%26aufirst%3DA.%26aulast%3DNakagawa%26aufirst%3DA.%26aulast%3DSakai%26aufirst%3DR.%26atitle%3DBiological%2520Role%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520in%2520Neuroblastoma%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2005%26volume%3D167%26spage%3D213%26epage%3D222%26doi%3D10.1016%2FS0002-9440%2810%2962966-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mossé, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laudenslager, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attiyeh, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquaglia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sennett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laureys, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speleman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakonarson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torkamani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schork, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonini, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappaport, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span> <span> </span><span class="NLM_article-title">Identification of ALK as a Major Familial Neuroblastoma Predisposition Gene</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>455</i></span>,  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">935</span>, <span class="refDoi"> DOI: 10.1038/nature07261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1038%2Fnature07261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=18724359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-935&author=Y.+P.+Moss%C3%A9author=M.+Laudenslagerauthor=L.+Longoauthor=K.+A.+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+Major+Familial+Neuroblastoma+Predisposition+Gene&doi=10.1038%2Fnature07261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of ALK as a major familial neuroblastoma predisposition gene</span></div><div class="casAuthors">Mosse, Yael P.; Laudenslager, Marci; Longo, Luca; Cole, Kristina A.; Wood, Andrew; Attiyeh, Edward F.; Laquaglia, Michael J.; Sennett, Rachel; Lynch, Jill E.; Perri, Patrizia; Laureys, Genevieve; Speleman, Frank; Kim, Cecilia; Hou, Cuiping; Hakonarson, Hakon; Torkamani, Ali; Schork, Nicholas J.; Brodeur, Garrett M.; Tonini, Gian P.; Rappaport, Eric; Devoto, Marcella; Maris, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">930-935</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma is a childhood cancer that can be inherited, but the genetic etiol. is largely unknown.  Here we show that germline mutations in the anaplastic lymphoma kinase (ALK) gene explain most hereditary neuroblastomas, and that activating mutations can also be somatically acquired.  We first identified a significant linkage signal at chromosome bands 2p23-24 using a whole-genome scan in neuroblastoma pedigrees.  Re-sequencing of regional candidate genes identified three sep. germline missense mutations in the tyrosine kinase domain of ALK that segregated with the disease in eight sep. families.  Re-sequencing in 194 high-risk neuroblastoma samples showed somatically acquired mutations in the tyrosine kinase domain in 12.4% of samples.  Nine of the ten mutations map to crit. regions of the kinase domain and were predicted, with high probability, to be oncogenic drivers.  Mutations resulted in constitutive phosphorylation, and targeted knockdown of ALK mRNA resulted in profound inhibition of growth in all cell lines harboring mutant or amplified ALK, as well as in two out of six wild-type cell lines for ALK.  Our results demonstrate that heritable mutations of ALK are the main cause of familial neuroblastoma, and that germline or acquired activation of this cell-surface kinase is a tractable therapeutic target for this lethal pediatric malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMNOcIFf5xjbVg90H21EOLACvtfcHk0ljzmz9ITA3Zlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP&md5=bb998ef8f6bfbd85f928263e13954ce4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnature07261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07261%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520Major%2520Familial%2520Neuroblastoma%2520Predisposition%2520Gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D935%26doi%3D10.1038%2Fnature07261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azarova, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautam, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span> <span> </span><span class="NLM_article-title">Emerging Importance of ALK in Neuroblastoma</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1016/j.semcancer.2011.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1016%2Fj.semcancer.2011.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=21945349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSktLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=267-275&author=A.+M.+Azarovaauthor=G.+Gautamauthor=R.+E.+George&title=Emerging+Importance+of+ALK+in+Neuroblastoma&doi=10.1016%2Fj.semcancer.2011.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging importance of ALK in neuroblastoma</span></div><div class="casAuthors">Azarova, Anna M.; Gautam, Gargi; George, Rani E.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">267-275</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Since the original descriptions of gain-of function mutations in anaplastic lymphoma kinase (ALK), interest in the role of this receptor tyrosine kinase in neuroblastoma development and as a potential therapeutic target has escalated.  As a group, the activating point mutations in full-length ALK, found in approx. 8% of all neuroblastoma tumors, are distributed evenly across different clin. stages.  However, the most frequent somatic mutation, F1174L, is assocd. with amplification of the MYCN oncogene.  This combination of features appears to confer a worse prognosis than MYCN amplification alone, suggesting a cooperative effect on neuroblastoma formation by these two proteins.  Indeed, F1174L has shown more potent transforming activity in vivo than the second most common activating mutation, R1275Q, and is responsible for innate and acquired resistance to crizotinib, a clin. relevant ALK inhibitor that will soon be com. available.  These advances cast ALK as a bona fide oncoprotein in neuroblastoma and emphasize the need to understand ALK-mediated signaling in this tumor.  This review addresses many of the current issues surrounding the role of ALK in normal development and neuroblastoma pathogenesis, and discusses the prospects for clin. effective targeted treatments based on ALK inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpqmFzh9Q3frVg90H21EOLACvtfcHk0ljzmz9ITA3Zlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSktLzN&md5=e07445aecd9829c465f1f4023124521f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2011.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2011.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DAzarova%26aufirst%3DA.%2BM.%26aulast%3DGautam%26aufirst%3DG.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26atitle%3DEmerging%2520Importance%2520of%2520ALK%2520in%2520Neuroblastoma%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2011%26volume%3D21%26spage%3D267%26epage%3D275%26doi%3D10.1016%2Fj.semcancer.2011.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beausoleil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innocenti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, T.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comb, M. J.</span></span> <span> </span><span class="NLM_article-title">Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">3312</span>– <span class="NLM_lpage">3323</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1158%2F0008-5472.CAN-11-3931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=22570254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFKku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3312-3323&author=H.+Renauthor=Z.-P.+Tanauthor=X.+Zhuauthor=K.+Crosbyauthor=H.+Haackauthor=J.+M.+Renauthor=S.+Beausoleilauthor=A.+Moritzauthor=G.+Innocentiauthor=J.+Rushauthor=Y.+Zhangauthor=X.-M.+Zhouauthor=T.-L.+Guauthor=Y.-F.+Yangauthor=M.+J.+Comb&title=Identification+of+Anaplastic+Lymphoma+Kinase+as+a+Potential+Therapeutic+Target+in+Ovarian+Cancer&doi=10.1158%2F0008-5472.CAN-11-3931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer</span></div><div class="casAuthors">Ren, Hong; Tan, Zhi-Ping; Zhu, Xin; Crosby, Katherine; Haack, Herbert; Ren, Jian-Min; Beausoleil, Sean; Moritz, Albrecht; Innocenti, Gregory; Rush, John; Zhang, Yi; Zhou, Xin-Min; Gu, Ting-Lei; Yang, Yi-Feng; Comb, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3312-3323</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Findings suggest the use of ALK kinase inhibitors now in clin. development as potential agents for treatment of some patients with serous ovarian carcinoma or stromal sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi924EZXGeJ7Vg90H21EOLACvtfcHk0lh3bmFMmjLKKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFKku7w%253D&md5=a263a135244b307b864c098769d10a7a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3931%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.-P.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DJ.%2BM.%26aulast%3DBeausoleil%26aufirst%3DS.%26aulast%3DMoritz%26aufirst%3DA.%26aulast%3DInnocenti%26aufirst%3DG.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.-M.%26aulast%3DGu%26aufirst%3DT.-L.%26aulast%3DYang%26aufirst%3DY.-F.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DIdentification%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520as%2520a%2520Potential%2520Therapeutic%2520Target%2520in%2520Ovarian%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D3312%26epage%3D3323%26doi%3D10.1158%2F0008-5472.CAN-11-3931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tuma, R. S.</span></span> <span> </span><span class="NLM_article-title">ALK Gene Amplified in Most Inflammatory Breast Cancers</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1093/jnci/djr553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1093%2Fjnci%2Fdjr553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=22215853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVWhsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2012&pages=87-88&author=R.+S.+Tuma&title=ALK+Gene+Amplified+in+Most+Inflammatory+Breast+Cancers&doi=10.1093%2Fjnci%2Fdjr553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">ALK Gene Amplified in Most Inflammatory Breast Cancers</span></div><div class="casAuthors">Tuma, Rabiya S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-88</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Inflammatory breast cancer (IBC) is a rare form of the disease that differs substantially from non-inflammatory breast cancer in presentation and response to therapy. Despite those differences, researchers have uncovered few mol. characteristics that distinguish IBC from non-inflammatory breast cancer, and IBC treatment generally relies on std. breast cancer regimens.  Recently, it has been reported that ALK gene amplification is a common feature of IBC tumors and that small-mol. ALK inhibitors are effective in mouse xenograft models.  Current developments on this recent report are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB9yX6fegRi7Vg90H21EOLACvtfcHk0lh3bmFMmjLKKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVWhsb0%253D&md5=46e7633055aadc3aacfc6bac9b4cb591</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjr553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjr553%26sid%3Dliteratum%253Aachs%26aulast%3DTuma%26aufirst%3DR.%2BS.%26atitle%3DALK%2520Gene%2520Amplified%2520in%2520Most%2520Inflammatory%2520Breast%2520Cancers%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2012%26volume%3D104%26spage%3D87%26epage%3D88%26doi%3D10.1093%2Fjnci%2Fdjr553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anzalone, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Underiner, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">498</span>, <span class="refDoi"> DOI: 10.1021/ml100158s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100158s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=493-498&author=G.+R.+Ottauthor=R.+Tripathyauthor=M.+Chengauthor=R.+McHughauthor=A.+V.+Anzaloneauthor=T.+L.+Underinerauthor=M.+A.+Curryauthor=M.+R.+Quailauthor=L.+Luauthor=W.+Wanauthor=T.+S.+Angelesauthor=M.+S.+Albomauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+a+Potent+Inhibitor+of+Anaplastic+Lymphoma+Kinase+with+in+Vivo+Antitumor+Activity&doi=10.1021%2Fml100158s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity</span></div><div class="casAuthors">Ott, Gregory R.; Tripathy, Rabindranath; Cheng, Mangeng; McHugh, Robert; Anzalone, Andrew V.; Underiner, Ted L.; Curry, Matthew A.; Quail, Matthew R.; Lu, Lihui; Wan, Weihua; Angeles, Thelma S.; Albom, Mark S.; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">493-498</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel 7-amino-1,3,4,5-tetrahydrobenzo[b]azepin-2-one derivs. within the diaminopyrimidine class of kinase inhibitors were identified that target anaplastic lymphoma kinase (ALK).  These inhibitors are potent against ALK in an isolated enzyme assay and inhibit autophosphorylation of the oncogenic fusion protein NPM-ALK in anaplastic large cell lymphoma (ALCL) cell lines.  The lead inhibitor 15 (I), which incorporates a bicyclo[2.2.1]hept-5-ene ring system in place of an aryl moiety, activates the pro-apoptotic caspases (3 and 7) and displays selective cytotoxicity against ALK-pos. ALCL cells.  Furthermore, 15 provides more than 40-fold selectivity against the structurally related insulin receptor, is orally bioavailable in multiple species, and displays in vivo antitumor efficacy when dosed orally in ALK-pos. ALCL tumor xenografts in Scid mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof0qilbcAbZ7Vg90H21EOLACvtfcHk0lidz65umG4Gyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ&md5=15d4f7aea64f212338d8c9cd88a36c64</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fml100158s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100158s%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DTripathy%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DMcHugh%26aufirst%3DR.%26aulast%3DAnzalone%26aufirst%3DA.%2BV.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DCurry%26aufirst%3DM.%2BA.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520with%2520in%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D493%26epage%3D498%26doi%3D10.1021%2Fml100158s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mesaros, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrish, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugan, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anzalone, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">Novel 2,3,4,5-Tetrahydro-benzo[d]azepine Derivatives of 2,4-Diaminopyrimidine, Selective and Orally Bioavailable ALK Inhibitors with Antitumor Efficacy in ALCL Mouse Models</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.10.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1016%2Fj.bmcl.2010.10.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=21074994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SqsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=463-466&author=E.+F.+Mesarosauthor=J.+P.+Burkeauthor=J.+D.+Parrishauthor=B.+J.+Duganauthor=A.+V.+Anzaloneauthor=T.+S.+Angelesauthor=M.+S.+Albomauthor=L.+D.+Aimoneauthor=M.+R.+Quailauthor=W.+Wanauthor=L.+Luauthor=Z.+Huangauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=M.+Chengauthor=G.+R.+Ottauthor=B.+D.+Dorsey&title=Novel+2%2C3%2C4%2C5-Tetrahydro-benzo%5Bd%5Dazepine+Derivatives+of+2%2C4-Diaminopyrimidine%2C+Selective+and+Orally+Bioavailable+ALK+Inhibitors+with+Antitumor+Efficacy+in+ALCL+Mouse+Models&doi=10.1016%2Fj.bmcl.2010.10.115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models</span></div><div class="casAuthors">Mesaros, Eugen F.; Burke, Jason P.; Parrish, Jonathan D.; Dugan, Benjamin J.; Anzalone, Andrew V.; Angeles, Thelma S.; Albom, Mark S.; Aimone, Lisa D.; Quail, Matthew R.; Wan, Weihua; Lu, Lihui; Huang, Zeqi; Ator, Mark A.; Ruggeri, Bruce A.; Cheng, Mangeng; Ott, Gregory R.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">463-466</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis and biol. evaluation of potent and selective anaplastic lymphoma kinase (ALK) inhibitors from a novel class of 2,4-diaminopyrimidines, incorporating 2,3,4,5-tetrahydro-benzo[d]azepine fragments, is described.  An orally bioavailable analog, I, that displayed antitumor efficacy in ALCL xenograft models in mice was identified and extensively profiled.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEIN3ozlaLo7Vg90H21EOLACvtfcHk0lidz65umG4Gyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SqsbvE&md5=f6fd9a9ff66139f77191f378d4a2dcb7</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.10.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.10.115%26sid%3Dliteratum%253Aachs%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DBurke%26aufirst%3DJ.%2BP.%26aulast%3DParrish%26aufirst%3DJ.%2BD.%26aulast%3DDugan%26aufirst%3DB.%2BJ.%26aulast%3DAnzalone%26aufirst%3DA.%2BV.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DNovel%25202%252C3%252C4%252C5-Tetrahydro-benzo%255Bd%255Dazepine%2520Derivatives%2520of%25202%252C4-Diaminopyrimidine%252C%2520Selective%2520and%2520Orally%2520Bioavailable%2520ALK%2520Inhibitors%2520with%2520Antitumor%2520Efficacy%2520in%2520ALCL%2520Mouse%2520Models%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D463%26epage%3D466%26doi%3D10.1016%2Fj.bmcl.2010.10.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milkiewicz, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roemmele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theroff, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Underiner, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zificsak, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-activity Relationships of 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazines as Potent and Selective Inhibitors of the Anaplastic Lymphoma Kinase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4351</span>– <span class="NLM_lpage">4362</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.04.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1016%2Fj.bmc.2010.04.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=20483621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntV2ruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=4351-4362&author=K.+L.+Milkiewiczauthor=L.+R.+Weinbergauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=M.+Chengauthor=A.+K.+Ghoseauthor=R.+C.+Roemmeleauthor=J.+P.+Theroffauthor=T.+L.+Underinerauthor=C.+A.+Zificsakauthor=B.+D.+Dorsey&title=Synthesis+and+Structure-activity+Relationships+of+1%2C2%2C3%2C4-Tetrahydropyrido%5B2%2C3-b%5Dpyrazines+as+Potent+and+Selective+Inhibitors+of+the+Anaplastic+Lymphoma+Kinase&doi=10.1016%2Fj.bmc.2010.04.087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase</span></div><div class="casAuthors">Milkiewicz, Karen L.; Weinberg, Linda R.; Albom, Mark S.; Angeles, Thelma S.; Cheng, Mangeng; Ghose, Arup K.; Roemmele, Renee C.; Theroff, Jay P.; Underiner, Ted L.; Zificsak, Craig A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4351-4362</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dysregulation of the anaplastic lymphoma kinase (ALK) is implicated in a variety of cancers.  A series of tetrahydropyrido[2,3-b]pyrazines was constructed as ring-constrained analogs of a known aminopyridine kinase scaffold.  Chem. was developed to rapidly elaborate the SAR, structural elements impacting ALK inhibitory activity were exploited, and kinase selective analogs were identified that inhibit ALK with IC50 values ∼10 nM (enzyme) and ∼150 nM (cell).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8a1ByMi_Z37Vg90H21EOLACvtfcHk0lidz65umG4Gyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntV2ruro%253D&md5=8fe973a224b19d133105d12178fd34a8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.04.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.04.087%26sid%3Dliteratum%253Aachs%26aulast%3DMilkiewicz%26aufirst%3DK.%2BL.%26aulast%3DWeinberg%26aufirst%3DL.%2BR.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DRoemmele%26aufirst%3DR.%2BC.%26aulast%3DTheroff%26aufirst%3DJ.%2BP.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DZificsak%26aufirst%3DC.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DSynthesis%2520and%2520Structure-activity%2520Relationships%2520of%25201%252C2%252C3%252C4-Tetrahydropyrido%255B2%252C3-b%255Dpyrazines%2520as%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520the%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D4351%26epage%3D4362%26doi%3D10.1016%2Fj.bmc.2010.04.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thieu, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesaros, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingrich, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">2,7-Disubstituted-pyrrolo[2,1-f][1,2,4]triazines: New Variant of an Old Template and Application to the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors with in Vivo Antitumor Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6328</span>– <span class="NLM_lpage">6341</span>, <span class="refDoi"> DOI: 10.1021/jm200758k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200758k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGmsr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6328-6341&author=G.+R.+Ottauthor=G.+J.+Wellsauthor=T.+V.+Thieuauthor=M.+R.+Quailauthor=J.+G.+Liskoauthor=E.+F.+Mesarosauthor=D.+E.+Gingrichauthor=A.+K.+Ghoseauthor=W.+Wanauthor=L.+Luauthor=M.+Chengauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=Z.+Huangauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=2%2C7-Disubstituted-pyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazines%3A+New+Variant+of+an+Old+Template+and+Application+to+the+Discovery+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitors+with+in+Vivo+Antitumor+Activity&doi=10.1021%2Fjm200758k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">2,7-Disubstituted-pyrrolo[2,1-f][1,2,4]triazines: New Variant of an Old Template and Application to the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors with in Vivo Antitumor Activity</span></div><div class="casAuthors">Ott, Gregory R.; Wells, Gregory J.; Thieu, Tho-V.; Quail, Matthew R.; Lisko, Joseph G.; Mesaros, Eugen F.; Gingrich, Diane E.; Ghose, Arup K.; Wan, Wei-Hua; Lu, Li-Hui; Cheng, Man-Geng; Albom, Mark S.; Angeles, Thelma S.; Huang, Ze-Qi; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6328-6341</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel 2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazine scaffold has been designed as a new kinase inhibitor platform mimicking the bioactive conformation of the well-known diaminopyrimidine motif.  Herein the design, synthesis, and validation of this new pyrrolo[2,1-f][1,2,4]triazine scaffold is described for inhibitors of anaplastic lymphoma kinase (ALK).  Importantly, incorporation of appropriate potency and selectivity determinants has led to the discovery of several advanced leads that were orally efficacious in animal models of anaplastic large cell lymphoma (ALCL).  A lead inhibitor I displaying superior efficacy was identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQP33sAtk5w7Vg90H21EOLACvtfcHk0liYFyBTOQj_Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGmsr%252FK&md5=a591238a89465683c709e6a965108212</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm200758k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200758k%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DWells%26aufirst%3DG.%2BJ.%26aulast%3DThieu%26aufirst%3DT.%2BV.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3D2%252C7-Disubstituted-pyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazines%253A%2520New%2520Variant%2520of%2520an%2520Old%2520Template%2520and%2520Application%2520to%2520the%2520Discovery%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitors%2520with%2520in%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6328%26epage%3D6341%26doi%3D10.1021%2Fjm200758k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gantla, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickens, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chucholowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, T. R.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of 5-Aryl-pyridone-carboxamides as Inhibitors of Anaplastic Lymphoma Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1006</span>– <span class="NLM_lpage">1015</span>, <span class="refDoi"> DOI: 10.1021/jm050824x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050824x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvFKhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=1006-1015&author=R.+Liauthor=L.+Xueauthor=T.+Zhuauthor=Q.+Jiangauthor=X.+Cuiauthor=Z.+Yanauthor=D.+McGeeauthor=J.+Wangauthor=V.+R.+Gantlaauthor=J.+C.+Pickensauthor=D.+McGrathauthor=A.+Chucholowskiauthor=S.+W.+Morrisauthor=T.+R.+Webb&title=Design+and+Synthesis+of+5-Aryl-pyridone-carboxamides+as+Inhibitors+of+Anaplastic+Lymphoma+Kinase&doi=10.1021%2Fjm050824x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of 5-Aryl-pyridone-carboxamides as Inhibitors of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Li, Rongshi; Xue, Liquan; Zhu, Tong; Jiang, Qin; Cui, Xiaoli; Yan, Zheng; McGee, Danny; Wang, Jian; Gantla, Vidyasagar Reddy; Pickens, Jason C.; McGrath, Doug; Chucholowski, Alexander; Morris, Stephan W.; Webb, Thomas R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1006-1015</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a promising new target for therapy of certain cancers such as anaplastic large-cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT).  The authors have identified a series of novel pyridones as kinase inhibitors of ALK by application of a stepwise process involving in vitro screening of a novel targeted library followed by iterative template modification based on medicinal chem. insights and computational ranking of virtual libraries.  Using this process, the authors discovered ALK-selective inhibitors with improved potency and selectivity.  Herein the details of the design process and synthesis of these novel pyridones, along with their enzymic and cell-based activity, are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXgfuXJ1QEMLVg90H21EOLACvtfcHk0liYFyBTOQj_Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvFKhsA%253D%253D&md5=818c046a4b447011f240e99d96370c30</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm050824x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050824x%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DR.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DMcGee%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGantla%26aufirst%3DV.%2BR.%26aulast%3DPickens%26aufirst%3DJ.%2BC.%26aulast%3DMcGrath%26aufirst%3DD.%26aulast%3DChucholowski%26aufirst%3DA.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DWebb%26aufirst%3DT.%2BR.%26atitle%3DDesign%2520and%2520Synthesis%2520of%25205-Aryl-pyridone-carboxamides%2520as%2520Inhibitors%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D1006%26epage%3D1015%26doi%3D10.1021%2Fjm050824x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabbatini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korenchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowand, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leperi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumble, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gontarek, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maksimchuk, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suravajjala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapierre, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shotwell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">GSK1838705A Inhibits the Insulin-like Growth Factor-1 Receptor and Anaplastic Lymphoma Kinase and Shows Antitumor Activity in Experimental Models of Human Cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2811</span>– <span class="NLM_lpage">2820</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1158%2F1535-7163.MCT-09-0423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=19825801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2811-2820&author=P.+Sabbatiniauthor=S.+Korenchukauthor=J.+L.+Rowandauthor=A.+Groyauthor=Q.+Liuauthor=D.+Leperiauthor=C.+Atkinsauthor=M.+Dumbleauthor=J.+Yangauthor=K.+Andersonauthor=R.+G.+Krugerauthor=R.+R.+Gontarekauthor=K.+R.+Maksimchukauthor=S.+Suravajjalaauthor=R.+R.+Lapierreauthor=J.+B.+Shotwellauthor=J.+W.+Wilsonauthor=S.+D.+Chamberlainauthor=S.+K.+Rabindranauthor=R.+Kumar&title=GSK1838705A+Inhibits+the+Insulin-like+Growth+Factor-1+Receptor+and+Anaplastic+Lymphoma+Kinase+and+Shows+Antitumor+Activity+in+Experimental+Models+of+Human+Cancers&doi=10.1158%2F1535-7163.MCT-09-0423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers</span></div><div class="casAuthors">Sabbatini, Peter; Korenchuk, Susan; Rowand, Jason L.; Groy, Arthur; Liu, Qi; Leperi, Dominic; Atkins, Charity; Dumble, Melissa; Yang, Jingsong; Anderson, Kelly; Kruger, Ryan G.; Gontarek, Richard R.; Maksimchuk, Kenneth R.; Suravajjala, Sapna; Lapierre, Russell R.; Shotwell, J. Brad; Wilson, Joseph W.; Chamberlain, Stanley D.; Rabindran, Sridhar K.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2811-2820</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The insulin-like growth factor-I receptor (IGF-IR) signaling pathway is activated in various tumors, and inhibition of IGF-IR kinase provides a therapeutic opportunity in these patients.  GSK1838705A is a small-mol. kinase inhibitor that inhibits IGF-IR and the insulin receptor with IC50s of 2.0 and 1.6 nmol/L, resp.  GSK1838705A blocks the in vitro proliferation of cell lines derived from solid and hematol. malignancies, including multiple myeloma and Ewing's sarcoma, and retards the growth of human tumor xenografts in vivo.  Despite the inhibitory effect of GSK1838705A on insulin receptor, minimal effects on glucose homeostasis were obsd. at efficacious doses.  GSK1838705A also inhibits the anaplastic lymphoma kinase (ALK), which drives the aberrant growth of anaplastic large-cell lymphomas, some neuroblastomas, and a subset of non-small cell lung cancers.  GSK1838705A inhibits ALK, with an IC50 of 0.5 nmol/L, and causes complete regression of ALK-dependent tumors in vivo at well-tolerated doses.  GSK1838705A is therefore a promising antitumor agent for therapeutic use in human cancers. [Mol Cancer Ther 2009;8(10):2811-20].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyQ0LEFOBer7Vg90H21EOLACvtfcHk0liuDm9Ejg8Akw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7N&md5=42e56e8dd4920322b82bedd13721be5b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0423%26sid%3Dliteratum%253Aachs%26aulast%3DSabbatini%26aufirst%3DP.%26aulast%3DKorenchuk%26aufirst%3DS.%26aulast%3DRowand%26aufirst%3DJ.%2BL.%26aulast%3DGroy%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLeperi%26aufirst%3DD.%26aulast%3DAtkins%26aufirst%3DC.%26aulast%3DDumble%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26aulast%3DGontarek%26aufirst%3DR.%2BR.%26aulast%3DMaksimchuk%26aufirst%3DK.%2BR.%26aulast%3DSuravajjala%26aufirst%3DS.%26aulast%3DLapierre%26aufirst%3DR.%2BR.%26aulast%3DShotwell%26aufirst%3DJ.%2BB.%26aulast%3DWilson%26aufirst%3DJ.%2BW.%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DGSK1838705A%2520Inhibits%2520the%2520Insulin-like%2520Growth%2520Factor-1%2520Receptor%2520and%2520Anaplastic%2520Lymphoma%2520Kinase%2520and%2520Shows%2520Antitumor%2520Activity%2520in%2520Experimental%2520Models%2520of%2520Human%2520Cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D2811%26epage%3D2820%26doi%3D10.1158%2F1535-7163.MCT-09-0423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choquette, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stellwagen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emkey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffran, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szilvassy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brake, R. L.</span></span> <span> </span><span class="NLM_article-title">The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6540</span>, <span class="refDoi"> DOI: 10.1021/jm3005866</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3005866" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC38XptF2hsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6523-6540&author=R.+T.+Lewisauthor=C.+M.+Bodeauthor=D.+M.+Choquetteauthor=M.+Potashmanauthor=K.+Romeroauthor=J.+C.+Stellwagenauthor=Y.+Tefferaauthor=E.+Mooreauthor=D.+A.+Whittingtonauthor=H.+Chenauthor=L.+F.+Epsteinauthor=R.+Emkeyauthor=P.+S.+Andrewsauthor=V.+L.+Yuauthor=D.+C.+Saffranauthor=M.+Xuauthor=A.+Drewauthor=P.+Merkelauthor=S.+Szilvassyauthor=R.+L.+Brake&title=The+Discovery+and+Optimization+of+a+Novel+Class+of+Potent%2C+Selective%2C+and+Orally+Bioavailable+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitors+with+Potential+Utility+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm3005866"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer</span></div><div class="casAuthors">Lewis, Richard T.; Bode, Christiane M.; Choquette, Deborah M.; Potashman, Michele; Romero, Karina; Stellwagen, John C.; Teffera, Yohannes; Moore, Earl; Whittington, Douglas A.; Chen, Hao; Epstein, Linda F.; Emkey, Renee; Andrews, Paul S.; Yu, Violeta L.; Saffran, Douglas C.; Xu, Man; Drew, Allison; Merkel, Patricia; Szilvassy, Steven; Brake, Rachael L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6523-6540</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A class of 2-acyliminobenzimidazoles has been developed as potent and selective inhibitors of anaplastic lymphoma kinase (ALK).  Structure based design facilitated the rapid development of structure-activity relationships (SAR) and the optimization of kinase selectivity.  Introduction of an optimally placed polar substituent was key to solving issues of metabolic stability and led to the development of potent, selective, orally bioavailable ALK inhibitors.  Compd. I [Ar = 3,5-F2Ph] achieved substantial tumor regression in an NPM-ALK driven murine tumor xenograft model when dosed qd.  Compd. I [Ar = 3,5-F2Ph, 4-FPh] show favorable potency and PK characteristics in preclin. species indicative of suitability for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDAwmBMVhyL7Vg90H21EOLACvtfcHk0liuDm9Ejg8Akw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptF2hsbo%253D&md5=a3c2f9e8dbf7d73319657e456bd45076</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm3005866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3005866%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DBode%26aufirst%3DC.%2BM.%26aulast%3DChoquette%26aufirst%3DD.%2BM.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DRomero%26aufirst%3DK.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DMoore%26aufirst%3DE.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DEmkey%26aufirst%3DR.%26aulast%3DAndrews%26aufirst%3DP.%2BS.%26aulast%3DYu%26aufirst%3DV.%2BL.%26aulast%3DSaffran%26aufirst%3DD.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DDrew%26aufirst%3DA.%26aulast%3DMerkel%26aufirst%3DP.%26aulast%3DSzilvassy%26aufirst%3DS.%26aulast%3DBrake%26aufirst%3DR.%2BL.%26atitle%3DThe%2520Discovery%2520and%2520Optimization%2520of%2520a%2520Novel%2520Class%2520of%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Bioavailable%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitors%2520with%2520Potential%2520Utility%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6523%26epage%3D6540%26doi%3D10.1021%2Fjm3005866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luther, W.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">384</span>, <span class="refDoi"> DOI: 10.1021/ml200002a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200002a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFersrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=379-384&author=X.+Dengauthor=J.+Wangauthor=J.+Zhangauthor=T.+Simauthor=N.+D.+Kimauthor=T.+Sasakiauthor=W.+Lutherauthor=R.+E.+Georgeauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Discovery+of+3%2C5-Diamino-1%2C2%2C4-triazole+Ureas+as+Potent+Anaplastic+Lymphoma+Kinase+Inhibitors&doi=10.1021%2Fml200002a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">Deng, Xianming; Wang, Jinhua; Zhang, Jianming; Sim, Taebo; Kim, Nam Doo; Sasaki, Takaaki; Luther, William, II; George, Rani E.; Janne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">379-384</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel 3,5-diamino-1,2,4-triazole benzyl ureas was identified as having potent anaplastic lymphoma kinase (ALK) inhibition exemplified by I (X = O), II, and I (X = S), which exhibited antiproliferative IC50 values of 70, 40, and 20 nM in Tel-ALK transformed Ba/F3 cells, resp.  Moreover, I (X = O, S) potently inhibited the growth and survival of NPM-ALK pos. anaplastic large cell lymphoma cell (SU-DHL-1) and neuroblastoma cell lines (KELLY, SH-SY5Y) contg. the F1174L ALK mutation.  These compds. provide novel leads for the development of small-mol. ALK inhibitors for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_KXj1NxtfHLVg90H21EOLACvtfcHk0ljHjgRJN0D0Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFersrc%253D&md5=cd4a0e5eefcf0b1b6e3c5dab5dc87d81</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fml200002a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200002a%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%25203%252C5-Diamino-1%252C2%252C4-triazole%2520Ureas%2520as%2520Potent%2520Anaplastic%2520Lymphoma%2520Kinase%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D379%26epage%3D384%26doi%3D10.1021%2Fml200002a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arango, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Los, G.</span></span> <span> </span><span class="NLM_article-title">Cytoreductive Antitumor Activity of PF-2341066, A Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Met, in Experimental Models of Anaplastic Large-cell Lymphoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">3314</span>– <span class="NLM_lpage">3322</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1158%2F1535-7163.MCT-07-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=18089725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3314-3322&author=J.+G.+Christensenauthor=H.+Y.+Zouauthor=M.+E.+Arangoauthor=Q.+Liauthor=J.+H.+Leeauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=G.+R.+Altonauthor=B.+Mroczkowskiauthor=G.+Los&title=Cytoreductive+Antitumor+Activity+of+PF-2341066%2C+A+Novel+Inhibitor+of+Anaplastic+Lymphoma+Kinase+and+c-Met%2C+in+Experimental+Models+of+Anaplastic+Large-cell+Lymphoma&doi=10.1158%2F1535-7163.MCT-07-0365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span></div><div class="casAuthors">Christensen, James G.; Zou, Helen Y.; Arango, Maria E.; Li, Qiuhua; Lee, Joseph H.; McDonnell, Scott R.; Yamazaki, Shinji; Alton, Gordon R.; Mroczkowski, Barbara; Los, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3314-3322</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A t(2;5) chromosomal translocation resulting in expression of an oncogenic kinase fusion protein known as nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL).  PF-2341066 was recently identified as a p.o. bioavailable, small-mol. inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK fusion protein.  PF-2341066 also potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC50 value, 24 nmol/L).  In biochem. and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacol. relevant concns. across a panel of >120 diverse kinases.  PF-2341066 potently inhibited cell proliferation, which was assocd. with G1-S-phase cell cycle arrest and induction of apoptosis in ALK-pos. ALCL cells (IC50 values, ∼30 nmol/L) but not ALK-neg. lymphoma cells.  The induction of apoptosis was confirmed using terminal deoxyribonucleotide transferase-mediated nick-end labeling and Annexin V staining (IC50 values, 25-50 nmol/L).  P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compd. administration.  A strong correlation was obsd. between antitumor response and inhibition of NPM-ALK phosphorylation and induction of apoptosis in tumor tissue.  In addn., inhibition of key NPM-ALK signaling mediators, including phospholipase C-γ, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 were obsd. at concns. or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.  Collectively, these data illustrate the potential clin. utility of inhibitors of NPM-ALK in treatment of patients with ALK-pos. ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptqY0tUwGnurVg90H21EOLACvtfcHk0ljHjgRJN0D0Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL&md5=04fbbaf43ca527408bde8cabcd38e1fd</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0365%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAlton%26aufirst%3DG.%2BR.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DLos%26aufirst%3DG.%26atitle%3DCytoreductive%2520Antitumor%2520Activity%2520of%2520PF-2341066%252C%2520A%2520Novel%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520and%2520c-Met%252C%2520in%2520Experimental%2520Models%2520of%2520Anaplastic%2520Large-cell%2520Lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3314%26epage%3D3322%26doi%3D10.1158%2F1535-7163.MCT-07-0365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran-Dubé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botrous, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grodsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padrique, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6342</span>– <span class="NLM_lpage">6363</span>, <span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dub%C3%A9author=H.+Shenauthor=M.+Nambuauthor=P.-P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+Based+Drug+Design+of+Crizotinib+%28PF-02341066%29%2C+a+Potent+and+Selective+Dual+Inhibitor+of+Mesenchymal%E2%80%93Epithelial+Transition+Factor+%28c-MET%29+Kinase+and+Anaplastic+Lymphoma+Kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0ljHjgRJN0D0Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520Based%2520Drug%2520Design%2520of%2520Crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520Potent%2520and%2520Selective%2520Dual%2520Inhibitor%2520of%2520Mesenchymal%25E2%2580%2593Epithelial%2520Transition%2520Factor%2520%2528c-MET%2529%2520Kinase%2520and%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkisova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferdekamper, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phimister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aycinena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanewsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P. Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5675</span>– <span class="NLM_lpage">5690</span>, <span class="refDoi"> DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.-Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.+Y.+Michellys&title=Synthesis%2C+Structure-Activity+Relationships%2C+and+in+Vivo+Efficacy+of+the+Novel+Potent+and+Selective+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor+5-Chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29phenyl%29-N4-%282-%28isopropylsulfonyl%29phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+Currently+in+Phase+1+and+Phase+2+Clinical+Trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span></div><div class="casAuthors">Marsilje, Thomas H.; Pei, Wei; Chen, Bei; Lu, Wenshuo; Uno, Tetsuo; Jin, Yunho; Jiang, Tao; Kim, Sungjoon; Li, Nanxin; Warmuth, Markus; Sarkisova, Yelena; Sun, Frank; Steffy, Auzon; Pferdekamper, AnneMarie C.; Li, Allen G.; Joseph, Sean B.; Kim, Young; Liu, Bo; Tuntland, Tove; Cui, Xiaoming; Gray, Nathanael S.; Steensma, Ruo; Wan, Yongqin; Jiang, Jiqing; Chopiuk, Greg; Li, Jie; Gordon, W. Perry; Richmond, Wendy; Johnson, Kevin; Chang, Jonathan; Groessl, Todd; He, You-Qun; Phimister, Andrew; Aycinena, Alex; Lee, Christian C.; Bursulaya, Badry; Karanewsky, Donald S.; Seidel, H. Martin; Harris, Jennifer L.; Michellys, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5675-5690</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis, preclin. profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor (I; LDK378) are described.  In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor (II; TAE684).  Compd. I is currently in phase 1 and phase 2 clin. trials with substantial antitumor activity being obsd. in ALK-pos. cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ-y7ZuX2XLLVg90H21EOLACvtfcHk0ljyjesWoFFWvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D&md5=4b8f66e4acb27efe814956d7d0016068</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.-Q.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26atitle%3DSynthesis%252C%2520Structure-Activity%2520Relationships%252C%2520and%2520in%2520Vivo%2520Efficacy%2520of%2520the%2520Novel%2520Potent%2520and%2520Selective%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%25205-Chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529phenyl%2529-N4-%25282-%2528isopropylsulfonyl%2529phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520Currently%2520in%2520Phase%25201%2520and%2520Phase%25202%2520Clinical%2520Trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiroshima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, Y.</span></span> <span> </span><span class="NLM_article-title">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2011.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1016%2Fj.ccr.2011.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=21575866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+Selective+ALK+Inhibitor+Capable+of+Blocking+the+Resistant+Gatekeeper+Mutant&doi=10.1016%2Fj.ccr.2011.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span></div><div class="casAuthors">Sakamoto, Hiroshi; Tsukaguchi, Toshiyuki; Hiroshima, Sayuri; Kodama, Tatsushi; Kobayashi, Takamitsu; Fukami, Takaaki A.; Oikawa, Nobuhiro; Tsukuda, Takuo; Ishii, Nobuya; Aoki, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">679-690</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in certain cancers, following gene alterations such as chromosomal translocation, amplification, or point mutation.  Here, the authors identified CH5424802, a potent, selective, and orally available ALK inhibitor with a unique chem. scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as non-small cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo.  CH5424802 inhibited ALK L1196M, which corresponds to the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK L1196M-driven cell growth.  The authors' results support the potential for clin. evaluation of CH5424802 for the treatment of patients with ALK-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrk3zvzF9p67Vg90H21EOLACvtfcHk0ljyjesWoFFWvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D&md5=cae32f3a3647926ba835293b68e776f8</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520Selective%2520ALK%2520Inhibitor%2520Capable%2520of%2520Blocking%2520the%2520Resistant%2520Gatekeeper%2520Mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690%26doi%3D10.1016%2Fj.ccr.2011.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuichi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span> <span> </span><span class="NLM_article-title">9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6286</span>– <span class="NLM_lpage">6294</span>, <span class="refDoi"> DOI: 10.1021/jm200652u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200652u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6286-6294&author=K.+Kinoshitaauthor=T.+Kobayashiauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Haraauthor=J.+Ohwadaauthor=K.+Hattoriauthor=T.+Miyagiauthor=W.-S.+Hongauthor=M.-J.+Parkauthor=K.+Takanashiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=9-Substituted+6%2C6-Dimethyl-11-oxo-6%2C11-dihydro-5H-benzo%5Bb%5Dcarbazoles+as+Highly+Selective+and+Potent+Anaplastic+Lymphoma+Kinase+Inhibitors&doi=10.1021%2Fjm200652u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">Kinoshita, Kazutomo; Kobayashi, Takamitsu; Asoh, Kohsuke; Furuichi, Noriyuki; Ito, Toshiya; Kawada, Hatsuo; Hara, Sousuke; Ohwada, Jun; Hattori, Kazuo; Miyagi, Takuho; Hong, Woo-Sang; Park, Min-Jeong; Takanashi, Kenji; Tsukaguchi, Toshiyuki; Sakamoto, Hiroshi; Tsukuda, Takuo; Oikawa, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6286-6294</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles were discovered as highly selective and potent anaplastic lymphoma kinase (ALK) inhibitors by structure-based drug design.  The high target selectivity was achieved by introducing a substituent close to the E0 region of the ATP binding site, which has a unique amino acid sequence.  Among the identified inhibitors, compd. 13d (I) showed highly selective and potent inhibitory activity against ALK with an IC50 value of 2.9 nM and strong antiproliferative activity against KARPAS-299 with an IC50 value of 12.8 nM.  The compd. also displayed significant antitumor efficacy in an established ALK fusion gene-pos. anaplastic large-cell lymphoma (ALCL) xenograft model in mice without body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfpJsdIdDvO7Vg90H21EOLACvtfcHk0lgb94Ldp8nfhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP&md5=6293368243c840e12beefc8c8d6bb69a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm200652u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200652u%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DMiyagi%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DW.-S.%26aulast%3DPark%26aufirst%3DM.-J.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3D9-Substituted%25206%252C6-Dimethyl-11-oxo-6%252C11-dihydro-5H-benzo%255Bb%255Dcarbazoles%2520as%2520Highly%2520Selective%2520and%2520Potent%2520Anaplastic%2520Lymphoma%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6286%26epage%3D6294%26doi%3D10.1021%2Fjm200652u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifshits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Strategies to Overcome Crizotinib Resistance in Non-small Cell Lung Cancers Harboring the Fusion Oncogene EML4-ALK</span>. <i>Proc. Natl. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">7535</span>– <span class="NLM_lpage">7540</span>, <span class="refDoi"> DOI: 10.1073/pnas.1019559108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1073%2Fpnas.1019559108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=21502504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=7535-7540&author=R.+Katayamaauthor=T.+M.+Khanauthor=C.+Benesauthor=E.+Lifshitsauthor=H.+Ebiauthor=V.+M.+Riveraauthor=W.+C.+Shakespeareauthor=A.+J.+Iafrateauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Therapeutic+Strategies+to+Overcome+Crizotinib+Resistance+in+Non-small+Cell+Lung+Cancers+Harboring+the+Fusion+Oncogene+EML4-ALK&doi=10.1073%2Fpnas.1019559108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span></div><div class="casAuthors">Katayama, Ryohei; Khan, Tahsin M.; Benes, Cyril; Lifshits, Eugene; Ebi, Hiromichi; Rivera, Victor M.; Shakespeare, William C.; Iafrate, A. John; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7535-7540, S7535/1-S7535/17</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene represents a mol. target in a small subset of non-small cell lung cancers (NSCLCs).  This fusion leads to constitutive ALK activation with potent transforming activity.  In a pivotal phase 1 clin. trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib (PF-02341066) demonstrated impressive antitumor activity in the majority of patients with NSCLC harboring ALK fusions.  However, despite these remarkable initial responses, cancers eventually develop resistance to crizotinib, usually within 1 y, thereby limiting the potential clin. benefit.  To det. how cancers acquire resistance to ALK inhibitors, we established a model of acquired resistance to crizotinib by exposing a highly sensitive EML4-ALK-pos. NSCLC cell line to increasing doses of crizotinib until resistance emerged.  We found that cells resistant to intermediate doses of crizotinib developed amplification of the EML4-ALK gene.  Cells resistant to higher doses (1 μM) also developed a gatekeeper mutation, L1196M, within the kinase domain, rendering EML4-ALK insensitive to crizotinib.  This gatekeeper mutation was readily detected using a unique and highly sensitive allele-specific PCR assay.  Although crizotinib was ineffectual against EML4-ALK harboring the gatekeeper mutation, we obsd. that two structurally different ALK inhibitors, NVPTAE684 and AP26113, were highly active against the resistant cancer cells in vitro and in vivo.  Furthermore, these resistant cells remained highly sensitive to the Hsp90 inhibitor 17-AAG.  Thus, we have developed a model of acquired resistance to ALK inhibitors and have shown that second-generation ALK TKIs or Hsp90 inhibitors are effective in treating crizotinib-resistant tumors harboring secondary gatekeeper mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPbiLG5xpg0LVg90H21EOLACvtfcHk0lgb94Ldp8nfhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D&md5=82f47736429e6f71f9fd5852e4df64cb</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1019559108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1019559108%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520Strategies%2520to%2520Overcome%2520Crizotinib%2520Resistance%2520in%2520Non-small%2520Cell%2520Lung%2520Cancers%2520Harboring%2520the%2520Fusion%2520Oncogene%2520EML4-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%26date%3D2011%26volume%3D108%26spage%3D7535%26epage%3D7540%26doi%3D10.1073%2Fpnas.1019559108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4720</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.-L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-Amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+Macrocyclic+Inhibitor+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+and+c-ros+Oncogene+1+%28ROS1%29+with+Preclinical+Brain+Exposure+and+Broad-Spectrum+Potency+against+ALK-Resistant+Mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0ljIbVHprdcHPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-Amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528metheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520Macrocyclic%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520and%2520c-ros%2520Oncogene%25201%2520%2528ROS1%2529%2520with%2520Preclinical%2520Brain%2520Exposure%2520and%2520Broad-Spectrum%2520Potency%2520against%2520ALK-Resistant%2520Mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitland, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahceci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A.</span></span> <span> </span><span class="NLM_article-title">First-in-human, Open-label Dose-escalation and Dose-expansion Study of the Safety, Pharmacokinetics, and Antitumor Effects of an Oral ALK inhibitor ASP3026 in Patients with Advanced Solid Tumors</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">23</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0254-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1186%2Fs13045-016-0254-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=26966027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1eisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=23&author=T.+Liauthor=P.+LoRussoauthor=M.+L.+Maitlandauthor=S.-H.+I.+Ouauthor=E.+Bahceciauthor=H.+A.+Ballauthor=J.+W.+Parkauthor=G.+Yuenauthor=A.+Tolcher&title=First-in-human%2C+Open-label+Dose-escalation+and+Dose-expansion+Study+of+the+Safety%2C+Pharmacokinetics%2C+and+Antitumor+Effects+of+an+Oral+ALK+inhibitor+ASP3026+in+Patients+with+Advanced+Solid+Tumors&doi=10.1186%2Fs13045-016-0254-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors</span></div><div class="casAuthors">Li, Tianhong; Lo Russo, Patricia; Maitland, Michael L.; Ou, Sai-Hong Ignatius; Bahceci, Erkut; Ball, Howard A.; Park, Jung Wook; Yuen, Geoffrey; Tolcher, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23/1-23/9</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: ASP3026 is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has potent in vitro activity against crizotinib-resistant ALK-pos. tumors.  This open-label, multicenter, first-in-human phase I study (NCT01284192) assessed the safety, pharmacokinetic profile, and antitumor activity of ASP3026.  Methods: Advanced solid tumor patients received oral ASP3026 in 3 + 3 dose-escalation cohorts at doses of 25-800 mg once daily in 28-day cycles.  The endpoints were to identify the max. tolerated dose (MTD), the recommended phase II dose (RP2D), and the pharmacokinetic profile of ASP3026.  A phase Ib expansion cohort enrolled patients with metastatic, crizotinib-resistant ALK-pos. solid tumors at the RP2D, and response was evaluated by RECIST 1.1.  Results: The dose-escalation cohort enrolled 33 patients, including three crizotinib-resistant, ALK-pos. patients, and the dose-expansion cohort enrolled another 13 crizotinib-resistant, ALK-pos. non-small cell lung cancer (NSCLC) patients.  ASP3026 demonstrated both linear pharmacokinetics and dose-proportional exposure for area under the plasma concn.-time curve and max. concn. obsd. with a median terminal half-life of 35 h, supporting the daily dosing.  Grade 3 rash and elevated transaminase concns. were dose-limiting toxicities obsd. at 800 mg; hence, 525 mg daily was the MTD and RP2D.  The most common treatment-related adverse events were nausea (38 %), fatigue (35 %), and vomiting (35 %).  Among the 16 patients with crizotinib-resistant ALK-pos. tumors (15 NSCLC, 1 neuroblastoma), eight patients achieved partial response (overall response rate 50 %; 95 % confidence interval 25-75 %) and seven patients (44 %) achieved stable disease.  Conclusions: ASP3026 was well tolerated and had therapeutic activity in patients with crizotinib-resistant ALKpos. advanced tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8s1yI8JbYIrVg90H21EOLACvtfcHk0ljIbVHprdcHPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1eisbc%253D&md5=ec3b634a66b3b310c8a0d6d83eeb9e62</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0254-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0254-5%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DMaitland%26aufirst%3DM.%2BL.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DBahceci%26aufirst%3DE.%26aulast%3DBall%26aufirst%3DH.%2BA.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26aulast%3DYuen%26aufirst%3DG.%26aulast%3DTolcher%26aufirst%3DA.%26atitle%3DFirst-in-human%252C%2520Open-label%2520Dose-escalation%2520and%2520Dose-expansion%2520Study%2520of%2520the%2520Safety%252C%2520Pharmacokinetics%252C%2520and%2520Antitumor%2520Effects%2520of%2520an%2520Oral%2520ALK%2520inhibitor%2520ASP3026%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D23%26doi%3D10.1186%2Fs13045-016-0254-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamauchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato-Nakai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishigai, M.</span></span> <span> </span><span class="NLM_article-title">In vitro Metabolism of Alectinib, a Novel Potent ALK Inhibitor, in Human: Contribution of CYP3A Enzymes</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">546</span>– <span class="NLM_lpage">554</span>, <span class="refDoi"> DOI: 10.1080/00498254.2017.1344910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1080%2F00498254.2017.1344910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=28657423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1WhsbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2018&pages=546-554&author=T.+Nakagawaauthor=S.+Fowlerauthor=K.+Takanashiauthor=K.+Youdimauthor=T.+Yamauchiauthor=K.+Kawashimaauthor=M.+Sato-Nakaiauthor=L.+Yuauthor=M.+Ishigai&title=In+vitro+Metabolism+of+Alectinib%2C+a+Novel+Potent+ALK+Inhibitor%2C+in+Human%3A+Contribution+of+CYP3A+Enzymes&doi=10.1080%2F00498254.2017.1344910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes</span></div><div class="casAuthors">Nakagawa, Toshito; Fowler, Stephen; Takanashi, Kenji; Youdim, Kuresh; Yamauchi, Tsuyoshi; Kawashima, Kosuke; Sato-Nakai, Mika; Yu, Li; Ishigai, Masaki</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">546-554</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">1. The in vitro metab. of alectinib, a potent and highly selective oral anaplastic lymphoma kinase inhibitor, was investigated.2.  The main metabolite (M4) in primary human hepatocytes was identified, which is produced by deethylation at the morpholine ring.  Three minor metabolites (M6, M1a, and M1b) were also identified, and a minor peak of hydroxylated alectinib (M5) was detected as a possible precursor of M4, M1a, and M1b.3.  M4, an important active major metabolite, was produced and further metabolized to M6 by CYP3A, indicating that CYP3A enzymes were the principal contributors to this route.  M5 is possibly produced by CYP3A and other isoforms as the primary step in metab., followed by oxidn. to M4 mainly by CYP3A.  Alternatively, M5 could be oxidized to M1a and M1b via an NAD-dependent process.  None of the non-CYP3A-mediated metab. appeared to be major.4.  In conclusion, this study suggests that involvement of multiple enzymes in the metab. of alectinib reduces its potential for drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXGMNSVBn1W7Vg90H21EOLACvtfcHk0ljIbVHprdcHPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1WhsbnE&md5=319fbc1f9599b373e2233235b4f72cd0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1080%2F00498254.2017.1344910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498254.2017.1344910%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DT.%26aulast%3DFowler%26aufirst%3DS.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DYoudim%26aufirst%3DK.%26aulast%3DYamauchi%26aufirst%3DT.%26aulast%3DKawashima%26aufirst%3DK.%26aulast%3DSato-Nakai%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DIshigai%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520Metabolism%2520of%2520Alectinib%252C%2520a%2520Novel%2520Potent%2520ALK%2520Inhibitor%252C%2520in%2520Human%253A%2520Contribution%2520of%2520CYP3A%2520Enzymes%26jtitle%3DXenobiotica%26date%3D2018%26volume%3D48%26spage%3D546%26epage%3D554%26doi%3D10.1080%2F00498254.2017.1344910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El Sayed, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Veken, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhooghe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hostyn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Baelen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemière, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, B. U. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joossens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haemers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieters, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustyns, K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Antiplasmodial Activity of Aminoalkylamino-Substituted Neocryptolepine Derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2979</span>– <span class="NLM_lpage">2988</span>, <span class="refDoi"> DOI: 10.1021/jm801490z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801490z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVSlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2979-2988&author=I.+El+Sayedauthor=P.+Van+der+Vekenauthor=K.+Steertauthor=L.+Dhoogheauthor=S.+Hostynauthor=G.+Van+Baelenauthor=G.+Lemi%C3%A8reauthor=B.+U.+W.+Maesauthor=P.+Cosauthor=L.+Maesauthor=J.+Joossensauthor=A.+Haemersauthor=L.+Pietersauthor=K.+Augustyns&title=Synthesis+and+Antiplasmodial+Activity+of+Aminoalkylamino-Substituted+Neocryptolepine+Derivatives&doi=10.1021%2Fjm801490z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Antiplasmodial Activity of Aminoalkylamino-Substituted Neocryptolepine Derivatives</span></div><div class="casAuthors">El Sayed, Ibrahim; Van der Veken, Pieter; Steert, Koen; Dhooghe, Liene; Hostyn, Steven; Van Baelen, Gitte; Lemiere, Guy; Maes, Bert U. W.; Cos, Paul; Maes, Louis; Joossens, Jurgen; Haemers, Achiel; Pieters, Luc; Augustyns, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2979-2988</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of chloro- and aminoalkylamino-substituted neocryptolepine (5-methyl-5H-indolo[2,3-b]quinoline) derivs. were synthesized and evaluated as antiplasmodial agents.  The evaluation also included cytotoxicity (MRC5 cells), inhibition of β-hematin formation, and DNA interactions (DNA-methyl green assay).  Introduction of aminoalkylamino chains increased the antiplasmodial activity of the neocryptolepine core substantially.  The most efficient compds. showed antiplasmodial activities in the nanomolar.  N1,N1-Diethyl-N4-(5-methyl-5H-indolo[2,3-b]quinolin-8-yl)pentane-1,4-diamine (I) showed an IC50 of 0.01 μM and a selectivity index of 1800.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXQqjB-FKMjbVg90H21EOLACvtfcHk0li1Qi5wZZITXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVSlsrk%253D&md5=3abbf5d6c2fc03e6ccfa516fe2d69e64</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm801490z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801490z%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BSayed%26aufirst%3DI.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26aulast%3DSteert%26aufirst%3DK.%26aulast%3DDhooghe%26aufirst%3DL.%26aulast%3DHostyn%26aufirst%3DS.%26aulast%3DVan%2BBaelen%26aufirst%3DG.%26aulast%3DLemi%25C3%25A8re%26aufirst%3DG.%26aulast%3DMaes%26aufirst%3DB.%2BU.%2BW.%26aulast%3DCos%26aufirst%3DP.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DJoossens%26aufirst%3DJ.%26aulast%3DHaemers%26aufirst%3DA.%26aulast%3DPieters%26aufirst%3DL.%26aulast%3DAugustyns%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520Antiplasmodial%2520Activity%2520of%2520Aminoalkylamino-Substituted%2520Neocryptolepine%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2979%26epage%3D2988%26doi%3D10.1021%2Fjm801490z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R.</span></span> <span> </span><span class="NLM_article-title">Development and Validation of a Genetic Algorithm for Flexible Docking</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">748</span>, <span class="refDoi"> DOI: 10.1006/jmbi.1996.0897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1006%2Fjmbi.1996.0897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=9126849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADyaK2sXis1KntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1997&pages=727-748&author=G.+Jonesauthor=P.+Willettauthor=R.+C.+Glenauthor=A.+R.+Leachauthor=R.+Taylor&title=Development+and+Validation+of+a+Genetic+Algorithm+for+Flexible+Docking&doi=10.1006%2Fjmbi.1996.0897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of a genetic algorithm for flexible docking</span></div><div class="casAuthors">Jones, Gareth; Willett, Peter; Glen, Robert C.; Leach, Andrew R.; Taylor, Robin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">727-748</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Prediction of small mol. binding modes to macromols. of known three-dimensional structure is a problem of paramount importance in rational drug design (the "docking" problem).  We report the development and validation of the program GOLD (Genetic Optimization for Ligand Docking).  GOLD is an automated ligand docking program that uses a genetic algorithm to explore the full range of ligand conformational flexibility with partial flexibility of the protein and satisfies the fundamental requirement that the ligand must displace loosely bound water on binding.  Numerous enhancements and modifications have been applied to the original technique resulting in a substantial increase in the reliability and the applicability of the algorithm.  The advanced algorithm has been tested on a dataset of 100 complexes extd. from the Brookhaven Protein Data Bank.  When used to dock the ligand back into the binding site, GOLD achieved a 71% success rate in identifying the exptl. binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP3I60Rl2uorVg90H21EOLACvtfcHk0li1Qi5wZZITXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1KntLo%253D&md5=476a2b1d8f80f3ba418052fe29d735ca</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1996.0897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1996.0897%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DG.%26aulast%3DWillett%26aufirst%3DP.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DTaylor%26aufirst%3DR.%26atitle%3DDevelopment%2520and%2520Validation%2520of%2520a%2520Genetic%2520Algorithm%2520for%2520Flexible%2520Docking%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1997%26volume%3D267%26spage%3D727%26epage%3D748%26doi%3D10.1006%2Fjmbi.1996.0897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdonk, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartshorn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. D.</span></span> <span> </span><span class="NLM_article-title">Improved Protein-ligand Docking Using GOLD</span>. <i>Proteins</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">623</span>, <span class="refDoi"> DOI: 10.1002/prot.10465</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1002%2Fprot.10465" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=12910460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvFGrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2003&pages=609-623&author=M.+L.+Verdonkauthor=J.+C.+Coleauthor=M.+J.+Hartshornauthor=C.+W.+Murrayauthor=R.+D.+Taylor&title=Improved+Protein-ligand+Docking+Using+GOLD&doi=10.1002%2Fprot.10465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Improved protein-ligand docking using GOLD</span></div><div class="casAuthors">Verdonk, Marcel L.; Cole, Jason C.; Hartshorn, Michael J.; Murray, Christopher W.; Taylor, Richard D.</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Genetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">609-623</span>CODEN:
                <span class="NLM_cas:coden">PSFGEY</span>;
        ISSN:<span class="NLM_cas:issn">0887-3585</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The Chemscore function was implemented as a scoring function for the protein-ligand docking program GOLD, and its performance compared to the original Goldscore function and two consensus docking protocols, "Goldscore-CS" and "Chemscore-GS," in terms of docking accuracy, prediction of binding affinities, and speed.  In the "Goldscore-CS" protocol, dockings produced with the Goldscore function are scored and ranked with the Chemscore function; in the "Chemscore-GS" protocol, dockings produced with the Chemscore function are scored and ranked with the Goldscore function.  Comparisons were made for a "clean" set of 224 protein-ligand complexes, and for two subsets of this set, one for which the ligands are "drug-like," the other for which they are "fragment-like.".  For "drug-like" and "fragment-like" ligands, the docking accuracies obtained with Chemscore and Goldscore functions are similar.  For larger ligands, Goldscore gives superior results.  Docking with the Chemscore function is up to three times faster than docking with the Goldscore function.  Both combined docking protocols give significant improvements in docking accuracy over the use of the Goldscore or Chemscore function alone.  "Goldscore-CS" gives success rates of up to 81% (top-ranked GOLD soln. within 2.0 Å of the exptl. binding mode) for the "clean list," but at the cost of long search times.  For most virtual screening applications, "Chemscore-GS" seems optimal; search settings that give docking speeds of around 0.25-1.3 min/compd. have success rates of about 78% for "drug-like" compds. and 85% for "fragment-like" compds.  In terms of producing binding energy ests., the Goldscore function appears to perform better than the Chemscore function and the two consensus protocols, particularly for faster search settings.  Even at docking speeds of around 1-2 min/compd., the Goldscore function predicts binding energies with a std. deviation of ∼10.5 kJ/mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKKgOct_CAcbVg90H21EOLACvtfcHk0li1Qi5wZZITXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvFGrsLg%253D&md5=73a627d99dab6de1ae364c8e8e5f0fea</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fprot.10465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.10465%26sid%3Dliteratum%253Aachs%26aulast%3DVerdonk%26aufirst%3DM.%2BL.%26aulast%3DCole%26aufirst%3DJ.%2BC.%26aulast%3DHartshorn%26aufirst%3DM.%2BJ.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DTaylor%26aufirst%3DR.%2BD.%26atitle%3DImproved%2520Protein-ligand%2520Docking%2520Using%2520GOLD%26jtitle%3DProteins%26date%3D2003%26volume%3D52%26spage%3D609%26epage%3D623%26doi%3D10.1002%2Fprot.10465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span> <i>MOE</i>; <span class="NLM_publisher-name">Chemical Computing Group</span>: <span class="NLM_publisher-loc">Montreal, Quebec, Canada</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+MOE%3B+Chemical+Computing+Group%3A+Montreal%2C+Quebec%2C+Canada%2C+2019."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DMOE%26pub%3DChemical%2520Computing%2520Group%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S. V.  Fedoseev</span>, <span class="hlFld-ContribAuthor ">O. E.  Ershov</span>. </span><span class="cited-content_cbyCitation_article-title">Reaction of 4-Halo-3-hydroxyfuro[3,4-c]pyridin-1(3H)-ones with Morpholine and Thiomorpholine. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>57 </em>
                                    (3)
                                     , 483-485. <a href="https://doi.org/10.1134/S1070428021030234" title="DOI URL">https://doi.org/10.1134/S1070428021030234</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428021030234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428021030234%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DReaction%252Bof%252B4-Halo-3-hydroxyfuro%25255B3%25252C4-c%25255Dpyridin-1%2525283H%252529-ones%252Bwith%252BMorpholine%252Band%252BThiomorpholine%26aulast%3DFedoseev%26aufirst%3DS.%2BV.%26date%3D2021%26date%3D2021%26volume%3D57%26issue%3D3%26spage%3D483%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of ALK inhibitors approved or currently in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Previously reported cocrystal structure of alectinib (CH5424802) in complex with ALK (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX">3AOX</a>). (B) Modeled structure of compound <b>7d</b> in complex with ALK. Four sites in <b>7d</b> identified for optimization are labeled with red arrows.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Interaction residues in ALK with alectinib in previously reported cocrystal structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX">3AOX</a>). (B) Interaction residues in ALK in our modeled structure of CJ2360 in complex with ALK. (C) Detailed hydrophobic and hydrogen bonding interactions between alectinib and ALK and between CJ-2360 and ALK, as analyzed by LigPlot.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pharmacodynamic study to evaluate CJ-2360 for its ability to inhibit ALK activity in KARPAS-299 tumors in mice. Mice were dosed with a single dose of CJ-2360 (2360) at 100 mg/kg or alectinib (Ale) at 20 mg/kg via oral gavage.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Antitumor activity of CJ-2360 in the KARPAS-299 xenograft tumor model. CJ-2360 was orally administered twice daily at 100 mg/kg and ceritinib was orally administered daily at 50 mg/kg for 22 days (from days 9 to 30).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>7a</b>–<b>7d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) NCS, DABCO, DCM, 0 °C, 2 h; (ii) trichloroacetic acid, DCM, RT, 2 h; (b) Ph<sub>2</sub>O, reflux, 1 h; (c) 4-morpholinopiperidine or 1-methylpiperazine, DIPEA, DMSO, 120–140 °C, 3 days.</p></p></figure><figure data-id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>8a</b>–<b>8e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) NCS, DABCO, DCM, 0 °C, 2 h; (ii) 4-bromo-3-fluoro-<i>N</i>-isopropylaniline, trichloroacetic acid, DCM, RT, 2 h; (b) Ph<sub>2</sub>O, reflux, 1 h; (c) 1-methylpiperazine, DIPEA, DMSO, 120–140 °C, 3 days; (d) (i) appropriate 4,4,5,5-tetramethyl-1,3,2-dioxaborolane, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>,CO<sub>3</sub>, DME/H<sub>2</sub>O, 80 °C; (ii) 10% Pd-C, H<sub>2</sub>, THF.</p></p></figure><figure data-id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>8f</b>–<b>8i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) NCS, DABCO, SCM, 0 °C, 2 h; (ii) trichloroacetic acid; appropriate anilines, RT, 2 h; (b) Ph<sub>2</sub>O, reflux, 1 h; (c) 1-methylpiperazine, DIPEA, DMSO, 120–140 °C, 3 days.</p></p></figure><figure data-id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <b>9a</b>–<b>9c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) NCS, DABCO, DCM, 0 °C, 2 h; (ii) trichloroacetic acid, appropriate anilines, RT, 2 h; (b) Ph<sub>2</sub>O, reflux, 1 h; (c) 1-methylpiperazine, DIPEA, DMSO, 120–140 °C, 3 days.</p></p></figure><figure data-id="sch5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <b>10a</b>–<b>10h</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) methyl 6-cyano-1<i>H</i>-indole-3-carboxylate, NCS, DABCO, DCM, 0 °C, 2 h; (ii) trichloroacetic acid, appropriate anilines, RT, 2 h; (b) Ph<sub>2</sub>O, reflux, 1 h; (c) 1-methylpiperazine, DIPEA, DMSO, 120–140 °C, 3 days.</p></p></figure><figure data-id="sch6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of ALK-73, CJ-2349-2351, and CJ-2356-2360<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) appropriate amines, DIPEA, DMSO, 120–140 °C, 3 days.</p></p></figure><figure data-id="sch7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/medium/jm0c01550_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of CJ-2212 and CJ-2224-2227<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01550&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) MeONa, MeOH, 0 °C to RT, 4 h, 55%; (b) <i>tert</i>-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridline-1(2<i>H</i>)-carboxylate, Pd(dppf)Cl<sub>2</sub>, and K<sub>2</sub>CO<sub>3</sub>, 92%; (c) 10% Pd-C, ethanol, RT, overnight, 92%; (d) acetone, acetic acid, NaBH(OAc)<sub>3</sub>, DCM, RT, 12 h, 94%; (e) (i) methyl 6-cyano-1<i>H</i>-indole-3-carboxylate, NCS, DABCO, DCM, 0 °C, 2 h; (ii) trichloroacetic acid, RT, 2 h, 69%; (f) (i) TFA; (ii) appropriate aldehyde or ketone, NaBH(OAc)<sub>3</sub>, acetic acid, DCM; (g) Ph<sub>2</sub>O, reflux, 1 h.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i121">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61072" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61072" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 36 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naeve, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirstein, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, D. P.</span></span> <span> </span><span class="NLM_article-title">ALK, the Chromosome 2 Gene Locus Altered by the t(2;5) in Non-Hodgkin’s Lymphoma, Encodes a Novel Neural Receptor Tyrosine Kinase that is Highly Related to Leukocyte Tyrosine Kinase (LTK)</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2175</span>– <span class="NLM_lpage">2188</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1201062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1038%2Fsj.onc.1201062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=9174053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=2175-2188&author=S.+W.+Morrisauthor=C.+Naeveauthor=P.+Mathewauthor=P.+L.+Jamesauthor=M.+N.+Kirsteinauthor=X.+Cuiauthor=D.+P.+Witte&title=ALK%2C+the+Chromosome+2+Gene+Locus+Altered+by+the+t%282%3B5%29+in+Non-Hodgkin%E2%80%99s+Lymphoma%2C+Encodes+a+Novel+Neural+Receptor+Tyrosine+Kinase+that+is+Highly+Related+to+Leukocyte+Tyrosine+Kinase+%28LTK%29&doi=10.1038%2Fsj.onc.1201062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)</span></div><div class="casAuthors">Morris, Stephan W.; Naeve, Clayton; Mathew, Prasad; James, Payton L.; Kirstein, Mark N.; Cui, Xiaoli; Witte, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2175-2188</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">Anaplastic Lymphoma Kinase (ALK) was originally identified as a member of the insulin receptor subfamily of receptor tyrosine kinases that acquires transforming capability when truncated and fused to nucleophosmin (NPM) in the t(2;5) chromosomal rearrangement assocd. with non-Hodgkin's lymphoma, but further insights into its normal structure and function are lacking.  Here, we characterize a full-length normal human ALK cDNA and its product, and det. the pattern of expression of its murine homolog in embryonic and adult tissues as a first step toward the functional assessment of the receptor.  Anal. of the 6226 bp ALK cDNA identified an open reading frame encoding a 1620-amino acid (aa) protein of predicted mass ∼177 kDa that is most closely related to leukocyte tyrosine kinase (LTK), the two exhibiting 57% aa identity and 71% similarity over their region of overlap.  Biochem. anal. demonstrated that the ∼177 kDa ALK polypeptide core undergoes co-translational N-linked glycosylation, emerging in its mature form as a 200 kDa single chain receptor.  Surface labeling studies indicated that the 200 kDa glycoprotein is exposed at the cell membrane, consistent with the prediction that ALK serves as the receptor for an unidentified ligand(s).  In situ hybridization studies revealed Alk expression beginning on embryonic day 11 and persisting into the neonatal and adult periods of development.  Alk transcripts were confined to the nervous system and included several thalamic and hypothalamic nuclei; the trigeminal, facial, and acoustic cranial ganglia; the anterior horns of the spinal cord in the region of the developing motor neurons; the sympathetic chain; and the ganglion cells of the gut.  Thus, ALK is a novel orphan receptor tyrosine kinase that appears to play an important role in the normal development and function of the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4F75l637BuLVg90H21EOLACvtfcHk0lgAChwXjbwJ0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnt7k%253D&md5=fdf7a14e88be831b2577891145cb6082</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1201062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1201062%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DNaeve%26aufirst%3DC.%26aulast%3DMathew%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DP.%2BL.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DWitte%26aufirst%3DD.%2BP.%26atitle%3DALK%252C%2520the%2520Chromosome%25202%2520Gene%2520Locus%2520Altered%2520by%2520the%2520t%25282%253B5%2529%2520in%2520Non-Hodgkin%25E2%2580%2599s%2520Lymphoma%252C%2520Encodes%2520a%2520Novel%2520Neural%2520Receptor%2520Tyrosine%2520Kinase%2520that%2520is%2520Highly%2520Related%2520to%2520Leukocyte%2520Tyrosine%2520Kinase%2520%2528LTK%2529%26jtitle%3DOncogene%26date%3D1997%26volume%3D14%26spage%3D2175%26epage%3D2188%26doi%3D10.1038%2Fsj.onc.1201062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Beau, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitter, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doane, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franklin, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadin, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vardiman, J. W.</span></span> <span> </span><span class="NLM_article-title">The T(2;5)(P23;Q35): a Recurring Chromosomal Abnormality in Ki-1-Positive Anaplastic Large Cell Lymphoma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">866</span>– <span class="NLM_lpage">870</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=2555633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A280%3ADyaK3c%252FmsFOhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1989&pages=866-870&author=M.+M.+Le+Beauauthor=M.+A.+Bitterauthor=R.+A.+Larsonauthor=L.+A.+Doaneauthor=E.+D.+Ellisauthor=W.+A.+Franklinauthor=C.+M.+Rubinauthor=M.+E.+Kadinauthor=J.+W.+Vardiman&title=The+T%282%3B5%29%28P23%3BQ35%29%3A+a+Recurring+Chromosomal+Abnormality+in+Ki-1-Positive+Anaplastic+Large+Cell+Lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma</span></div><div class="casAuthors">Le Beau M M; Bitter M A; Larson R A; Doane L A; Ellis E D; Franklin W A; Rubin C M; Kadin M E; Vardiman J W</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">866-70</span>
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    </div><div class="casAbstract">In lymphoid neoplasms, nonrandom cytogenetic abnormalities correlate with clinical, morphologic and immunophenotypic features.  A subtype of non-Hodgkin's lymphoma, which expresses the Ki-1 antigen (CD30) and has distinct morphologic and clinical features, has recently been described.  We now report the association of a reciprocal translocation involving the short arm of chromosome 2 (band p23) and the long arm of chromosome 5 (band q35), t(2;5)(p23;q35), with Ki-1 positive anaplastic large cell lymphoma.  Rearrangement of the genes that are located at the breakpoints on chromosomes 2 and 5 may be a critical step in the pathogenesis of this lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfhXSXFhBAtZZoeNcnHOQ9fW6udTcc2ebalzbW7bwigLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3c%252FmsFOhug%253D%253D&md5=83cdde3ddd6263fe6037d18f0eca846d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BBeau%26aufirst%3DM.%2BM.%26aulast%3DBitter%26aufirst%3DM.%2BA.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DDoane%26aufirst%3DL.%2BA.%26aulast%3DEllis%26aufirst%3DE.%2BD.%26aulast%3DFranklin%26aufirst%3DW.%2BA.%26aulast%3DRubin%26aufirst%3DC.%2BM.%26aulast%3DKadin%26aufirst%3DM.%2BE.%26aulast%3DVardiman%26aufirst%3DJ.%2BW.%26atitle%3DThe%2520T%25282%253B5%2529%2528P23%253BQ35%2529%253A%2520a%2520Recurring%2520Chromosomal%2520Abnormality%2520in%2520Ki-1-Positive%2520Anaplastic%2520Large%2520Cell%2520Lymphoma%26jtitle%3DLeukemia%26date%3D1989%26volume%3D3%26spage%3D866%26epage%3D870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirstein, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittmer, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, A. T.</span></span> <span> </span><span class="NLM_article-title">Fusion of a Kinase Gene, Alk, to a Nucleolar Protein Gene, Npm, in Non-Hodgkins-Lymphoma</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>263</i></span>,  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1284</span>, <span class="refDoi"> DOI: 10.1126/science.8122112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1126%2Fscience.8122112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=8122112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+G.+Dittmerauthor=D.+N.+Shapiroauthor=D.+L.+Saltmanauthor=A.+T.+Look&title=Fusion+of+a+Kinase+Gene%2C+Alk%2C+to+a+Nucleolar+Protein+Gene%2C+Npm%2C+in+Non-Hodgkins-Lymphoma&doi=10.1126%2Fscience.8122112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma</span></div><div class="casAuthors">Morris, Stephan, W.; Kirstein, Mark, N.; Valentine, Marcus B.; Dittmer, Kristopher G.; Shapiro, David N.; Saltman, David L.; Look, A. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5151</span>),
    <span class="NLM_cas:pages">1281-4</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The 2;5 chromosomal translocation occurs in most anaplastic large-cell non-Hodgkin's lymphomas arising from activated T lymphocytes.  This rearrangement was shown to fuse the NPM nucleolar phosphoprotein gene on chromosome 5q35 to a previously unidentified protein tyrosine kinase gene, ALK, on chromosome 2p23.  In the predicted hybrid protein, the amino terminus of nucleophosmin (NPM) is linked to the catalytic domain of anaplastic lymphoma kinase (ALK).  Expressed in the small intestine, testis, and brain but not in normal lymphoid cells, ALK shows greatest sequence similarity to the insulin receptor subfamily of kinases.  Unscheduled expression of the truncated ALK may contribute to malignant transformation in these lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3KZnxLYaerVg90H21EOLACvtfcHk0ljG5pDAwMEHMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D&md5=219ee9615e613be456a05f8f1ded6066</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.8122112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8122112%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%2BG.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DFusion%2520of%2520a%2520Kinase%2520Gene%252C%2520Alk%252C%2520to%2520a%2520Nucleolar%2520Protein%2520Gene%252C%2520Npm%252C%2520in%2520Non-Hodgkins-Lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284%26doi%3D10.1126%2Fscience.8122112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Webb, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slavish, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rentrop, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span> <span> </span><span class="NLM_article-title">Anaplastic Lymphoma Kinase: Role in Cancer Pathogenesis and Small-Molecule Inhibitor Development for Therapy</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1586/14737140.9.3.331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1586%2F14737140.9.3.331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=19275511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFaltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=331-356&author=T.+R.+Webbauthor=J.+Slavishauthor=R.+E.+Georgeauthor=A.+T.+Lookauthor=L.+Xueauthor=Q.+Jiangauthor=X.+Cuiauthor=W.+B.+Rentropauthor=S.+W.+Morris&title=Anaplastic+Lymphoma+Kinase%3A+Role+in+Cancer+Pathogenesis+and+Small-Molecule+Inhibitor+Development+for+Therapy&doi=10.1586%2F14737140.9.3.331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy</span></div><div class="casAuthors">Webb, Thomas R.; Slavish, Jake; George, Rani E.; Look, A. Thomas; Xue, Liquan; Jiang, Qin; Cui, Xiaoli; Rentrop, Walter B.; Morris, Stephan W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">331-356</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, was initially identified in constitutively activated oncogenic fusion forms - the most common being nucleophosmin-ALK - in anaplastic large-cell lymphomas, and subsequent studies have identified ALK fusions in diffuse large B-cell lymphomas, systemic histiocytosis, inflammatory myofibroblastic tumors, esophageal squamous cell carcinomas and non-small-cell lung carcinomas.  More recently, genomic DNA amplification and protein overexpression, as well as activating point mutations, of ALK have been described in neuroblastomas.  In addn. to those cancers for which a causative role for aberrant ALK activity is well validated, more circumstantial links implicate the full-length, normal ALK receptor in the genesis of other malignancies - including glioblastoma and breast cancer - via a mechanism of receptor activation involving autocrine and/or paracrine growth loops with the reported ALK ligands, pleiotrophin and midkine.  This review summarizes normal ALK biol., the confirmed and putative roles of ALK in the development of human cancers and efforts to target ALK using small-mol. kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoERzbvlik_c7Vg90H21EOLACvtfcHk0ljG5pDAwMEHMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFaltrc%253D&md5=a980ef18ac316bd3894b72ddd2748c17</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1586%2F14737140.9.3.331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.9.3.331%26sid%3Dliteratum%253Aachs%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DSlavish%26aufirst%3DJ.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DRentrop%26aufirst%3DW.%2BB.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26atitle%3DAnaplastic%2520Lymphoma%2520Kinase%253A%2520Role%2520in%2520Cancer%2520Pathogenesis%2520and%2520Small-Molecule%2520Inhibitor%2520Development%2520for%2520Therapy%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2009%26volume%3D9%26spage%3D331%26epage%3D356%26doi%3D10.1586%2F14737140.9.3.331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellingham, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlman, E. J.</span></span> <span> </span><span class="NLM_article-title">Recurrent Involvement of 2p23 in Inflammatory Myofibroblastic Tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2776</span>– <span class="NLM_lpage">2780</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10383129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=2776-2780&author=C.+A.+Griffinauthor=A.+L.+Hawkinsauthor=C.+Dvorakauthor=C.+Henkleauthor=T.+Ellinghamauthor=E.+J.+Perlman&title=Recurrent+Involvement+of+2p23+in+Inflammatory+Myofibroblastic+Tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors</span></div><div class="casAuthors">Griffin, Constance A.; Hawkins, Anita L.; Dvorak, Cecily; Henkle, Carol; Ellingham, Tara; Perlman, Elizabeth J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2776-2780</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Inflammatory myofibroblastic tumor (IMT) is a relatively rare soft tissue tumor.  The reactive vs. neoplastic pathogenesis of this tumor is unresolved.  We found clonal chromosome aberrations involving 2p23 upon metaphase anal. of two IMTs.  Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 demonstrated rearrangement of the probe in both of these cases and in a third case, and immunohistochem. revealed ALK expression in all three cases.  A 2p22-24 involvement has been reported previously in four addnl. cases of IMT.  We suggest that chromosomal rearrangements involving 2p23 near or within ALK are recurrent alterations in IMT and that ALK may have a novel role outside its previously recognized realm of lymphoid neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocvXV2ukz3crVg90H21EOLACvtfcHk0lguPeIPZosQvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D&md5=8054eeaaf0cb85ee85afff461797c84c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DC.%2BA.%26aulast%3DHawkins%26aufirst%3DA.%2BL.%26aulast%3DDvorak%26aufirst%3DC.%26aulast%3DHenkle%26aufirst%3DC.%26aulast%3DEllingham%26aufirst%3DT.%26aulast%3DPerlman%26aufirst%3DE.%2BJ.%26atitle%3DRecurrent%2520Involvement%2520of%25202p23%2520in%2520Inflammatory%2520Myofibroblastic%2520Tumors%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D2776%26epage%3D2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gascoyne, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamant, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Subero, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lestou, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Hermelink, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsman, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auvigne, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delsol, G.</span></span> <span> </span><span class="NLM_article-title">ALK-positive Diffuse Large B-cell Lymphoma is Associated with Clathrin-ALK Rearrangements: Report of 6 Cases</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">2568</span>– <span class="NLM_lpage">2573</span>, <span class="refDoi"> DOI: 10.1182/blood-2003-03-0786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1182%2Fblood-2003-03-0786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=12763927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnslykurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=2568-2573&author=R.+D.+Gascoyneauthor=L.+Lamantauthor=J.+I.+Martin-Suberoauthor=V.+S.+Lestouauthor=N.+L.+Harrisauthor=H.+K.+M%C3%BCller-Hermelinkauthor=J.+F.+Seymourauthor=L.+J.+Campbellauthor=D.+E.+Horsmanauthor=I.+Auvigneauthor=E.+Espinosauthor=R.+Siebertauthor=G.+Delsol&title=ALK-positive+Diffuse+Large+B-cell+Lymphoma+is+Associated+with+Clathrin-ALK+Rearrangements%3A+Report+of+6+Cases&doi=10.1182%2Fblood-2003-03-0786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">ALK-positive diffuse large B-cell lymphoma is associated with clathrin-ALK rearrangements: Report of 6 cases</span></div><div class="casAuthors">Gascoyne, Randy D.; Lamant, Laurence; Martin-Subero, Jose I.; Lestou, Valia S.; Harris, Nancy Lee; Mueller-Hermelink, Hans-Konrad; Seymour, John F.; Campbell, Lynda J.; Horsman, Douglas E.; Auvigne, Isabelle; Espinos, Estelle; Siebert, Reiner; Delsol, Georges</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2568-2573</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Expression of ALK protein by lymphoid cells and the description of variant anaplastic lymphoma kinase (ALK) translocations have typically been restricted to cases of T-cell and null anaplastic large-cell lymphoma (ALCL).  All such cases result from a novel fusion created by the ALK gene on chromosome 2p23 and NPM on 5q35 or other variant translocation partners.  A rare variant of diffuse large B-cell lymphoma (DLBCL), originally described in 1997, was thought to overexpress full-length ALK in contrast to a chimeric protein characteristic of ALCL.  However, full-length ALK protein lacks tyrosine kinase activity and thus the mechanism of oncogenesis has remained elusive.  We describe 6 cases of ALK+ DLBCL characterized by a simple or complex t(2;17)(p23;q23) involving the clathrin gene (CLTC) at chromosome band 17q23 and the ALK gene at chromosome band 2p23.  All cases were studied using fluorescence in situ hybridization (FISH), complemented in one case with std. cytogenetic anal., multicolor karyotyping (M-FISH), and reverse transcriptase-polymerase chain reaction.  These results clearly demonstrate that most cases of ALK+ DLBCL share the same mechanism of deregulated ALK expression.  Moreover, these results demonstrate the presence of CLTC-ALK fusions in these tumors and extend the list of diseases assocd. with this genetic abnormality to include classical T-cell or null ALCL, ALK+ DLBCL, and inflammatory myofibroblastic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3UcmsuahiXLVg90H21EOLACvtfcHk0lguPeIPZosQvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnslykurw%253D&md5=9eedc8c22c580dbadee982b4d3da35a8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-03-0786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-03-0786%26sid%3Dliteratum%253Aachs%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DLamant%26aufirst%3DL.%26aulast%3DMartin-Subero%26aufirst%3DJ.%2BI.%26aulast%3DLestou%26aufirst%3DV.%2BS.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DM%25C3%25BCller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26aulast%3DCampbell%26aufirst%3DL.%2BJ.%26aulast%3DHorsman%26aufirst%3DD.%2BE.%26aulast%3DAuvigne%26aufirst%3DI.%26aulast%3DEspinos%26aufirst%3DE.%26aulast%3DSiebert%26aufirst%3DR.%26aulast%3DDelsol%26aufirst%3DG.%26atitle%3DALK-positive%2520Diffuse%2520Large%2520B-cell%2520Lymphoma%2520is%2520Associated%2520with%2520Clathrin-ALK%2520Rearrangements%253A%2520Report%2520of%25206%2520Cases%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D2568%26epage%3D2573%26doi%3D10.1182%2Fblood-2003-03-0786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jazii, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najafi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malekzadeh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrads, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziaee, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abnet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yazdznbod, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkhane, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salekdeh, G. H.</span></span> <span> </span><span class="NLM_article-title">Identification of Squamous Cell Carcinoma Associated Proteins by Proteomics and Loss of Beta Tropomyosin Expression in Esophageal Cancer</span>. <i>World J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">7104</span>– <span class="NLM_lpage">7112</span>, <span class="refDoi"> DOI: 10.3748/wjg.v12.i44.7104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.3748%2Fwjg.v12.i44.7104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=17131471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD2sXls1GksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=7104-7112&author=F.+R.+Jaziiauthor=Z.+Najafiauthor=R.+Malekzadehauthor=T.+P.+Conradsauthor=A.+A.+Ziaeeauthor=C.+Abnetauthor=M.+Yazdznbodauthor=A.+A.+Karkhaneauthor=G.+H.+Salekdeh&title=Identification+of+Squamous+Cell+Carcinoma+Associated+Proteins+by+Proteomics+and+Loss+of+Beta+Tropomyosin+Expression+in+Esophageal+Cancer&doi=10.3748%2Fwjg.v12.i44.7104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer</span></div><div class="casAuthors">Jazii, Ferdous Rastgar; Najafi, Zahra; Malekzadeh, Reza; Conrads, Thomas P.; Ziaee, Abed Ali; Abnet, Christian; Yazdznbod, Mansour; Karkhane, Ali Asghar; Salekdeh, Ghasem H.</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">7104-7112</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">1007-9327</span>.
    
            (<span class="NLM_cas:orgname">World Journal of Gastroenterology</span>)
        </div><div class="casAbstract">To assess the proteome of normal vs. tumor tissue in squamous cell carcinoma of the esophagus (SCCE) in Iranian patients and compare our results with former reports by using proteomics.  Protein was extd. from normal and tumor tissues.  Two dimensional electrophoresis was carried out and spots with differential expression were identified with mass spectrometry.  RNA extn. and RT-PCR along with immunodetection were performed.  Fourteen proteins were found whose expression levels differed in tumor compared to normal tissues.  Mass spectrometric anal. resulted in the identification of β-tropomyosin (TMβ), myosin light chain 2 (and its isoform), myosin regulatory light chain 2, peroxyredoxin 2, annexin I and an unknown polypeptide as the down regulated polypeptides in tumor tissue.  Heat shock protein 70 (HSP70), TPM4-ALK fusion oncoprotein 2, myosin light polypeptide 6, keratin I, GH16431p and calreticulin were the up-regulated polypeptides found in tumor tissue.  Several of these proteins, such as TMβ, HSP70, annexin I, calreticulin, TPM4-ALK and isoforms of myosins, have been well recognized in tumorigenesis of esophageal or other types of cancers.  The study not only supports the involvement of some of the formerly reported proteins in SCCE but also introduces addnl. proteins found to be lost in SCCE, including TMβ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqQBiL27ZRH7Vg90H21EOLACvtfcHk0lguPeIPZosQvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1GksA%253D%253D&md5=2de4e4dc1639b4414afa8ea6e072c22c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v12.i44.7104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v12.i44.7104%26sid%3Dliteratum%253Aachs%26aulast%3DJazii%26aufirst%3DF.%2BR.%26aulast%3DNajafi%26aufirst%3DZ.%26aulast%3DMalekzadeh%26aufirst%3DR.%26aulast%3DConrads%26aufirst%3DT.%2BP.%26aulast%3DZiaee%26aufirst%3DA.%2BA.%26aulast%3DAbnet%26aufirst%3DC.%26aulast%3DYazdznbod%26aufirst%3DM.%26aulast%3DKarkhane%26aufirst%3DA.%2BA.%26aulast%3DSalekdeh%26aufirst%3DG.%2BH.%26atitle%3DIdentification%2520of%2520Squamous%2520Cell%2520Carcinoma%2520Associated%2520Proteins%2520by%2520Proteomics%2520and%2520Loss%2520of%2520Beta%2520Tropomyosin%2520Expression%2520in%2520Esophageal%2520Cancer%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2006%26volume%3D12%26spage%3D7104%26epage%3D7112%26doi%3D10.3748%2Fwjg.v12.i44.7104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enomoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurashina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bando, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">Identification of the Transforming EML4-ALK Fusion Gene in Non-small-cell Lung Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nature05945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.-i.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+Transforming+EML4-ALK+Fusion+Gene+in+Non-small-cell+Lung+Cancer&doi=10.1038%2Fnature05945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0liNpEm8mGNjVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.-i.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520Transforming%2520EML4-ALK%2520Fusion%2520Gene%2520in%2520Non-small-cell%2520Lung%2520Cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnature05945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">Non-solid Oncogenes in Solid Tumors: EML4-ALK Fusion Genes in Lung Cancer</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">2349</span>– <span class="NLM_lpage">2355</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2008.00972.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1111%2Fj.1349-7006.2008.00972.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=19032370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisF2gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2008&pages=2349-2355&author=H.+Mano&title=Non-solid+Oncogenes+in+Solid+Tumors%3A+EML4-ALK+Fusion+Genes+in+Lung+Cancer&doi=10.1111%2Fj.1349-7006.2008.00972.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer</span></div><div class="casAuthors">Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2349-2355</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  It is generally accepted that recurrent chromosome translocations play a major role in the mol. pathogenesis of hematol. malignancies but not of solid tumors.  However, chromosome translocations involving the e26 transformation-specific sequence transcription factor loci have been demonstrated recently in many prostate cancer cases.  Furthermore, through a functional screening with retroviral cDNA expression libraries, we have discovered the fusion-type protein tyrosine kinase echinoderm microtubule-assocd. protein like-4 (EML4)-anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) specimens.  A recurrent chromosome translocation, inv(2)(p21p23), in NSCLC generates fused mRNA encoding the amino-terminal half of EML4 ligated to the intracellular region of the receptor-type protein tyrosine kinase ALK.  EML4-ALK oligomerizes constitutively in cells through the coiled coil domain within the EML4 region, and becomes activated to exert a marked oncogenicity both in vitro and in vivo.  Break and fusion points within the EML4 locus may diverge in NSCLC cells to generate various isoforms of EML4-ALK, which may constitute -5% of NSCLC cases, at least in the Asian ethnic group.  In the present review I summarize how detection of EML4-ALK cDNA may become a sensitive diagnostic means for NSCLC cases that are pos. for the fusion gene, and discuss whether suppression of ALK enzymic activity could be an effective treatment strategy against this intractable disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbxSS7U51wKbVg90H21EOLACvtfcHk0liNpEm8mGNjVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisF2gsw%253D%253D&md5=84386550daedbd29b3a34b11a4774684</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2008.00972.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2008.00972.x%26sid%3Dliteratum%253Aachs%26aulast%3DMano%26aufirst%3DH.%26atitle%3DNon-solid%2520Oncogenes%2520in%2520Solid%2520Tumors%253A%2520EML4-ALK%2520Fusion%2520Genes%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Sci.%26date%3D2008%26volume%3D99%26spage%3D2349%26epage%3D2355%26doi%3D10.1111%2Fj.1349-7006.2008.00972.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B.</span></span> <span> </span><span class="NLM_article-title">Targeting Anaplastic Lymphoma Kinase in Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2081</span>– <span class="NLM_lpage">2086</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-1591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1158%2F1078-0432.CCR-10-1591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=21288922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslCgs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2081-2086&author=A.+T.+Shawauthor=B.+Solomon&title=Targeting+Anaplastic+Lymphoma+Kinase+in+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-10-1591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Anaplastic Lymphoma Kinase in Lung Cancer</span></div><div class="casAuthors">Shaw, Alice T.; Solomon, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2081-2086</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Several decades of cancer research have revealed a pivotal role for tyrosine kinases as key regulators of signaling pathways, controlling cell growth and differentiation.  Deregulation of tyrosine kinase-mediated signaling occurs frequently in cancer and is believed to drive the initiation and progression of disease.  Chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (ALK) occur in a variety of human malignancies including non-small cell lung cancer (NSCLC), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.  The aberrant activation of ALK signaling leads to "oncogene addiction" and marked sensitivity to ALK inhibitors such as crizotinib (PF-02341066).  This review focuses on ALK rearrangements in NSCLC, starting with the discovery of the EML4-ALK fusion oncogene, and culminating in the recent validation of ALK as a therapeutic target in patients with ALK-rearranged NSCLC.  Current efforts seek to expand the role of ALK kinase inhibition in lung and other cancers and to address the mol. basis for the development of resistance.  Clin Cancer Res; 17(8); 2081-6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCqEzvXv0qJrVg90H21EOLACvtfcHk0liNpEm8mGNjVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslCgs7k%253D&md5=6d0f5e1174ba934f00c10a877a3b17e1</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-1591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-1591%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB.%26atitle%3DTargeting%2520Anaplastic%2520Lymphoma%2520Kinase%2520in%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D2081%26epage%3D2086%26doi%3D10.1158%2F1078-0432.CCR-10-1591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osajima-Hakomori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, R.</span></span> <span> </span><span class="NLM_article-title">Biological Role of Anaplastic Lymphoma Kinase in Neuroblastoma</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1016/S0002-9440(10)62966-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1016%2FS0002-9440%2810%2962966-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=15972965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD2MXms1eitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2005&pages=213-222&author=Y.+Osajima-Hakomoriauthor=I.+Miyakeauthor=M.+Ohiraauthor=A.+Nakagawaraauthor=A.+Nakagawaauthor=R.+Sakai&title=Biological+Role+of+Anaplastic+Lymphoma+Kinase+in+Neuroblastoma&doi=10.1016%2FS0002-9440%2810%2962966-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Biological role of anaplastic lymphoma kinase in neuroblastoma</span></div><div class="casAuthors">Osajima-Hakomori, Yuko; Miyake, Izumi; Ohira, Miki; Nakagawara, Akira; Nakagawa, Atsuko; Sakai, Ryuichi</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">213-222</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor originally identified as part of the chimeric nucleophosmin-ALK protein in the t(2;5) chromosomal rearrangement assocd. with anaplastic large cell lymphoma.  We recently demonstrated that the ALK kinase is constitutively activated by gene amplification at the ALK locus in several neuroblastoma cell lines.  Forming a stable complex with hyperphosphorylated ShcC, activated ALK modifies the responsiveness of the mitogen-activated protein kinase pathway to growth factors.  In the present study, the biol. role of activated ALK was examd. by suppressing the expression of ALK kinase in neuroblastoma cell lines using an RNA interference technique.  The suppression of activated ALK in neuroblastoma cells by RNA interference significantly reduced the phosphorylation of ShcC, mitogen-activated protein kinases, and Akt, inducing rapid apoptosis in the cells.  By immunohistochem. anal., the cytoplasmic expression of ALK was detected in most of the samples of neuroblastoma tissues regardless of the stage of the tumor, whereas significant amplification of ALK was obsd. in only 1 of 85 cases of human neuroblastoma samples.  These data demonstrate the limited frequency of ALK activation in the real progression of neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3yzyhgfKX4rVg90H21EOLACvtfcHk0lhRd5zf8gAGRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXms1eitrc%253D&md5=591aceb254b3e707d315b6309ec5fba0</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2962966-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252962966-5%26sid%3Dliteratum%253Aachs%26aulast%3DOsajima-Hakomori%26aufirst%3DY.%26aulast%3DMiyake%26aufirst%3DI.%26aulast%3DOhira%26aufirst%3DM.%26aulast%3DNakagawara%26aufirst%3DA.%26aulast%3DNakagawa%26aufirst%3DA.%26aulast%3DSakai%26aufirst%3DR.%26atitle%3DBiological%2520Role%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520in%2520Neuroblastoma%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2005%26volume%3D167%26spage%3D213%26epage%3D222%26doi%3D10.1016%2FS0002-9440%2810%2962966-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mossé, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laudenslager, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attiyeh, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquaglia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sennett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laureys, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speleman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakonarson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torkamani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schork, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonini, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappaport, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span> <span> </span><span class="NLM_article-title">Identification of ALK as a Major Familial Neuroblastoma Predisposition Gene</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>455</i></span>,  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">935</span>, <span class="refDoi"> DOI: 10.1038/nature07261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1038%2Fnature07261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=18724359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-935&author=Y.+P.+Moss%C3%A9author=M.+Laudenslagerauthor=L.+Longoauthor=K.+A.+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+Major+Familial+Neuroblastoma+Predisposition+Gene&doi=10.1038%2Fnature07261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of ALK as a major familial neuroblastoma predisposition gene</span></div><div class="casAuthors">Mosse, Yael P.; Laudenslager, Marci; Longo, Luca; Cole, Kristina A.; Wood, Andrew; Attiyeh, Edward F.; Laquaglia, Michael J.; Sennett, Rachel; Lynch, Jill E.; Perri, Patrizia; Laureys, Genevieve; Speleman, Frank; Kim, Cecilia; Hou, Cuiping; Hakonarson, Hakon; Torkamani, Ali; Schork, Nicholas J.; Brodeur, Garrett M.; Tonini, Gian P.; Rappaport, Eric; Devoto, Marcella; Maris, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">930-935</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma is a childhood cancer that can be inherited, but the genetic etiol. is largely unknown.  Here we show that germline mutations in the anaplastic lymphoma kinase (ALK) gene explain most hereditary neuroblastomas, and that activating mutations can also be somatically acquired.  We first identified a significant linkage signal at chromosome bands 2p23-24 using a whole-genome scan in neuroblastoma pedigrees.  Re-sequencing of regional candidate genes identified three sep. germline missense mutations in the tyrosine kinase domain of ALK that segregated with the disease in eight sep. families.  Re-sequencing in 194 high-risk neuroblastoma samples showed somatically acquired mutations in the tyrosine kinase domain in 12.4% of samples.  Nine of the ten mutations map to crit. regions of the kinase domain and were predicted, with high probability, to be oncogenic drivers.  Mutations resulted in constitutive phosphorylation, and targeted knockdown of ALK mRNA resulted in profound inhibition of growth in all cell lines harboring mutant or amplified ALK, as well as in two out of six wild-type cell lines for ALK.  Our results demonstrate that heritable mutations of ALK are the main cause of familial neuroblastoma, and that germline or acquired activation of this cell-surface kinase is a tractable therapeutic target for this lethal pediatric malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMNOcIFf5xjbVg90H21EOLACvtfcHk0lgr6h5Z1v5dlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP&md5=bb998ef8f6bfbd85f928263e13954ce4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnature07261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07261%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520Major%2520Familial%2520Neuroblastoma%2520Predisposition%2520Gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D935%26doi%3D10.1038%2Fnature07261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azarova, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautam, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span> <span> </span><span class="NLM_article-title">Emerging Importance of ALK in Neuroblastoma</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1016/j.semcancer.2011.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1016%2Fj.semcancer.2011.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=21945349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSktLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=267-275&author=A.+M.+Azarovaauthor=G.+Gautamauthor=R.+E.+George&title=Emerging+Importance+of+ALK+in+Neuroblastoma&doi=10.1016%2Fj.semcancer.2011.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging importance of ALK in neuroblastoma</span></div><div class="casAuthors">Azarova, Anna M.; Gautam, Gargi; George, Rani E.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">267-275</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Since the original descriptions of gain-of function mutations in anaplastic lymphoma kinase (ALK), interest in the role of this receptor tyrosine kinase in neuroblastoma development and as a potential therapeutic target has escalated.  As a group, the activating point mutations in full-length ALK, found in approx. 8% of all neuroblastoma tumors, are distributed evenly across different clin. stages.  However, the most frequent somatic mutation, F1174L, is assocd. with amplification of the MYCN oncogene.  This combination of features appears to confer a worse prognosis than MYCN amplification alone, suggesting a cooperative effect on neuroblastoma formation by these two proteins.  Indeed, F1174L has shown more potent transforming activity in vivo than the second most common activating mutation, R1275Q, and is responsible for innate and acquired resistance to crizotinib, a clin. relevant ALK inhibitor that will soon be com. available.  These advances cast ALK as a bona fide oncoprotein in neuroblastoma and emphasize the need to understand ALK-mediated signaling in this tumor.  This review addresses many of the current issues surrounding the role of ALK in normal development and neuroblastoma pathogenesis, and discusses the prospects for clin. effective targeted treatments based on ALK inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpqmFzh9Q3frVg90H21EOLACvtfcHk0lgr6h5Z1v5dlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSktLzN&md5=e07445aecd9829c465f1f4023124521f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2011.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2011.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DAzarova%26aufirst%3DA.%2BM.%26aulast%3DGautam%26aufirst%3DG.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26atitle%3DEmerging%2520Importance%2520of%2520ALK%2520in%2520Neuroblastoma%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2011%26volume%3D21%26spage%3D267%26epage%3D275%26doi%3D10.1016%2Fj.semcancer.2011.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beausoleil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innocenti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, T.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comb, M. J.</span></span> <span> </span><span class="NLM_article-title">Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">3312</span>– <span class="NLM_lpage">3323</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1158%2F0008-5472.CAN-11-3931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=22570254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFKku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3312-3323&author=H.+Renauthor=Z.-P.+Tanauthor=X.+Zhuauthor=K.+Crosbyauthor=H.+Haackauthor=J.+M.+Renauthor=S.+Beausoleilauthor=A.+Moritzauthor=G.+Innocentiauthor=J.+Rushauthor=Y.+Zhangauthor=X.-M.+Zhouauthor=T.-L.+Guauthor=Y.-F.+Yangauthor=M.+J.+Comb&title=Identification+of+Anaplastic+Lymphoma+Kinase+as+a+Potential+Therapeutic+Target+in+Ovarian+Cancer&doi=10.1158%2F0008-5472.CAN-11-3931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer</span></div><div class="casAuthors">Ren, Hong; Tan, Zhi-Ping; Zhu, Xin; Crosby, Katherine; Haack, Herbert; Ren, Jian-Min; Beausoleil, Sean; Moritz, Albrecht; Innocenti, Gregory; Rush, John; Zhang, Yi; Zhou, Xin-Min; Gu, Ting-Lei; Yang, Yi-Feng; Comb, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3312-3323</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Findings suggest the use of ALK kinase inhibitors now in clin. development as potential agents for treatment of some patients with serous ovarian carcinoma or stromal sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi924EZXGeJ7Vg90H21EOLACvtfcHk0lgr6h5Z1v5dlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFKku7w%253D&md5=a263a135244b307b864c098769d10a7a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3931%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.-P.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DJ.%2BM.%26aulast%3DBeausoleil%26aufirst%3DS.%26aulast%3DMoritz%26aufirst%3DA.%26aulast%3DInnocenti%26aufirst%3DG.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.-M.%26aulast%3DGu%26aufirst%3DT.-L.%26aulast%3DYang%26aufirst%3DY.-F.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DIdentification%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520as%2520a%2520Potential%2520Therapeutic%2520Target%2520in%2520Ovarian%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D3312%26epage%3D3323%26doi%3D10.1158%2F0008-5472.CAN-11-3931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tuma, R. S.</span></span> <span> </span><span class="NLM_article-title">ALK Gene Amplified in Most Inflammatory Breast Cancers</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1093/jnci/djr553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1093%2Fjnci%2Fdjr553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=22215853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVWhsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2012&pages=87-88&author=R.+S.+Tuma&title=ALK+Gene+Amplified+in+Most+Inflammatory+Breast+Cancers&doi=10.1093%2Fjnci%2Fdjr553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">ALK Gene Amplified in Most Inflammatory Breast Cancers</span></div><div class="casAuthors">Tuma, Rabiya S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-88</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Inflammatory breast cancer (IBC) is a rare form of the disease that differs substantially from non-inflammatory breast cancer in presentation and response to therapy. Despite those differences, researchers have uncovered few mol. characteristics that distinguish IBC from non-inflammatory breast cancer, and IBC treatment generally relies on std. breast cancer regimens.  Recently, it has been reported that ALK gene amplification is a common feature of IBC tumors and that small-mol. ALK inhibitors are effective in mouse xenograft models.  Current developments on this recent report are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB9yX6fegRi7Vg90H21EOLACvtfcHk0lgku76JOMzleA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVWhsb0%253D&md5=46e7633055aadc3aacfc6bac9b4cb591</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjr553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjr553%26sid%3Dliteratum%253Aachs%26aulast%3DTuma%26aufirst%3DR.%2BS.%26atitle%3DALK%2520Gene%2520Amplified%2520in%2520Most%2520Inflammatory%2520Breast%2520Cancers%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2012%26volume%3D104%26spage%3D87%26epage%3D88%26doi%3D10.1093%2Fjnci%2Fdjr553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anzalone, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Underiner, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">498</span>, <span class="refDoi"> DOI: 10.1021/ml100158s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100158s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=493-498&author=G.+R.+Ottauthor=R.+Tripathyauthor=M.+Chengauthor=R.+McHughauthor=A.+V.+Anzaloneauthor=T.+L.+Underinerauthor=M.+A.+Curryauthor=M.+R.+Quailauthor=L.+Luauthor=W.+Wanauthor=T.+S.+Angelesauthor=M.+S.+Albomauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+a+Potent+Inhibitor+of+Anaplastic+Lymphoma+Kinase+with+in+Vivo+Antitumor+Activity&doi=10.1021%2Fml100158s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity</span></div><div class="casAuthors">Ott, Gregory R.; Tripathy, Rabindranath; Cheng, Mangeng; McHugh, Robert; Anzalone, Andrew V.; Underiner, Ted L.; Curry, Matthew A.; Quail, Matthew R.; Lu, Lihui; Wan, Weihua; Angeles, Thelma S.; Albom, Mark S.; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">493-498</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel 7-amino-1,3,4,5-tetrahydrobenzo[b]azepin-2-one derivs. within the diaminopyrimidine class of kinase inhibitors were identified that target anaplastic lymphoma kinase (ALK).  These inhibitors are potent against ALK in an isolated enzyme assay and inhibit autophosphorylation of the oncogenic fusion protein NPM-ALK in anaplastic large cell lymphoma (ALCL) cell lines.  The lead inhibitor 15 (I), which incorporates a bicyclo[2.2.1]hept-5-ene ring system in place of an aryl moiety, activates the pro-apoptotic caspases (3 and 7) and displays selective cytotoxicity against ALK-pos. ALCL cells.  Furthermore, 15 provides more than 40-fold selectivity against the structurally related insulin receptor, is orally bioavailable in multiple species, and displays in vivo antitumor efficacy when dosed orally in ALK-pos. ALCL tumor xenografts in Scid mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof0qilbcAbZ7Vg90H21EOLACvtfcHk0lgku76JOMzleA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ&md5=15d4f7aea64f212338d8c9cd88a36c64</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fml100158s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100158s%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DTripathy%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DMcHugh%26aufirst%3DR.%26aulast%3DAnzalone%26aufirst%3DA.%2BV.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DCurry%26aufirst%3DM.%2BA.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520with%2520in%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D493%26epage%3D498%26doi%3D10.1021%2Fml100158s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mesaros, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrish, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugan, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anzalone, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">Novel 2,3,4,5-Tetrahydro-benzo[d]azepine Derivatives of 2,4-Diaminopyrimidine, Selective and Orally Bioavailable ALK Inhibitors with Antitumor Efficacy in ALCL Mouse Models</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.10.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1016%2Fj.bmcl.2010.10.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=21074994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SqsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=463-466&author=E.+F.+Mesarosauthor=J.+P.+Burkeauthor=J.+D.+Parrishauthor=B.+J.+Duganauthor=A.+V.+Anzaloneauthor=T.+S.+Angelesauthor=M.+S.+Albomauthor=L.+D.+Aimoneauthor=M.+R.+Quailauthor=W.+Wanauthor=L.+Luauthor=Z.+Huangauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=M.+Chengauthor=G.+R.+Ottauthor=B.+D.+Dorsey&title=Novel+2%2C3%2C4%2C5-Tetrahydro-benzo%5Bd%5Dazepine+Derivatives+of+2%2C4-Diaminopyrimidine%2C+Selective+and+Orally+Bioavailable+ALK+Inhibitors+with+Antitumor+Efficacy+in+ALCL+Mouse+Models&doi=10.1016%2Fj.bmcl.2010.10.115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models</span></div><div class="casAuthors">Mesaros, Eugen F.; Burke, Jason P.; Parrish, Jonathan D.; Dugan, Benjamin J.; Anzalone, Andrew V.; Angeles, Thelma S.; Albom, Mark S.; Aimone, Lisa D.; Quail, Matthew R.; Wan, Weihua; Lu, Lihui; Huang, Zeqi; Ator, Mark A.; Ruggeri, Bruce A.; Cheng, Mangeng; Ott, Gregory R.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">463-466</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis and biol. evaluation of potent and selective anaplastic lymphoma kinase (ALK) inhibitors from a novel class of 2,4-diaminopyrimidines, incorporating 2,3,4,5-tetrahydro-benzo[d]azepine fragments, is described.  An orally bioavailable analog, I, that displayed antitumor efficacy in ALCL xenograft models in mice was identified and extensively profiled.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEIN3ozlaLo7Vg90H21EOLACvtfcHk0lgku76JOMzleA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SqsbvE&md5=f6fd9a9ff66139f77191f378d4a2dcb7</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.10.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.10.115%26sid%3Dliteratum%253Aachs%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DBurke%26aufirst%3DJ.%2BP.%26aulast%3DParrish%26aufirst%3DJ.%2BD.%26aulast%3DDugan%26aufirst%3DB.%2BJ.%26aulast%3DAnzalone%26aufirst%3DA.%2BV.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DNovel%25202%252C3%252C4%252C5-Tetrahydro-benzo%255Bd%255Dazepine%2520Derivatives%2520of%25202%252C4-Diaminopyrimidine%252C%2520Selective%2520and%2520Orally%2520Bioavailable%2520ALK%2520Inhibitors%2520with%2520Antitumor%2520Efficacy%2520in%2520ALCL%2520Mouse%2520Models%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D463%26epage%3D466%26doi%3D10.1016%2Fj.bmcl.2010.10.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milkiewicz, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roemmele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theroff, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Underiner, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zificsak, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-activity Relationships of 1,2,3,4-Tetrahydropyrido[2,3-b]pyrazines as Potent and Selective Inhibitors of the Anaplastic Lymphoma Kinase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4351</span>– <span class="NLM_lpage">4362</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.04.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1016%2Fj.bmc.2010.04.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=20483621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntV2ruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=4351-4362&author=K.+L.+Milkiewiczauthor=L.+R.+Weinbergauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=M.+Chengauthor=A.+K.+Ghoseauthor=R.+C.+Roemmeleauthor=J.+P.+Theroffauthor=T.+L.+Underinerauthor=C.+A.+Zificsakauthor=B.+D.+Dorsey&title=Synthesis+and+Structure-activity+Relationships+of+1%2C2%2C3%2C4-Tetrahydropyrido%5B2%2C3-b%5Dpyrazines+as+Potent+and+Selective+Inhibitors+of+the+Anaplastic+Lymphoma+Kinase&doi=10.1016%2Fj.bmc.2010.04.087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase</span></div><div class="casAuthors">Milkiewicz, Karen L.; Weinberg, Linda R.; Albom, Mark S.; Angeles, Thelma S.; Cheng, Mangeng; Ghose, Arup K.; Roemmele, Renee C.; Theroff, Jay P.; Underiner, Ted L.; Zificsak, Craig A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4351-4362</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dysregulation of the anaplastic lymphoma kinase (ALK) is implicated in a variety of cancers.  A series of tetrahydropyrido[2,3-b]pyrazines was constructed as ring-constrained analogs of a known aminopyridine kinase scaffold.  Chem. was developed to rapidly elaborate the SAR, structural elements impacting ALK inhibitory activity were exploited, and kinase selective analogs were identified that inhibit ALK with IC50 values ∼10 nM (enzyme) and ∼150 nM (cell).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8a1ByMi_Z37Vg90H21EOLACvtfcHk0ljHXjh2dCIMag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntV2ruro%253D&md5=8fe973a224b19d133105d12178fd34a8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.04.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.04.087%26sid%3Dliteratum%253Aachs%26aulast%3DMilkiewicz%26aufirst%3DK.%2BL.%26aulast%3DWeinberg%26aufirst%3DL.%2BR.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DRoemmele%26aufirst%3DR.%2BC.%26aulast%3DTheroff%26aufirst%3DJ.%2BP.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DZificsak%26aufirst%3DC.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DSynthesis%2520and%2520Structure-activity%2520Relationships%2520of%25201%252C2%252C3%252C4-Tetrahydropyrido%255B2%252C3-b%255Dpyrazines%2520as%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520the%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D4351%26epage%3D4362%26doi%3D10.1016%2Fj.bmc.2010.04.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thieu, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesaros, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingrich, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeles, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aimone, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ator, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, B. D.</span></span> <span> </span><span class="NLM_article-title">2,7-Disubstituted-pyrrolo[2,1-f][1,2,4]triazines: New Variant of an Old Template and Application to the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors with in Vivo Antitumor Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6328</span>– <span class="NLM_lpage">6341</span>, <span class="refDoi"> DOI: 10.1021/jm200758k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200758k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGmsr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6328-6341&author=G.+R.+Ottauthor=G.+J.+Wellsauthor=T.+V.+Thieuauthor=M.+R.+Quailauthor=J.+G.+Liskoauthor=E.+F.+Mesarosauthor=D.+E.+Gingrichauthor=A.+K.+Ghoseauthor=W.+Wanauthor=L.+Luauthor=M.+Chengauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=Z.+Huangauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=2%2C7-Disubstituted-pyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazines%3A+New+Variant+of+an+Old+Template+and+Application+to+the+Discovery+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitors+with+in+Vivo+Antitumor+Activity&doi=10.1021%2Fjm200758k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">2,7-Disubstituted-pyrrolo[2,1-f][1,2,4]triazines: New Variant of an Old Template and Application to the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors with in Vivo Antitumor Activity</span></div><div class="casAuthors">Ott, Gregory R.; Wells, Gregory J.; Thieu, Tho-V.; Quail, Matthew R.; Lisko, Joseph G.; Mesaros, Eugen F.; Gingrich, Diane E.; Ghose, Arup K.; Wan, Wei-Hua; Lu, Li-Hui; Cheng, Man-Geng; Albom, Mark S.; Angeles, Thelma S.; Huang, Ze-Qi; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6328-6341</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel 2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazine scaffold has been designed as a new kinase inhibitor platform mimicking the bioactive conformation of the well-known diaminopyrimidine motif.  Herein the design, synthesis, and validation of this new pyrrolo[2,1-f][1,2,4]triazine scaffold is described for inhibitors of anaplastic lymphoma kinase (ALK).  Importantly, incorporation of appropriate potency and selectivity determinants has led to the discovery of several advanced leads that were orally efficacious in animal models of anaplastic large cell lymphoma (ALCL).  A lead inhibitor I displaying superior efficacy was identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQP33sAtk5w7Vg90H21EOLACvtfcHk0ljHXjh2dCIMag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGmsr%252FK&md5=a591238a89465683c709e6a965108212</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm200758k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200758k%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DWells%26aufirst%3DG.%2BJ.%26aulast%3DThieu%26aufirst%3DT.%2BV.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3D2%252C7-Disubstituted-pyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazines%253A%2520New%2520Variant%2520of%2520an%2520Old%2520Template%2520and%2520Application%2520to%2520the%2520Discovery%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitors%2520with%2520in%2520Vivo%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6328%26epage%3D6341%26doi%3D10.1021%2Fjm200758k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gantla, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickens, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chucholowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, T. R.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of 5-Aryl-pyridone-carboxamides as Inhibitors of Anaplastic Lymphoma Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1006</span>– <span class="NLM_lpage">1015</span>, <span class="refDoi"> DOI: 10.1021/jm050824x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050824x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvFKhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=1006-1015&author=R.+Liauthor=L.+Xueauthor=T.+Zhuauthor=Q.+Jiangauthor=X.+Cuiauthor=Z.+Yanauthor=D.+McGeeauthor=J.+Wangauthor=V.+R.+Gantlaauthor=J.+C.+Pickensauthor=D.+McGrathauthor=A.+Chucholowskiauthor=S.+W.+Morrisauthor=T.+R.+Webb&title=Design+and+Synthesis+of+5-Aryl-pyridone-carboxamides+as+Inhibitors+of+Anaplastic+Lymphoma+Kinase&doi=10.1021%2Fjm050824x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of 5-Aryl-pyridone-carboxamides as Inhibitors of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Li, Rongshi; Xue, Liquan; Zhu, Tong; Jiang, Qin; Cui, Xiaoli; Yan, Zheng; McGee, Danny; Wang, Jian; Gantla, Vidyasagar Reddy; Pickens, Jason C.; McGrath, Doug; Chucholowski, Alexander; Morris, Stephan W.; Webb, Thomas R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1006-1015</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a promising new target for therapy of certain cancers such as anaplastic large-cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT).  The authors have identified a series of novel pyridones as kinase inhibitors of ALK by application of a stepwise process involving in vitro screening of a novel targeted library followed by iterative template modification based on medicinal chem. insights and computational ranking of virtual libraries.  Using this process, the authors discovered ALK-selective inhibitors with improved potency and selectivity.  Herein the details of the design process and synthesis of these novel pyridones, along with their enzymic and cell-based activity, are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXgfuXJ1QEMLVg90H21EOLACvtfcHk0lgG-JnsneCTZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvFKhsA%253D%253D&md5=818c046a4b447011f240e99d96370c30</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm050824x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050824x%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DR.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DMcGee%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGantla%26aufirst%3DV.%2BR.%26aulast%3DPickens%26aufirst%3DJ.%2BC.%26aulast%3DMcGrath%26aufirst%3DD.%26aulast%3DChucholowski%26aufirst%3DA.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DWebb%26aufirst%3DT.%2BR.%26atitle%3DDesign%2520and%2520Synthesis%2520of%25205-Aryl-pyridone-carboxamides%2520as%2520Inhibitors%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D1006%26epage%3D1015%26doi%3D10.1021%2Fjm050824x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabbatini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korenchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowand, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leperi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumble, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gontarek, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maksimchuk, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suravajjala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapierre, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shotwell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">GSK1838705A Inhibits the Insulin-like Growth Factor-1 Receptor and Anaplastic Lymphoma Kinase and Shows Antitumor Activity in Experimental Models of Human Cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2811</span>– <span class="NLM_lpage">2820</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1158%2F1535-7163.MCT-09-0423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=19825801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2811-2820&author=P.+Sabbatiniauthor=S.+Korenchukauthor=J.+L.+Rowandauthor=A.+Groyauthor=Q.+Liuauthor=D.+Leperiauthor=C.+Atkinsauthor=M.+Dumbleauthor=J.+Yangauthor=K.+Andersonauthor=R.+G.+Krugerauthor=R.+R.+Gontarekauthor=K.+R.+Maksimchukauthor=S.+Suravajjalaauthor=R.+R.+Lapierreauthor=J.+B.+Shotwellauthor=J.+W.+Wilsonauthor=S.+D.+Chamberlainauthor=S.+K.+Rabindranauthor=R.+Kumar&title=GSK1838705A+Inhibits+the+Insulin-like+Growth+Factor-1+Receptor+and+Anaplastic+Lymphoma+Kinase+and+Shows+Antitumor+Activity+in+Experimental+Models+of+Human+Cancers&doi=10.1158%2F1535-7163.MCT-09-0423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers</span></div><div class="casAuthors">Sabbatini, Peter; Korenchuk, Susan; Rowand, Jason L.; Groy, Arthur; Liu, Qi; Leperi, Dominic; Atkins, Charity; Dumble, Melissa; Yang, Jingsong; Anderson, Kelly; Kruger, Ryan G.; Gontarek, Richard R.; Maksimchuk, Kenneth R.; Suravajjala, Sapna; Lapierre, Russell R.; Shotwell, J. Brad; Wilson, Joseph W.; Chamberlain, Stanley D.; Rabindran, Sridhar K.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2811-2820</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The insulin-like growth factor-I receptor (IGF-IR) signaling pathway is activated in various tumors, and inhibition of IGF-IR kinase provides a therapeutic opportunity in these patients.  GSK1838705A is a small-mol. kinase inhibitor that inhibits IGF-IR and the insulin receptor with IC50s of 2.0 and 1.6 nmol/L, resp.  GSK1838705A blocks the in vitro proliferation of cell lines derived from solid and hematol. malignancies, including multiple myeloma and Ewing's sarcoma, and retards the growth of human tumor xenografts in vivo.  Despite the inhibitory effect of GSK1838705A on insulin receptor, minimal effects on glucose homeostasis were obsd. at efficacious doses.  GSK1838705A also inhibits the anaplastic lymphoma kinase (ALK), which drives the aberrant growth of anaplastic large-cell lymphomas, some neuroblastomas, and a subset of non-small cell lung cancers.  GSK1838705A inhibits ALK, with an IC50 of 0.5 nmol/L, and causes complete regression of ALK-dependent tumors in vivo at well-tolerated doses.  GSK1838705A is therefore a promising antitumor agent for therapeutic use in human cancers. [Mol Cancer Ther 2009;8(10):2811-20].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyQ0LEFOBer7Vg90H21EOLACvtfcHk0lgG-JnsneCTZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Cqur7N&md5=42e56e8dd4920322b82bedd13721be5b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0423%26sid%3Dliteratum%253Aachs%26aulast%3DSabbatini%26aufirst%3DP.%26aulast%3DKorenchuk%26aufirst%3DS.%26aulast%3DRowand%26aufirst%3DJ.%2BL.%26aulast%3DGroy%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLeperi%26aufirst%3DD.%26aulast%3DAtkins%26aufirst%3DC.%26aulast%3DDumble%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DKruger%26aufirst%3DR.%2BG.%26aulast%3DGontarek%26aufirst%3DR.%2BR.%26aulast%3DMaksimchuk%26aufirst%3DK.%2BR.%26aulast%3DSuravajjala%26aufirst%3DS.%26aulast%3DLapierre%26aufirst%3DR.%2BR.%26aulast%3DShotwell%26aufirst%3DJ.%2BB.%26aulast%3DWilson%26aufirst%3DJ.%2BW.%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DGSK1838705A%2520Inhibits%2520the%2520Insulin-like%2520Growth%2520Factor-1%2520Receptor%2520and%2520Anaplastic%2520Lymphoma%2520Kinase%2520and%2520Shows%2520Antitumor%2520Activity%2520in%2520Experimental%2520Models%2520of%2520Human%2520Cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D2811%26epage%3D2820%26doi%3D10.1158%2F1535-7163.MCT-09-0423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choquette, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stellwagen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emkey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffran, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szilvassy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brake, R. L.</span></span> <span> </span><span class="NLM_article-title">The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6540</span>, <span class="refDoi"> DOI: 10.1021/jm3005866</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3005866" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC38XptF2hsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6523-6540&author=R.+T.+Lewisauthor=C.+M.+Bodeauthor=D.+M.+Choquetteauthor=M.+Potashmanauthor=K.+Romeroauthor=J.+C.+Stellwagenauthor=Y.+Tefferaauthor=E.+Mooreauthor=D.+A.+Whittingtonauthor=H.+Chenauthor=L.+F.+Epsteinauthor=R.+Emkeyauthor=P.+S.+Andrewsauthor=V.+L.+Yuauthor=D.+C.+Saffranauthor=M.+Xuauthor=A.+Drewauthor=P.+Merkelauthor=S.+Szilvassyauthor=R.+L.+Brake&title=The+Discovery+and+Optimization+of+a+Novel+Class+of+Potent%2C+Selective%2C+and+Orally+Bioavailable+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitors+with+Potential+Utility+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm3005866"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer</span></div><div class="casAuthors">Lewis, Richard T.; Bode, Christiane M.; Choquette, Deborah M.; Potashman, Michele; Romero, Karina; Stellwagen, John C.; Teffera, Yohannes; Moore, Earl; Whittington, Douglas A.; Chen, Hao; Epstein, Linda F.; Emkey, Renee; Andrews, Paul S.; Yu, Violeta L.; Saffran, Douglas C.; Xu, Man; Drew, Allison; Merkel, Patricia; Szilvassy, Steven; Brake, Rachael L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6523-6540</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A class of 2-acyliminobenzimidazoles has been developed as potent and selective inhibitors of anaplastic lymphoma kinase (ALK).  Structure based design facilitated the rapid development of structure-activity relationships (SAR) and the optimization of kinase selectivity.  Introduction of an optimally placed polar substituent was key to solving issues of metabolic stability and led to the development of potent, selective, orally bioavailable ALK inhibitors.  Compd. I [Ar = 3,5-F2Ph] achieved substantial tumor regression in an NPM-ALK driven murine tumor xenograft model when dosed qd.  Compd. I [Ar = 3,5-F2Ph, 4-FPh] show favorable potency and PK characteristics in preclin. species indicative of suitability for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDAwmBMVhyL7Vg90H21EOLACvtfcHk0lgG-JnsneCTZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptF2hsbo%253D&md5=a3c2f9e8dbf7d73319657e456bd45076</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm3005866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3005866%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DBode%26aufirst%3DC.%2BM.%26aulast%3DChoquette%26aufirst%3DD.%2BM.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DRomero%26aufirst%3DK.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DMoore%26aufirst%3DE.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DEmkey%26aufirst%3DR.%26aulast%3DAndrews%26aufirst%3DP.%2BS.%26aulast%3DYu%26aufirst%3DV.%2BL.%26aulast%3DSaffran%26aufirst%3DD.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DDrew%26aufirst%3DA.%26aulast%3DMerkel%26aufirst%3DP.%26aulast%3DSzilvassy%26aufirst%3DS.%26aulast%3DBrake%26aufirst%3DR.%2BL.%26atitle%3DThe%2520Discovery%2520and%2520Optimization%2520of%2520a%2520Novel%2520Class%2520of%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Bioavailable%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitors%2520with%2520Potential%2520Utility%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6523%26epage%3D6540%26doi%3D10.1021%2Fjm3005866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luther, W.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">384</span>, <span class="refDoi"> DOI: 10.1021/ml200002a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200002a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFersrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=379-384&author=X.+Dengauthor=J.+Wangauthor=J.+Zhangauthor=T.+Simauthor=N.+D.+Kimauthor=T.+Sasakiauthor=W.+Lutherauthor=R.+E.+Georgeauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Discovery+of+3%2C5-Diamino-1%2C2%2C4-triazole+Ureas+as+Potent+Anaplastic+Lymphoma+Kinase+Inhibitors&doi=10.1021%2Fml200002a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">Deng, Xianming; Wang, Jinhua; Zhang, Jianming; Sim, Taebo; Kim, Nam Doo; Sasaki, Takaaki; Luther, William, II; George, Rani E.; Janne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">379-384</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel 3,5-diamino-1,2,4-triazole benzyl ureas was identified as having potent anaplastic lymphoma kinase (ALK) inhibition exemplified by I (X = O), II, and I (X = S), which exhibited antiproliferative IC50 values of 70, 40, and 20 nM in Tel-ALK transformed Ba/F3 cells, resp.  Moreover, I (X = O, S) potently inhibited the growth and survival of NPM-ALK pos. anaplastic large cell lymphoma cell (SU-DHL-1) and neuroblastoma cell lines (KELLY, SH-SY5Y) contg. the F1174L ALK mutation.  These compds. provide novel leads for the development of small-mol. ALK inhibitors for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_KXj1NxtfHLVg90H21EOLACvtfcHk0lgHNcsVG--VpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFersrc%253D&md5=cd4a0e5eefcf0b1b6e3c5dab5dc87d81</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fml200002a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200002a%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%25203%252C5-Diamino-1%252C2%252C4-triazole%2520Ureas%2520as%2520Potent%2520Anaplastic%2520Lymphoma%2520Kinase%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D379%26epage%3D384%26doi%3D10.1021%2Fml200002a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arango, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Los, G.</span></span> <span> </span><span class="NLM_article-title">Cytoreductive Antitumor Activity of PF-2341066, A Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Met, in Experimental Models of Anaplastic Large-cell Lymphoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">3314</span>– <span class="NLM_lpage">3322</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1158%2F1535-7163.MCT-07-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=18089725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3314-3322&author=J.+G.+Christensenauthor=H.+Y.+Zouauthor=M.+E.+Arangoauthor=Q.+Liauthor=J.+H.+Leeauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=G.+R.+Altonauthor=B.+Mroczkowskiauthor=G.+Los&title=Cytoreductive+Antitumor+Activity+of+PF-2341066%2C+A+Novel+Inhibitor+of+Anaplastic+Lymphoma+Kinase+and+c-Met%2C+in+Experimental+Models+of+Anaplastic+Large-cell+Lymphoma&doi=10.1158%2F1535-7163.MCT-07-0365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span></div><div class="casAuthors">Christensen, James G.; Zou, Helen Y.; Arango, Maria E.; Li, Qiuhua; Lee, Joseph H.; McDonnell, Scott R.; Yamazaki, Shinji; Alton, Gordon R.; Mroczkowski, Barbara; Los, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3314-3322</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A t(2;5) chromosomal translocation resulting in expression of an oncogenic kinase fusion protein known as nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL).  PF-2341066 was recently identified as a p.o. bioavailable, small-mol. inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK fusion protein.  PF-2341066 also potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC50 value, 24 nmol/L).  In biochem. and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacol. relevant concns. across a panel of >120 diverse kinases.  PF-2341066 potently inhibited cell proliferation, which was assocd. with G1-S-phase cell cycle arrest and induction of apoptosis in ALK-pos. ALCL cells (IC50 values, ∼30 nmol/L) but not ALK-neg. lymphoma cells.  The induction of apoptosis was confirmed using terminal deoxyribonucleotide transferase-mediated nick-end labeling and Annexin V staining (IC50 values, 25-50 nmol/L).  P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compd. administration.  A strong correlation was obsd. between antitumor response and inhibition of NPM-ALK phosphorylation and induction of apoptosis in tumor tissue.  In addn., inhibition of key NPM-ALK signaling mediators, including phospholipase C-γ, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 were obsd. at concns. or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.  Collectively, these data illustrate the potential clin. utility of inhibitors of NPM-ALK in treatment of patients with ALK-pos. ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptqY0tUwGnurVg90H21EOLACvtfcHk0lgHNcsVG--VpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL&md5=04fbbaf43ca527408bde8cabcd38e1fd</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0365%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAlton%26aufirst%3DG.%2BR.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DLos%26aufirst%3DG.%26atitle%3DCytoreductive%2520Antitumor%2520Activity%2520of%2520PF-2341066%252C%2520A%2520Novel%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520and%2520c-Met%252C%2520in%2520Experimental%2520Models%2520of%2520Anaplastic%2520Large-cell%2520Lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3314%26epage%3D3322%26doi%3D10.1158%2F1535-7163.MCT-07-0365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran-Dubé, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botrous, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grodsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padrique, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6342</span>– <span class="NLM_lpage">6363</span>, <span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dub%C3%A9author=H.+Shenauthor=M.+Nambuauthor=P.-P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+Based+Drug+Design+of+Crizotinib+%28PF-02341066%29%2C+a+Potent+and+Selective+Dual+Inhibitor+of+Mesenchymal%E2%80%93Epithelial+Transition+Factor+%28c-MET%29+Kinase+and+Anaplastic+Lymphoma+Kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0lhMSi-Vbb59Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520Based%2520Drug%2520Design%2520of%2520Crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520Potent%2520and%2520Selective%2520Dual%2520Inhibitor%2520of%2520Mesenchymal%25E2%2580%2593Epithelial%2520Transition%2520Factor%2520%2528c-MET%2529%2520Kinase%2520and%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkisova, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferdekamper, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopiuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phimister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aycinena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanewsky, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P. Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5675</span>– <span class="NLM_lpage">5690</span>, <span class="refDoi"> DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.-Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.+Y.+Michellys&title=Synthesis%2C+Structure-Activity+Relationships%2C+and+in+Vivo+Efficacy+of+the+Novel+Potent+and+Selective+Anaplastic+Lymphoma+Kinase+%28ALK%29+Inhibitor+5-Chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29phenyl%29-N4-%282-%28isopropylsulfonyl%29phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+Currently+in+Phase+1+and+Phase+2+Clinical+Trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span></div><div class="casAuthors">Marsilje, Thomas H.; Pei, Wei; Chen, Bei; Lu, Wenshuo; Uno, Tetsuo; Jin, Yunho; Jiang, Tao; Kim, Sungjoon; Li, Nanxin; Warmuth, Markus; Sarkisova, Yelena; Sun, Frank; Steffy, Auzon; Pferdekamper, AnneMarie C.; Li, Allen G.; Joseph, Sean B.; Kim, Young; Liu, Bo; Tuntland, Tove; Cui, Xiaoming; Gray, Nathanael S.; Steensma, Ruo; Wan, Yongqin; Jiang, Jiqing; Chopiuk, Greg; Li, Jie; Gordon, W. Perry; Richmond, Wendy; Johnson, Kevin; Chang, Jonathan; Groessl, Todd; He, You-Qun; Phimister, Andrew; Aycinena, Alex; Lee, Christian C.; Bursulaya, Badry; Karanewsky, Donald S.; Seidel, H. Martin; Harris, Jennifer L.; Michellys, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5675-5690</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis, preclin. profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor (I; LDK378) are described.  In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor (II; TAE684).  Compd. I is currently in phase 1 and phase 2 clin. trials with substantial antitumor activity being obsd. in ALK-pos. cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ-y7ZuX2XLLVg90H21EOLACvtfcHk0lhMSi-Vbb59Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D&md5=4b8f66e4acb27efe814956d7d0016068</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.-Q.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26atitle%3DSynthesis%252C%2520Structure-Activity%2520Relationships%252C%2520and%2520in%2520Vivo%2520Efficacy%2520of%2520the%2520Novel%2520Potent%2520and%2520Selective%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520Inhibitor%25205-Chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529phenyl%2529-N4-%25282-%2528isopropylsulfonyl%2529phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520Currently%2520in%2520Phase%25201%2520and%2520Phase%25202%2520Clinical%2520Trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiroshima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, Y.</span></span> <span> </span><span class="NLM_article-title">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2011.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1016%2Fj.ccr.2011.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=21575866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+Selective+ALK+Inhibitor+Capable+of+Blocking+the+Resistant+Gatekeeper+Mutant&doi=10.1016%2Fj.ccr.2011.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span></div><div class="casAuthors">Sakamoto, Hiroshi; Tsukaguchi, Toshiyuki; Hiroshima, Sayuri; Kodama, Tatsushi; Kobayashi, Takamitsu; Fukami, Takaaki A.; Oikawa, Nobuhiro; Tsukuda, Takuo; Ishii, Nobuya; Aoki, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">679-690</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in certain cancers, following gene alterations such as chromosomal translocation, amplification, or point mutation.  Here, the authors identified CH5424802, a potent, selective, and orally available ALK inhibitor with a unique chem. scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as non-small cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo.  CH5424802 inhibited ALK L1196M, which corresponds to the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK L1196M-driven cell growth.  The authors' results support the potential for clin. evaluation of CH5424802 for the treatment of patients with ALK-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrk3zvzF9p67Vg90H21EOLACvtfcHk0lhMSi-Vbb59Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D&md5=cae32f3a3647926ba835293b68e776f8</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520Selective%2520ALK%2520Inhibitor%2520Capable%2520of%2520Blocking%2520the%2520Resistant%2520Gatekeeper%2520Mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690%26doi%3D10.1016%2Fj.ccr.2011.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuichi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikawa, N.</span></span> <span> </span><span class="NLM_article-title">9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6286</span>– <span class="NLM_lpage">6294</span>, <span class="refDoi"> DOI: 10.1021/jm200652u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200652u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6286-6294&author=K.+Kinoshitaauthor=T.+Kobayashiauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Haraauthor=J.+Ohwadaauthor=K.+Hattoriauthor=T.+Miyagiauthor=W.-S.+Hongauthor=M.-J.+Parkauthor=K.+Takanashiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=9-Substituted+6%2C6-Dimethyl-11-oxo-6%2C11-dihydro-5H-benzo%5Bb%5Dcarbazoles+as+Highly+Selective+and+Potent+Anaplastic+Lymphoma+Kinase+Inhibitors&doi=10.1021%2Fjm200652u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">Kinoshita, Kazutomo; Kobayashi, Takamitsu; Asoh, Kohsuke; Furuichi, Noriyuki; Ito, Toshiya; Kawada, Hatsuo; Hara, Sousuke; Ohwada, Jun; Hattori, Kazuo; Miyagi, Takuho; Hong, Woo-Sang; Park, Min-Jeong; Takanashi, Kenji; Tsukaguchi, Toshiyuki; Sakamoto, Hiroshi; Tsukuda, Takuo; Oikawa, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6286-6294</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles were discovered as highly selective and potent anaplastic lymphoma kinase (ALK) inhibitors by structure-based drug design.  The high target selectivity was achieved by introducing a substituent close to the E0 region of the ATP binding site, which has a unique amino acid sequence.  Among the identified inhibitors, compd. 13d (I) showed highly selective and potent inhibitory activity against ALK with an IC50 value of 2.9 nM and strong antiproliferative activity against KARPAS-299 with an IC50 value of 12.8 nM.  The compd. also displayed significant antitumor efficacy in an established ALK fusion gene-pos. anaplastic large-cell lymphoma (ALCL) xenograft model in mice without body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfpJsdIdDvO7Vg90H21EOLACvtfcHk0lg6jFEij6qlIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP&md5=6293368243c840e12beefc8c8d6bb69a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm200652u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200652u%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DMiyagi%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DW.-S.%26aulast%3DPark%26aufirst%3DM.-J.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3D9-Substituted%25206%252C6-Dimethyl-11-oxo-6%252C11-dihydro-5H-benzo%255Bb%255Dcarbazoles%2520as%2520Highly%2520Selective%2520and%2520Potent%2520Anaplastic%2520Lymphoma%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6286%26epage%3D6294%26doi%3D10.1021%2Fjm200652u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifshits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Strategies to Overcome Crizotinib Resistance in Non-small Cell Lung Cancers Harboring the Fusion Oncogene EML4-ALK</span>. <i>Proc. Natl. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">7535</span>– <span class="NLM_lpage">7540</span>, <span class="refDoi"> DOI: 10.1073/pnas.1019559108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1073%2Fpnas.1019559108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=21502504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=7535-7540&author=R.+Katayamaauthor=T.+M.+Khanauthor=C.+Benesauthor=E.+Lifshitsauthor=H.+Ebiauthor=V.+M.+Riveraauthor=W.+C.+Shakespeareauthor=A.+J.+Iafrateauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Therapeutic+Strategies+to+Overcome+Crizotinib+Resistance+in+Non-small+Cell+Lung+Cancers+Harboring+the+Fusion+Oncogene+EML4-ALK&doi=10.1073%2Fpnas.1019559108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span></div><div class="casAuthors">Katayama, Ryohei; Khan, Tahsin M.; Benes, Cyril; Lifshits, Eugene; Ebi, Hiromichi; Rivera, Victor M.; Shakespeare, William C.; Iafrate, A. John; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7535-7540, S7535/1-S7535/17</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene represents a mol. target in a small subset of non-small cell lung cancers (NSCLCs).  This fusion leads to constitutive ALK activation with potent transforming activity.  In a pivotal phase 1 clin. trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib (PF-02341066) demonstrated impressive antitumor activity in the majority of patients with NSCLC harboring ALK fusions.  However, despite these remarkable initial responses, cancers eventually develop resistance to crizotinib, usually within 1 y, thereby limiting the potential clin. benefit.  To det. how cancers acquire resistance to ALK inhibitors, we established a model of acquired resistance to crizotinib by exposing a highly sensitive EML4-ALK-pos. NSCLC cell line to increasing doses of crizotinib until resistance emerged.  We found that cells resistant to intermediate doses of crizotinib developed amplification of the EML4-ALK gene.  Cells resistant to higher doses (1 μM) also developed a gatekeeper mutation, L1196M, within the kinase domain, rendering EML4-ALK insensitive to crizotinib.  This gatekeeper mutation was readily detected using a unique and highly sensitive allele-specific PCR assay.  Although crizotinib was ineffectual against EML4-ALK harboring the gatekeeper mutation, we obsd. that two structurally different ALK inhibitors, NVPTAE684 and AP26113, were highly active against the resistant cancer cells in vitro and in vivo.  Furthermore, these resistant cells remained highly sensitive to the Hsp90 inhibitor 17-AAG.  Thus, we have developed a model of acquired resistance to ALK inhibitors and have shown that second-generation ALK TKIs or Hsp90 inhibitors are effective in treating crizotinib-resistant tumors harboring secondary gatekeeper mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPbiLG5xpg0LVg90H21EOLACvtfcHk0lg6jFEij6qlIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D&md5=82f47736429e6f71f9fd5852e4df64cb</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1019559108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1019559108%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520Strategies%2520to%2520Overcome%2520Crizotinib%2520Resistance%2520in%2520Non-small%2520Cell%2520Lung%2520Cancers%2520Harboring%2520the%2520Fusion%2520Oncogene%2520EML4-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%26date%3D2011%26volume%3D108%26spage%3D7535%26epage%3D7540%26doi%3D10.1073%2Fpnas.1019559108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4720</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.-L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-Amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+Macrocyclic+Inhibitor+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+and+c-ros+Oncogene+1+%28ROS1%29+with+Preclinical+Brain+Exposure+and+Broad-Spectrum+Potency+against+ALK-Resistant+Mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0lhXGAfaad36VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-Amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528metheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520Macrocyclic%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520and%2520c-ros%2520Oncogene%25201%2520%2528ROS1%2529%2520with%2520Preclinical%2520Brain%2520Exposure%2520and%2520Broad-Spectrum%2520Potency%2520against%2520ALK-Resistant%2520Mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitland, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahceci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A.</span></span> <span> </span><span class="NLM_article-title">First-in-human, Open-label Dose-escalation and Dose-expansion Study of the Safety, Pharmacokinetics, and Antitumor Effects of an Oral ALK inhibitor ASP3026 in Patients with Advanced Solid Tumors</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">23</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0254-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1186%2Fs13045-016-0254-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=26966027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1eisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=23&author=T.+Liauthor=P.+LoRussoauthor=M.+L.+Maitlandauthor=S.-H.+I.+Ouauthor=E.+Bahceciauthor=H.+A.+Ballauthor=J.+W.+Parkauthor=G.+Yuenauthor=A.+Tolcher&title=First-in-human%2C+Open-label+Dose-escalation+and+Dose-expansion+Study+of+the+Safety%2C+Pharmacokinetics%2C+and+Antitumor+Effects+of+an+Oral+ALK+inhibitor+ASP3026+in+Patients+with+Advanced+Solid+Tumors&doi=10.1186%2Fs13045-016-0254-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors</span></div><div class="casAuthors">Li, Tianhong; Lo Russo, Patricia; Maitland, Michael L.; Ou, Sai-Hong Ignatius; Bahceci, Erkut; Ball, Howard A.; Park, Jung Wook; Yuen, Geoffrey; Tolcher, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23/1-23/9</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: ASP3026 is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has potent in vitro activity against crizotinib-resistant ALK-pos. tumors.  This open-label, multicenter, first-in-human phase I study (NCT01284192) assessed the safety, pharmacokinetic profile, and antitumor activity of ASP3026.  Methods: Advanced solid tumor patients received oral ASP3026 in 3 + 3 dose-escalation cohorts at doses of 25-800 mg once daily in 28-day cycles.  The endpoints were to identify the max. tolerated dose (MTD), the recommended phase II dose (RP2D), and the pharmacokinetic profile of ASP3026.  A phase Ib expansion cohort enrolled patients with metastatic, crizotinib-resistant ALK-pos. solid tumors at the RP2D, and response was evaluated by RECIST 1.1.  Results: The dose-escalation cohort enrolled 33 patients, including three crizotinib-resistant, ALK-pos. patients, and the dose-expansion cohort enrolled another 13 crizotinib-resistant, ALK-pos. non-small cell lung cancer (NSCLC) patients.  ASP3026 demonstrated both linear pharmacokinetics and dose-proportional exposure for area under the plasma concn.-time curve and max. concn. obsd. with a median terminal half-life of 35 h, supporting the daily dosing.  Grade 3 rash and elevated transaminase concns. were dose-limiting toxicities obsd. at 800 mg; hence, 525 mg daily was the MTD and RP2D.  The most common treatment-related adverse events were nausea (38 %), fatigue (35 %), and vomiting (35 %).  Among the 16 patients with crizotinib-resistant ALK-pos. tumors (15 NSCLC, 1 neuroblastoma), eight patients achieved partial response (overall response rate 50 %; 95 % confidence interval 25-75 %) and seven patients (44 %) achieved stable disease.  Conclusions: ASP3026 was well tolerated and had therapeutic activity in patients with crizotinib-resistant ALKpos. advanced tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8s1yI8JbYIrVg90H21EOLACvtfcHk0lhXGAfaad36VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1eisbc%253D&md5=ec3b634a66b3b310c8a0d6d83eeb9e62</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0254-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0254-5%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DMaitland%26aufirst%3DM.%2BL.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DBahceci%26aufirst%3DE.%26aulast%3DBall%26aufirst%3DH.%2BA.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26aulast%3DYuen%26aufirst%3DG.%26aulast%3DTolcher%26aufirst%3DA.%26atitle%3DFirst-in-human%252C%2520Open-label%2520Dose-escalation%2520and%2520Dose-expansion%2520Study%2520of%2520the%2520Safety%252C%2520Pharmacokinetics%252C%2520and%2520Antitumor%2520Effects%2520of%2520an%2520Oral%2520ALK%2520inhibitor%2520ASP3026%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D23%26doi%3D10.1186%2Fs13045-016-0254-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamauchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato-Nakai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishigai, M.</span></span> <span> </span><span class="NLM_article-title">In vitro Metabolism of Alectinib, a Novel Potent ALK Inhibitor, in Human: Contribution of CYP3A Enzymes</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">546</span>– <span class="NLM_lpage">554</span>, <span class="refDoi"> DOI: 10.1080/00498254.2017.1344910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1080%2F00498254.2017.1344910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=28657423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1WhsbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2018&pages=546-554&author=T.+Nakagawaauthor=S.+Fowlerauthor=K.+Takanashiauthor=K.+Youdimauthor=T.+Yamauchiauthor=K.+Kawashimaauthor=M.+Sato-Nakaiauthor=L.+Yuauthor=M.+Ishigai&title=In+vitro+Metabolism+of+Alectinib%2C+a+Novel+Potent+ALK+Inhibitor%2C+in+Human%3A+Contribution+of+CYP3A+Enzymes&doi=10.1080%2F00498254.2017.1344910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes</span></div><div class="casAuthors">Nakagawa, Toshito; Fowler, Stephen; Takanashi, Kenji; Youdim, Kuresh; Yamauchi, Tsuyoshi; Kawashima, Kosuke; Sato-Nakai, Mika; Yu, Li; Ishigai, Masaki</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">546-554</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">1. The in vitro metab. of alectinib, a potent and highly selective oral anaplastic lymphoma kinase inhibitor, was investigated.2.  The main metabolite (M4) in primary human hepatocytes was identified, which is produced by deethylation at the morpholine ring.  Three minor metabolites (M6, M1a, and M1b) were also identified, and a minor peak of hydroxylated alectinib (M5) was detected as a possible precursor of M4, M1a, and M1b.3.  M4, an important active major metabolite, was produced and further metabolized to M6 by CYP3A, indicating that CYP3A enzymes were the principal contributors to this route.  M5 is possibly produced by CYP3A and other isoforms as the primary step in metab., followed by oxidn. to M4 mainly by CYP3A.  Alternatively, M5 could be oxidized to M1a and M1b via an NAD-dependent process.  None of the non-CYP3A-mediated metab. appeared to be major.4.  In conclusion, this study suggests that involvement of multiple enzymes in the metab. of alectinib reduces its potential for drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXGMNSVBn1W7Vg90H21EOLACvtfcHk0lgmoUfX9DEudA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1WhsbnE&md5=319fbc1f9599b373e2233235b4f72cd0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1080%2F00498254.2017.1344910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498254.2017.1344910%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DT.%26aulast%3DFowler%26aufirst%3DS.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DYoudim%26aufirst%3DK.%26aulast%3DYamauchi%26aufirst%3DT.%26aulast%3DKawashima%26aufirst%3DK.%26aulast%3DSato-Nakai%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DIshigai%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520Metabolism%2520of%2520Alectinib%252C%2520a%2520Novel%2520Potent%2520ALK%2520Inhibitor%252C%2520in%2520Human%253A%2520Contribution%2520of%2520CYP3A%2520Enzymes%26jtitle%3DXenobiotica%26date%3D2018%26volume%3D48%26spage%3D546%26epage%3D554%26doi%3D10.1080%2F00498254.2017.1344910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El Sayed, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Veken, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhooghe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hostyn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Baelen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemière, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, B. U. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joossens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haemers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieters, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustyns, K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Antiplasmodial Activity of Aminoalkylamino-Substituted Neocryptolepine Derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2979</span>– <span class="NLM_lpage">2988</span>, <span class="refDoi"> DOI: 10.1021/jm801490z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801490z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVSlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2979-2988&author=I.+El+Sayedauthor=P.+Van+der+Vekenauthor=K.+Steertauthor=L.+Dhoogheauthor=S.+Hostynauthor=G.+Van+Baelenauthor=G.+Lemi%C3%A8reauthor=B.+U.+W.+Maesauthor=P.+Cosauthor=L.+Maesauthor=J.+Joossensauthor=A.+Haemersauthor=L.+Pietersauthor=K.+Augustyns&title=Synthesis+and+Antiplasmodial+Activity+of+Aminoalkylamino-Substituted+Neocryptolepine+Derivatives&doi=10.1021%2Fjm801490z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Antiplasmodial Activity of Aminoalkylamino-Substituted Neocryptolepine Derivatives</span></div><div class="casAuthors">El Sayed, Ibrahim; Van der Veken, Pieter; Steert, Koen; Dhooghe, Liene; Hostyn, Steven; Van Baelen, Gitte; Lemiere, Guy; Maes, Bert U. W.; Cos, Paul; Maes, Louis; Joossens, Jurgen; Haemers, Achiel; Pieters, Luc; Augustyns, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2979-2988</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of chloro- and aminoalkylamino-substituted neocryptolepine (5-methyl-5H-indolo[2,3-b]quinoline) derivs. were synthesized and evaluated as antiplasmodial agents.  The evaluation also included cytotoxicity (MRC5 cells), inhibition of β-hematin formation, and DNA interactions (DNA-methyl green assay).  Introduction of aminoalkylamino chains increased the antiplasmodial activity of the neocryptolepine core substantially.  The most efficient compds. showed antiplasmodial activities in the nanomolar.  N1,N1-Diethyl-N4-(5-methyl-5H-indolo[2,3-b]quinolin-8-yl)pentane-1,4-diamine (I) showed an IC50 of 0.01 μM and a selectivity index of 1800.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXQqjB-FKMjbVg90H21EOLACvtfcHk0lgmoUfX9DEudA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVSlsrk%253D&md5=3abbf5d6c2fc03e6ccfa516fe2d69e64</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm801490z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801490z%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BSayed%26aufirst%3DI.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26aulast%3DSteert%26aufirst%3DK.%26aulast%3DDhooghe%26aufirst%3DL.%26aulast%3DHostyn%26aufirst%3DS.%26aulast%3DVan%2BBaelen%26aufirst%3DG.%26aulast%3DLemi%25C3%25A8re%26aufirst%3DG.%26aulast%3DMaes%26aufirst%3DB.%2BU.%2BW.%26aulast%3DCos%26aufirst%3DP.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DJoossens%26aufirst%3DJ.%26aulast%3DHaemers%26aufirst%3DA.%26aulast%3DPieters%26aufirst%3DL.%26aulast%3DAugustyns%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520Antiplasmodial%2520Activity%2520of%2520Aminoalkylamino-Substituted%2520Neocryptolepine%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2979%26epage%3D2988%26doi%3D10.1021%2Fjm801490z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R.</span></span> <span> </span><span class="NLM_article-title">Development and Validation of a Genetic Algorithm for Flexible Docking</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">748</span>, <span class="refDoi"> DOI: 10.1006/jmbi.1996.0897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1006%2Fjmbi.1996.0897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=9126849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADyaK2sXis1KntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1997&pages=727-748&author=G.+Jonesauthor=P.+Willettauthor=R.+C.+Glenauthor=A.+R.+Leachauthor=R.+Taylor&title=Development+and+Validation+of+a+Genetic+Algorithm+for+Flexible+Docking&doi=10.1006%2Fjmbi.1996.0897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of a genetic algorithm for flexible docking</span></div><div class="casAuthors">Jones, Gareth; Willett, Peter; Glen, Robert C.; Leach, Andrew R.; Taylor, Robin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">727-748</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Prediction of small mol. binding modes to macromols. of known three-dimensional structure is a problem of paramount importance in rational drug design (the "docking" problem).  We report the development and validation of the program GOLD (Genetic Optimization for Ligand Docking).  GOLD is an automated ligand docking program that uses a genetic algorithm to explore the full range of ligand conformational flexibility with partial flexibility of the protein and satisfies the fundamental requirement that the ligand must displace loosely bound water on binding.  Numerous enhancements and modifications have been applied to the original technique resulting in a substantial increase in the reliability and the applicability of the algorithm.  The advanced algorithm has been tested on a dataset of 100 complexes extd. from the Brookhaven Protein Data Bank.  When used to dock the ligand back into the binding site, GOLD achieved a 71% success rate in identifying the exptl. binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP3I60Rl2uorVg90H21EOLACvtfcHk0lgmoUfX9DEudA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1KntLo%253D&md5=476a2b1d8f80f3ba418052fe29d735ca</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1996.0897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1996.0897%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DG.%26aulast%3DWillett%26aufirst%3DP.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DTaylor%26aufirst%3DR.%26atitle%3DDevelopment%2520and%2520Validation%2520of%2520a%2520Genetic%2520Algorithm%2520for%2520Flexible%2520Docking%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1997%26volume%3D267%26spage%3D727%26epage%3D748%26doi%3D10.1006%2Fjmbi.1996.0897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdonk, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartshorn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. D.</span></span> <span> </span><span class="NLM_article-title">Improved Protein-ligand Docking Using GOLD</span>. <i>Proteins</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">623</span>, <span class="refDoi"> DOI: 10.1002/prot.10465</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=10.1002%2Fprot.10465" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=12910460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvFGrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2003&pages=609-623&author=M.+L.+Verdonkauthor=J.+C.+Coleauthor=M.+J.+Hartshornauthor=C.+W.+Murrayauthor=R.+D.+Taylor&title=Improved+Protein-ligand+Docking+Using+GOLD&doi=10.1002%2Fprot.10465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Improved protein-ligand docking using GOLD</span></div><div class="casAuthors">Verdonk, Marcel L.; Cole, Jason C.; Hartshorn, Michael J.; Murray, Christopher W.; Taylor, Richard D.</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Genetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">609-623</span>CODEN:
                <span class="NLM_cas:coden">PSFGEY</span>;
        ISSN:<span class="NLM_cas:issn">0887-3585</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The Chemscore function was implemented as a scoring function for the protein-ligand docking program GOLD, and its performance compared to the original Goldscore function and two consensus docking protocols, "Goldscore-CS" and "Chemscore-GS," in terms of docking accuracy, prediction of binding affinities, and speed.  In the "Goldscore-CS" protocol, dockings produced with the Goldscore function are scored and ranked with the Chemscore function; in the "Chemscore-GS" protocol, dockings produced with the Chemscore function are scored and ranked with the Goldscore function.  Comparisons were made for a "clean" set of 224 protein-ligand complexes, and for two subsets of this set, one for which the ligands are "drug-like," the other for which they are "fragment-like.".  For "drug-like" and "fragment-like" ligands, the docking accuracies obtained with Chemscore and Goldscore functions are similar.  For larger ligands, Goldscore gives superior results.  Docking with the Chemscore function is up to three times faster than docking with the Goldscore function.  Both combined docking protocols give significant improvements in docking accuracy over the use of the Goldscore or Chemscore function alone.  "Goldscore-CS" gives success rates of up to 81% (top-ranked GOLD soln. within 2.0 Å of the exptl. binding mode) for the "clean list," but at the cost of long search times.  For most virtual screening applications, "Chemscore-GS" seems optimal; search settings that give docking speeds of around 0.25-1.3 min/compd. have success rates of about 78% for "drug-like" compds. and 85% for "fragment-like" compds.  In terms of producing binding energy ests., the Goldscore function appears to perform better than the Chemscore function and the two consensus protocols, particularly for faster search settings.  Even at docking speeds of around 1-2 min/compd., the Goldscore function predicts binding energies with a std. deviation of ∼10.5 kJ/mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKKgOct_CAcbVg90H21EOLACvtfcHk0lgwzcz-to6yLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvFGrsLg%253D&md5=73a627d99dab6de1ae364c8e8e5f0fea</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fprot.10465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.10465%26sid%3Dliteratum%253Aachs%26aulast%3DVerdonk%26aufirst%3DM.%2BL.%26aulast%3DCole%26aufirst%3DJ.%2BC.%26aulast%3DHartshorn%26aufirst%3DM.%2BJ.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DTaylor%26aufirst%3DR.%2BD.%26atitle%3DImproved%2520Protein-ligand%2520Docking%2520Using%2520GOLD%26jtitle%3DProteins%26date%3D2003%26volume%3D52%26spage%3D609%26epage%3D623%26doi%3D10.1002%2Fprot.10465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span> <i>MOE</i>; <span class="NLM_publisher-name">Chemical Computing Group</span>: <span class="NLM_publisher-loc">Montreal, Quebec, Canada</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+MOE%3B+Chemical+Computing+Group%3A+Montreal%2C+Quebec%2C+Canada%2C+2019."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DMOE%26pub%3DChemical%2520Computing%2520Group%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX','PDB','3AOX'); return false;">PDB: 3AOX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AOX3','PDB','3AOX3'); return false;">PDB: 3AOX3</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i119"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01550">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_50123"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01550?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01550</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Summary of KINOMEscan screening data for CJ-2360 against 468 kinases; HPLC trace of CJ-2360 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01550/suppl_file/jm0c01550_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Modeled structure for compound <b>7d</b> in complex with ALK (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01550/suppl_file/jm0c01550_si_002.pdb">PDB</a>)</p></li><li><p class="inline">Modeled structure for CJ-2369 in complex with ALK (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01550/suppl_file/jm0c01550_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Molecular string file for all the final target compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01550/suppl_file/jm0c01550_si_004.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01550/suppl_file/jm0c01550_si_001.pdf">jm0c01550_si_001.pdf (934.56 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01550/suppl_file/jm0c01550_si_002.pdb">jm0c01550_si_002.pdb (452.18 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01550/suppl_file/jm0c01550_si_003.pdb">jm0c01550_si_003.pdb (452.96 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01550/suppl_file/jm0c01550_si_004.csv">jm0c01550_si_004.csv (3.4 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01550&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01550%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-22" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01550" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6798f4deec4a3d9a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
